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Summary 
The reactive stroma in prostate cancer is predominantly composed of myofibroblasts, 
which are thought to be required for tumour progression. Bone-marrow derived 
mesenchymal stem cells (BM-MSCs) are known to migrate into the tumour and are one 
of the many potential precursors of myofibroblasts. The factors secreted by cancer cells 
which may drive myofibroblastic differentiation of MSC, however are poorly 
understood. The aim of this thesis was to explore for the first time, the impact of TGF-
β1 expressing exosomes (nano-sized vesicles) secreted by prostate cancer cells in 
directing the differentiation of BM-MSCs and subsequently the functions of exosome 
differentiated BM-MSCs. 
 
Exosomes isolated from prostate cancer cells skewed BM-MSCs away from 
differentiating into adipocytes, and instead towards alpha-smooth muscle actin (α-SMA) 
positive myofibroblasts. BM-MSCs treated with exosomes exhibited enhanced secretion 
of VEGF-A, HGF and had an altered transcript profile with heightened matrix 
metalloproteinases (MMP-1, -3 and -13).  
 
Impairing the secretion of exosomes by Rab27a knockdown or depleting exosomes from 
prostate cancer cells culture media by high speed ultracentrifugation, attenuated 
myofibroblastic differentiation of BM-MSCs, demonstrating exosomes as the key driving 
factor for this. Furthermore, differentiation of BM-MSCs into myofibroblasts was 
dependent on exosomally tethered TGF-β1, however BM-MSCs treated with soluble 
TGF-β1 at the same dose, failed to obtain the same myofibroblastic phenotype. 
 
The exosome-differentiated MSCs enhanced endothelial and cancer cell proliferation 
and migration, supported endothelial vessel formation and promoted tumour cell 
invasion into peri-tumoural matrix in vitro.  
 
In conclusion, this study reports prostate cancer exosomes expressing TGF-β1, to 
dominantly modulate the fate of BM-MSCs, generating cells with tumour promoting 
myofibroblastic traits. 
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1.1 Prostate cancer 
1.1.1 Aetiology and risk factors 
Prostate cancer (PCa) is now the most common cancer in men in the UK, where more 
than 41,700 men are diagnosed each year (NICE 2009). The risk factors for developing 
PCa are not well understood but age and family history have been reported as risk 
factors. A study carried out over 8 countries including the UK showed that men over 
75yrs had higher incidence than men under 50yrs (Hsing et al. 2000). Family history is 
also a risk factor for PCa, in which, hereditary PCa is estimated to account for 5-10% of 
all cases of PCa. Both meta-analysis studies and cohort-based studies have discovered 
that patients who have 2 or more relatives with PCa have a 2-3 fold higher risk of 
developing PCa in comparison to men with no family history (Zeegers et al. 2003; Carter 
et al. 1992; Cannon et al. 1982; Kiciński et al. 2011). Although the reason for this 
difference in risk is unknown, possible hypotheses have included X-linked or recessive 
inheritance. 
 
Furthermore, there is a world-wide disparity between ethnicity and the incidence of 
PCa. The risk of developing PCa was found to be highest among African-Americans, who 
were 2 or 3 times more likely to develop PCa than Caucasians. In contrast, the lowest 
risk was found amongst native Japanese and Chinese (Moul et al. 1995; Stanford et al. 
1999). Therefore race may also be a risk factor for PCa development. However this may 
be biased due to the availability and differences of screening and diagnosis methods 
among different countries (Altekruse et al. 2010; Bunker et al. 2002; Ross et al. 1998). 
Nevertheless, the variation of PCa development between the different races may be real 
and the differences may arise due to both inherited genes and environmental factors. 
Such environmental factors include diet, where Southeast Asian men typically consume 
soy products which contain PCa protective agent called phytoestrogen and this may 
contribute to the low risk of PCa among the Southeast Asian population (Barnes et al. 
2001: Goetzl et al. 2007). Thus along with major risk factors such as age and family 
history, the world-wide disparity in the incidence rates of PCa, suggests that 
environmental factors such as dietary agents may also affect the risk of PCa 
development. 
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1.1.2 Diagnosis and Treatment 
Prostate cancer has similar symptoms to other problems of the prostate, such as 
prostatitis and benign prostate hyperplasia (BPH) which is a non-cancerous enlargement 
of the prostate. Therefore, discrimination between these conditions are challenging 
(Xue et al. 2015), and accurate diagnosis is essential, as different treatments are 
required. 
 
Diagnosis 
The methods used for PCa detection is testing for abnormally high levels of prostate 
specific antigen (PSA) in serum as well as rectal examination and prostatic 
ultrasonography. PSA is a glycoprotein, specifically secreted by prostate epithelial cells 
and all men have PSA in their blood, which increases with age (Catalona et al. 1991; 
Oesterling et al. 1993). Men under 60yrs of age have PSA level of 3ng/ml which increases 
to 4ng/ml by age of 60 and a further increase to 5ng/ml for men in their 70’s and over 
(Punglia et al. 2003). A result higher than these values but less than 10ng/ml are usually 
due to benign prostatic hyperplasia (BPH). PSA levels of more than 10ng/ml can also be 
caused by BPH but are more likely to be caused by PCa (Punglia et al. 2003). The PSA 
test is still a commonly used approach for detecting PCa but is very insensitive as a study 
revealed around 15% of men with normal PSA level, actually have PCa, whereas 60% of 
men with abnormally high PSA levels do not have PCa after further investigations 
(Thompson et al. 2004). The PSA test, thus cannot solely diagnose PCa, as it only 
indicates a problem with the prostate, which may be due to BPH, prostatitis or infections 
of the prostate (McConnell et al. 1994; Selley et al.1997; Azab et al. 2012).  
 
The digital rectal examination (DRE) involves the back surface of the prostate being felt 
for an oversized prostate or any hard lumpy area which may suggest PCa. DRE has high 
specificity, as false negative test results are rare (Hoogendam et al. 1999) and so a 
combinational use of PSA test and DRE increases the overall rate of PCa detection, 
compared to either test alone  (Carroll et al. 2001; Catalona et al. 1994; Bretton et al. 
1994). The DRE is however, not very sensitive, as examination can miss early stages of 
the disease. Hence the diagnosis of PCa is further examined by taking a biopsy using the 
trans-rectal ultra sound (TRUS) needle biopsy. This procedure involves insertion of an 
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ultrasound probe containing needle through the rectum and the probe helps guide the 
needle to the prostate for tissue sample collection. The sample can then be histologically 
examined. Biopsy is the most accurate way of finding out whether PCa is present in the 
prostate gland and for classifying the stage of the cancer, if present. Samples from two 
areas are graded from 1-5, and the number of grades are added to give a Gleason score 
between 2- 10.  A higher score indicates the cancerous tissues is more aggressive and 
has a worse prognosis than those with lesser scores (Cimitan et al. 2015; Szot et al. 2014; 
Heidenreich et al. 2008). Since the location of cancer is not known, TRUS examinations 
have a low sensitivity, because the needle may sample a non-cancerous area, missing 
the cancerous lesion, resulting in a lot of “false negatives” (Catalona et al. 1994). 
Therefore, “false negatives” should not rule out cancer completely as the samples 
collected may have been from a non-cancerous region. Even though TRUS is more 
reliable than a PSA test, TRUS is not recommended as the primary screening test for PCa 
because of its low sensitivity. Prostatic biopsy is only considered when the PSA levels are 
high or DRE indicates possible PCa. Overall, the combination of PSA test, rectal 
examination, with ultrasonography is the better method for diagnosis of PCa than either 
one test alone. 
 
Current Treatments 
The treatment of PCa aims to prevent death and disability whilst minimising 
intervention-related complications. Treatment for PCa depends on the combination of 
the PSA level, age and Gleason score and every treatment is considered individually for 
men with PCa. Furthermore, cancers that are small and retained in the prostate gland 
(known as localised prostate cancer) may require different treatments to that of cancers 
that have metastasised to secondary sites (known as advanced prostate cancer) 
(Kupelian et al. 2004). The main treatments include surgery, radiotherapy and hormone 
therapy. 
 
Men with good health with localised PCa can have it removed by surgery known as 
radical prostatectomy (Murphy et al. 1994; Onik et al. 1993). Surgery is restricted to men 
with good health as there are some risk such as blood loss and infection (Gao et al. 2013) 
which may be detrimental to men with poor health. Another major problem which can 
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arise post-surgery is impotency and so radical prostatectomy may not be the best 
approach for treatment of PCa. Low level of PSA can be measured to ensure treatment 
has been successful. If PSA starts to rise again, the patient may require other treatments 
such a radiotherapy and hormone therapy. 
 
Radiotherapy is a better option for men who are not fit or well enough for surgery. 
Radiation can be used to treat localised PCa, but may also be suitable for advanced PCa. 
Patients can undergo external radiation therapy, which involves exposure of high-
energy X-rays directed to the prostate gland from outside the body (Zelefsky et al. 2002). 
This attenuates tumour growth by damaging the cancer cells. Alternatively, patients can 
be treated using a 3D conformal radiotherapy (3D-CRT). With this procedure, the 
radiation beam matches the shape of the prostate. This helps prevent damage to the 
surrounding tissues, thus reducing the side effects (Zelefsky et al. 1998). A newer and 
better approach is the intensity modulated radiotherapy (IMRT), where the beam of 
radiation matches the size, shape and position of the prostate. Intensity of the radiation 
beam can also be controlled so that the region of the prostate where cancer cells are 
accumulated will get a higher dose in comparison to the outer regions where cancer 
cells are lower. Additionally, the risk of side effects, such as bowel, urinary and erection 
problems are usually lower with IMRT than 3D-CRT (Zelefsky et al. 2002).  Another 
option is the internal radiation therapy, also known as brachytherapy (Langley and Liang 
2004), which involves implantation of radioactive seeds into the tumour in the prostate 
gland or at secondary sites. The radiation from the seeds kills the tumour cells 
(Peinemann et al. 2011; Langley and Liang 2004), however the side effects are similar to 
others, such as urinary, bowel and erectile complication (Chen et al. 2006). Lastly, 
palliative radiotherapy is suitable for advanced PCa, as a large area of the body is treated 
with radiation in one go and can also provide some relief from bone pain for example. 
 
Testosterone is an androgen hormone with multiple functions, one of which is the 
requirement for the development and function of the male reproductive system. In 
aggressive cancer, testosterone accelerates tumour growth (Xiao et al. 2003). Therefore 
orchiectomy was a popular surgical option to remove the testicles where testosterone 
is mainly released from. Orchiectomy reduces testosterone level by 90-95%, whilst the 
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rest was produced by the adrenal glands. Alternatively, androgen derived therapy using 
anti-androgen agents can be used instead to keep testosterone levels low (Shore et al. 
2013). Androgen-deprivation therapy (ADT) along with the surgery was shown to obtain 
maximal androgen blockage resulting in a greater survival, in comparison to patients 
who underwent surgery but had no hormone therapy, over 5 years of assessment in 
randomised trials (Schmitt et al. 2000). Additionally the requirement of any further 
treatment declined at 5yrs, thus combinational treatment with hormone therapy and 
surgery are beneficial (Schmitt et al. 2000). However ADT can increase adverse effects 
such as stroke (Azoulay et al. 2011) and reduction in cognitive function (Nelson et al. 
2008; Jamadar et al. 2012) and so must be taken with consideration. ADT is very 
effective in tumour regression, however such treatment results in the recurrence of 
highly aggressive and metastatic PCa that is androgen independent, making it more 
difficult to treat (Menon and Walsh 1979; Isaacs and Coffey 1981). 
 
PCa patients may undergo chemotherapy which utilises drugs like mitoxantrone, 
cabazitaxel and docetaxel, to reduce the tumour size and halt tumour progression (Bahl 
et al. 2013; Collins et al. 2006; Serpa Neto et al. 2011).  However it is not the primary 
line of treatment for patients at early stage. It is offered to patients with advanced or 
metastatic PCa patients who are not responding to hormone therapy (Doyle-Lindrud et 
al. 2012; Colloca et al. 2010). This is because there are serious side effects, such as 
bleeding, bowel problems and infection, and so it is recommended that the patient is 
healthy and fit for consideration of chemotherapy (Tipton et al. 2007; Husson et al. 
2011). Despite the advances in diagnosis and treatment, the majority of patients with 
metastatic disease are incurable.  Therefore, it remains important to understand the 
cellular biology and molecular mechanisms involved in tumour growth and metastasis, 
which may allow us to identify new targets to prevent disease progression. 
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1.2 Cancer Associated Stroma 
The prostate is composed of two compartments, an epithelial compartment which 
includes the secretory exocrine glands and the surrounding connective tissue stroma. 
Interactions between the stroma and epithelium are required for the normal 
development and function of the prostate (Sun et al. 2009). However the interaction has 
also been reported to play a crucial role in the development and progression of tumours 
and tumour metastasis (Orimo et al. 2005; Giannoni et al. 2010). Most therapeutics, 
however are targeted towards the cancer cells, but the stroma is also an important 
player in tumour progression and so targeting the stroma may be an effective 
therapeutic approach for treating cancer.  
  
1.2.1 The reactive stroma 
The stroma of the prostate is heterogeneous and consists of endothelial cells, 
fibroblasts, immune cells, nerve cells, smooth muscle cells and mesenchymal stem cells. 
The smooth muscle cells are the major stromal cell type in the normal prostate 
(Grossfeld et al. 1998). However, in prostate carcinoma, the neoplastic cells are 
surrounded by an altered stromal tissue, called the “desmoplastic reactive” tissue, but 
are also referred to as the reactive stroma. This reactive stroma is altered in comparison 
to the normal stroma, in which the interstitial smooth muscle cells are displaced by α-
smooth muscle actin and vimentin positive myofibroblasts (Tuxhorn et al. 2002) as 
shown in figure 1.1. Prostatic intraepithelial neoplasia (PIN) is considered as a precursor 
of PCa, because the frequency and incidence of PIN was found to be greater in men with 
PCa than without (Sakr et al. 1994; Sakr et al. 1999). However, similar observations by 
pre-neoplastic myofibroblasts are also seen in PIN. Therefore stromal changes are not 
secondary to tumour development, rather it can occur hand in hand with epithelial 
changes in PCa.  
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(A) 
 
 
 
 
Stromal changes from healthy to diseased stroma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.1: Smooth muscle cells are replaced by myofibroblasts.   
Healthy and cancerous prostatic specimen obtained from radical prostectomy were dual-
labelled with α-SMA (green) and vimentin (red) and analysed by immunofluorescence. The 
healthy stroma contains co-localisation (yellow) of α-SMA and vimentin only at the blood vessel 
walls. Increased co-localisation of α-SMA and vimentin, indicative of myofibroblasts was 
observed in the stroma of cancerous prostate. DAPI used to stain nuclei (blue). (A). 
Immunostaining of vimentin was observed in stromal cells adjacent to PIN (brown) (top). Dual-
labelling of fluorescence antibodies against α-SMA (green) and vimentin (red) were used to 
identify myofibroblasts (co-localisation; yellow) (bottom) adjacent to the PIN (B) X 400 
Source: Tuxhorn et al. 2002 
α-SMA Vimentin 
α-SMA 
α-SMA & 
Vimentin 
Reactive stroma in PIN 
(B) 
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1.2.2. Tumour associated myofibroblasts 
There are multiple potential cellular precursors of myofibroblasts, such as pericytes, 
smooth muscle cells (Rajkumar et al. 2005), fibroblasts (Hinz 2007; Desmouliére et al. 
1993), epithelial cells, endothelial cells, circulating fibrocytes (Abe et al. 2001; Direkze 
et al. 2003), adipose tissue derived cells and mesenchymal stem cells (McAnulty et al. 
2007; Őstman and Augsten 2009; Micallef et al. 2012). The myofibroblastic 
differentiation of fibroblasts has been studied the most, especially in the realm of 
granulation during wound healing, as illustrated in figure 1.2. Firstly, the fibroblasts 
evolves into proto-myofibroblasts which are characterised by the formation of β and ƴ 
cytoplasmic actins (Hinz et al. 2001; Kapanci et al. 1992). The stimuli to trigger this 
process is not very well understood, but mechanical tension has been shown to generate 
proto-myofibroblasts from the fibroblasts (Tomasek et al. 2002). Secondly, the proto-
myofibroblasts are stimulated to develop into differentiated myofibroblasts in response 
to transforming growth factor-β1 (TGF-β1) and extracellular matrix (ECM) components 
like ED-A fibronectin and mechanical stress (Tomasek et al. 2002). The differentiated 
myofibroblasts are characterised by the neoexpression of α-smooth muscle actin (Darby 
et al. 1990; Ronnov-Jessen et al. 1996) and the incorporation of α-SMA into stress fibres 
provides contractile features of myofibroblastic cells (Hinz et al. 2001).  
 
Functionally, the differentiated myofibroblasts can generate a greater contractile force 
than the proto-myofibroblasts for matrix remodelling. This is reflected by higher 
organisation of α-SMA stress fibres to the extracellular fibronectin fibrils via focal 
adhesion complexes (figure 1.2) (Dugina et al. 2001; Singer et al. 1984). Due to this 
connection the myofibroblasts possesses a mechanotransduction system where the 
force generated by the actin stress fibres can be transmitted to the surrounding ECM 
(Burridge and Chrzanowska-Wodnicka 1996). Once the original structure of the ECM is 
reconstituted at the wound site, the myofibroblasts may undergo apoptosis (Hata et al. 
2013) or may revert back into fibroblasts (Darby et al. 2014), but the latter has not been 
clearly demonstrated. Nevertheless, myofibroblasts are more likely to undergo 
apoptosis and be cleared by macrophages. 
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Myofibroblastic differentiation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Myofibroblast differentiation from resting fibroblasts at wound sites 
Under mechanical stress, fibroblasts can differentiated into proto-myofibroblasts, which form 
cytoplasmic actin-containing stress fibres that terminate in focal adhesion complexes. Proto-
myofibroblasts also express and organise cellular fibronectin, including ED-A fibronectin and 
these proto-myofibroblasts. Transforming growth factor-β1 (TGF-β1) can increase the 
expression of ED-A fibronectin and both factors, along with mechanical stress, can stimulate the 
proto-myofibroblasts to modulate into differentiated myofibroblasts. The differentiated 
myofibroblasts are characterised by the de-novo expression of α-smooth muscle actin in more 
extensively developed stress fibres. Once tissue-healing is complete, myofibroblasts may 
undergo apoptosis or revert back into a myofibroblasts but the mechanism behind this is 
unknown. 
Source: Gabbiani et al. 2003 
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1.2.3 Tumour associated myofibroblasts promote cancer progression 
Alterations of the stroma during tumorigenesis has led researchers to assess the role of 
stromal-epithelial interactions with regard to tumour progression.  In one experiment, 
myofibroblasts taken from invasive breast cancer patients, promoted the growth of 
breast carcinoma cells in vivo, to a much greater extent than that of normal mammary 
fibroblasts taken from the same patients (Orimo et al. 2005). In another experiment, 
myofibroblasts, taken from human prostate tumours, or fibroblasts taken from benign 
prostate hyperplasia (BPH) were administered with immortalised non-tumourigenic 
prostate epithelial cells in mice and tumour growth was assessed (figure 1.3). Tissue 
recombinants of myofibroblasts with the epithelial cells strikingly enhanced growth by 
500 times in comparison to fibroblasts with the epithelial cells (Olumi et al. 1999). 
Therefore stromal activation, resulting in enhanced myofibroblasts is recognised as a 
rate limiting step in tumour progression. Furthermore, there is a clear correlation 
between the extent of stromal changes and the clinical prognosis of various cancers. 
One example is a study conducted amongst 60 breast cancer patients with known 
prognosis. Immunohistochemical (IHC) analysis of biopsies revealed, patients with 
metastatic breast cancer to be significantly abundant in α-SMA expressing 
myofibroblasts in comparison to patients with non-invasive breast cancer (Yamashita et 
al. 2012). In another study, the stroma from prostate cancer patients after radical 
prostatectomy for clinically localised PCa was analysed by IHC, revealing a significant 
correlation between the myofibroblast phenotype and the length of disease-free period. 
Therefore, in PCa patients who have identical Gleason score, the intensity of stroma 
changes i.e. the increase in myofibroblast phenotype could identify patients with a 
higher risk of PCa relapse (Tomas et al. 2010). Similarly, the use of myofibroblasts as an  
independent prognostic factor has been shown in various other cancers including 
oesophageal adenocarcinoma, oral squamous carcinoma, colorectal cancer and 
pancreatic cancer (Underwood et al. 2015; Marsh et al. 2011; Surowiak et al. 2007; 
Tsujino et al. 2007; De Monte et al. 2011) emphasising the importance of the stroma in 
directing and influencing disease outcomes. 
 
Myofibroblasts exert tumour promoting functions by enhancing proliferation of the 
cancer cells, most likely in a hepatocyte growth factor (HGF)-dependent manner as 
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shown in hepatocellular carcinoma (Jia et al 2013), prostate carcinoma (Olumi et al 
1999) and breast carcinoma (Surowiak et al 2006). Myofibroblasts have also been shown 
to support tumour progression by enhancing angiogenesis, tumour migration and 
invasion.  
 
Angiogenesis 
Angiogenesis is the formation of new capillaries from pre-existing blood vessels and is 
essential for the growth and progression of the tumour (Reinhart-King 2008). Capillaries 
are a monolayer of endothelial cells, creating a semi-permeable barrier between the 
blood and the surrounding tissue, for the exchange of nutrients and waste products to 
and from the tumour cells (Reinhart-King 2008; Eliceiri and Cheresh 2001). Tumourigenic 
tissues exhibit abnormally high blood vessel densities in comparison to non-
tumourigenic tissues (Olumi et al. 1999; Kamoun et al. 2010; Yang et al. 2005). 
Additionally, the blood vessels were reported to increase during early tumour formation 
(Kamoun et al. 2010), indicating their importance in tumour growth. 
 
For angiogenesis to occur, endothelial cells migrate from pre-existing blood vessels, 
proliferate and reorganise with vascular smooth muscle cells and pericytes to form a 
new capillary network (Davis and Senger 2005; Lamalice et al. 2007). The process of 
angiogenesis is regulated by a balance between anti- and pro- angiogenic agents. 
Examples of pro-angiogenic factors are vascular endothelial growth factor-A (VEGF-A), 
fibroblast growth factor (FGF), hepatocyte growth factor (HGF) and platelet derived 
growth factor (PDGF) (Lamalice et al. 2007; Bouïs et al. 2006). Tumour promoting 
myofibroblasts have been reported to secrete pro-angiogenic factors such as VEGF-A 
and HGF which may aid angiogenesis at tumour sites (Webber et al. 2014; Orimo et al. 
2001).  
 
Myofibroblasts may have the capacity to induce endothelial recruitment into the 
tumour site and hence support angiogenesis for tumour progression. This assumption 
was based on studies where myofibroblasts from breast cancer stroma were able to 
mobilise endothelial cells in vitro in a Boyden transwell chamber (Orimo et al. 2005). In 
contrast non-cancerous stromal cells such as fibroblasts failed to recruit the endothelial 
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cells. The mobilisation of endothelial cells were reported to be dependent on the 
chemokine, stromal derived growth factor-1 (SDF-1) secreted by myofibroblasts, as 
shown using SDF-1 blocking experiments (Orimo et al. 2005). Furthermore, 
administration of anti-SDF-1 neutralising antibody into nude mice with breast cancer 
cells admixed with myofibroblasts greatly reduced tumour growth in vivo (Orimo et al. 
2005) and this may be due to the lack of recruitment of endothelial cells into the tumour 
site required for angiogenesis. In addition, co-culturing of diseased stromal cells from 
the prostate with endothelial cells promoted vessel-like structure formation in vitro 
(Webber et al. 2014). The diseased stromal cells were identified to be α-SMA positive, 
indicating a myofibroblast phenotype. Therefore myofibroblasts promote tumour 
progression at least in part by enhancing formation of vessels. 
 
Tumour invasion and metastasis 
The ability of cancer cells to move and invade, allows the escape of cells from the 
primary tumour site to a distant site to form a secondary tumour. Myofibroblasts are 
abundantly present at the invasive front of primary tumours, such as in colon cancer in 
vivo (De Wever et al. 2004) and are thus speculated to play a role in supporting tumour 
invasion. In vitro studies demonstrate myofibroblasts promote tumour cell invasion. For 
example, conditioned medium (CM) from myofibroblasts obtained from colon cancer 
and squamous carcinoma were found to promote invasion of the colon and squamous 
cancer cells, respectively in a collagen gel matrix (De Wever et al. 2004; Cat et al. 2006). 
In contrast, CM from standard culture media or from non-cancerous fibroblasts from 
healthy stroma of the same patients failed to support tumour cell invasion. 
Furthermore, lowering the amount of myofibroblasts, reduced the invasive capacity of 
tumour cells (Cat et al. 2006), thus the invasion of cancer cells can be directed by 
myofibroblasts. 
 
Myofibroblasts have increased secretion of hepatocyte growth factor (HGF) in 
comparison to their precursors, such as the fibroblasts. Blocking experiments revealed 
tumour cell invasion to be partially dependent on HGF (De Wever et al. 2004).  There 
are additional factors such as matrix metalloproteinases (MMPs) which may also be 
involved in promoting tumour cell invasion. MMPs are enzymes which are used by cells 
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to break down structural proteins within the ECM such as collagen, laminin, elastin and 
fibronectin (Sternlicht and Werb 2001). Conditioned medium (CM) of myofibroblasts 
derived from breast cancer contained higher levels of MMP-1 than that of normal 
fibroblasts (Boire et al. 2005). Similarly, myofibroblasts from prostate cancer were found 
to have elevated MMP-2 expression (Giannoni et al. 2010). Blocking experiments 
revealed MMP-1 is required for the motility of breast cancer cells and MMP-2 for the 
motility of prostate cancer cells in a Boyden transwell chamber (Boire et al. 2005; 
Giannoni et al. 2010). Therefore myofibroblasts provide components to support the 
motility and invasive capacity of the cancer cells, which are required for tumour 
metastasis. Giannoni and group (2010) have observed prostate cancer cells to 
metastasise to the lung when admixed with myofibroblasts in a xenograft model. This 
spontaneous metastasis was not observed, however, when prostate cancer cells were 
injected in mice alone or with fibroblasts from healthy stroma. Even though 
myofibroblasts are essential elements involved in promoting metastasis, the paracrine 
factors involved are, however poorly understood. 
 
Various studies, have shown that in comparison to normal fibroblasts, tumour 
associated myofibroblasts secrete high levels of soluble factors such as insulin-like 
growth factor-1 (IGF-1), epidermal growth factor (EGF), vascular endothelial growth 
factor- A (VEGF-A), HGF and interleukin-6 (IL-6), as shown using ELISA, 
immunohistochemistry and qPCR analysis (Webber et al. 2014; Orimo et al. 2001; Cat et 
al. 2006). These factors may participate in tumour progression by stimulating tumour 
cell proliferation, angiogenesis, tumour cell invasion and metastasis, making 
myofibroblasts essential for tumours to progress. Hence understanding the mechanisms 
involved in the generation of myofibroblasts is of great importance if we are to ever 
devise therapeutic approaches to target this rate-limiting step in disease progression. 
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Tumour associated myofibroblasts support tumour growth 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1.3: Tumour associated myofibroblasts enhance tumour growth. 
Image shows the gross appearance of tissue recombinants harvested after 85 days of growth 
in nude mice. Myofibroblasts (taken from prostate cancer) administered with prostate 
epithelial cells weighed 1250mg (Left hand side). Normal fibroblasts (taken from BPH) 
administered with prostate epithelial cells weighed 10mg (Right hand side). Scale bar; 1cm 
Source: Olumi et al. 1999 
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1.3 Transforming Growth Factor-β 
1.3.1 TGF-β1 within the reactive stroma 
The Transforming Growth Factor-β1 (TGF-β1) is a member of the TGF-β superfamily of 
cytokines. There are three isoforms of TGF-β (-1, -2 and -3) and the TGF-β1 isoform has 
been the most widely studied in the context of myofibroblastic differentiation. The 
mRNA and protein for TGF-β1 is overexpressed in many types of human cancers, 
including colon cancer (Coffey et al. 1986) and breast cancer tissues (Barette-Lee et al. 
1990) in comparison to the normal colon and breast tissues, respectively. 
Overexpression of TGF-β1 is also observed in human prostate cancer tissues, in 
comparison to the normal prostate tissue or BPH (Eastham et al. 1995; Gerdes et al. 
1998). Additionally, rat prostate cancer cells genetically manipulated to overexpress 
TGF-β1 enhanced tumour size by 50% and produced a more extensive metastatic 
disease in vivo, in comparison to the un-manipulated tumour cells (Steiner and Barrack 
1992). Therefore TGF-β1 is believed to be an essential factor for tumour progression. 
 
Similar to fibrosis at wound sites, TGF-β1 from cancer cells has been reported to drive 
the differentiation of stromal fibroblasts into myofibroblasts as characterised by the de-
novo expression of α-SMA expression. Such examples are seen in squamous cell 
carcinoma (Lewis et al. 2004) and prostate cancer (Tuxhorn et al. 2001). Moreover, 
blocking TGF-β1 signalling via the TGF-β1 neutralising antibody or inhibiting the TGF-β1 
receptor (Alk-5), resulted in attenuation of fibroblasts differentiating into α-SMA 
positive myofibroblasts (Tuxhorn et al. 2001; Webber et al. 2010).  Therefore TGF-β1 is 
important for directing the differentiation of fibroblasts into myofibroblasts. 
 
1.3.2 TGF-β1 signalling pathway 
TGF-β1, a polypeptide homodimer is secreted by cells as a large latent complex, 
consisting of dimeric propeptides called latency associated protein (LAP), which are 
bound to the latent TGF-β binding protein (LTBP) (Gerdes et al. 1998). LTBP contain 
multiple epidermal-growth-factor-like repeats as well as unique domains containing 
eight cysteine residues (8-cys domains). Immunoblotting of the protein complexes 
indicated that the third 8-Cys repeat of LTBP binds covalently to the LAP region of the 
TGF-β1 (Saharinen et al. 1996). Additionally, disulphide linkages are formed between 
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the cysteine residues of LAP and cysteine residues in the LTBP (Saharinen et al. 1996). 
Due to this interaction, the TGF-β is incapable of interacting with the TGF-β receptors as 
shown by multi-light scattering mass measurements (Shi et al. 2011). 
 
Cleavage of the bond between the LAP and LTBP is required for activation of TGF-β 
(Annes et al. 2003) and this can be accomplished by proteases, integrins, 
thrombospondin, heat and pH (Wipff and Hinz 2008; Lyons et al. 1988), most of which 
are found to be up-regulated in response to injury. Once activated, TGF-β1 triggers a 
downstream signalling pathway as illustrated in figure 1.4. Activated TGF-β1 binds to the 
serine/threonine kinase domain of the TGF-β receptor II (TGF-βR II), which in turn 
phosphorylates the TGF-β receptor I (TGF-βR I) as it forms a receptor complex with it 
(Roberts 1999). Additionally, TGF-β1 may also be presented to the TGF-β receptor II by 
the accessory protein, betaglycan (also known as TGF-β receptor III) or endoglin (De 
Crescenzo et al. 2003; Midgley et al. 2013; Guerrero-Esteo et al. 2002). The activation of 
TGFβRI phosphorylates members of the Smad family, in particular the receptor-
activated Smad protein (R-SMAD) such as SMAD-2 and SMAD-3. The phosphorylated 
SMAD-2 or SMAD-3 forms a heterodimeric complex with Co-Smad (SMAD-4) which then 
translocates into the nucleus and interacts with Smad-binding elements (SBE) in the DNA 
to regulate transcription of target genes and thus the synthesis of proteins such as α-
SMA. Therefore the active form of TGF-β1 has the capacity to differentiate stromal cells 
into α-SMA positive myofibroblasts. Various studies use the TGF-βR I (Alk-5), inhibitor 
called SB43152 to block the receptor and hence the corresponding downstream 
signalling, to investigate the TGFβ-SMAD dependent pathway involved in the 
differentiation of cells into α-SMA positive myofibroblasts (Webber et al. 2010; Gu et al. 
2012). 
 
The accessory proteins which deliver TGF-β1, can also modify the cellular response to 
TGF-β1, for example overexpression of endoglin in fibroblasts, suppressed Smad-3 
dependent activity (Leask et al. 2002). Another experiment showed the suppression of 
Smad 3 via genetic manipulation repressed the generation of α-SMA expressing 
myofibroblast in response to TGF-β1 (Gu et al. 2007). In a similar experiment, 
suppression of Smad 2 activity (phsophorylation) caused by inhibition of TGF-βR I (Nyati 
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et al. 2011) attenuated myofibroblastic differentiation of fibroblasts (Webber et al. 
2010). Thus myofibroblast differentiation is dependent on Smad 2 and 3 activity.  
 
Recently, fibroblast-to-myofibroblast differentiation in response to TGF-β1 was shown 
to be dependent on the polysaccharide hyaluronan (HA) (Webber et al. 2009) via the 
epidermal growth factor receptor (EGFR) and CD44 (Midgley et al. 2013). The EGFR and 
CD44, however, also triggers downstream mitogen-activated protein kinase (MAPK) and 
calcium-calmodulin kinase II activation (Ito et al. 2004; Midgley et al. 2013). In addition, 
knock down of these receptors, abrogates HA and attenuates the downstream MAPK 
signalling and myofibroblastic differentiation (Midgley et al. 2013). Thus other pathways 
independent of the Smad signalling, such as MAPK are also involved in the 
myofibroblastic differentiation process (Hashimoto et al. 2001; Hough et al. 2012). 
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Figure 1.4: The TGF-β driven pathway involved in myofibroblastic differentiation. 
Latent TGF-β is activated by the dissociation of LAP from LTBP in response to certain 
activators. Active TGF-β may bind to TGFBR II directly or with the aid of TGFβ-III (betaglycan). 
TGFβRII in turn phosphorylates TGFβRI, by forming heterodimerisation of the receptors. 
TGFβRI can phosphorylate receptor-associated Smads (R-Smads), such as Smad-2 and Smad-
3. The phosphorylated Smad-2,-3 forms a complex with Smad-4, a co-Smad, which 
translocates into the nucleaus and binds to Smad Binding Element (SBE) which can influence 
the transcription of target genes and thus the synthesis of target proteins. SB43152 can bind 
to the Alk-5 TGFβRI and inhibit the downstream TGF-β pathway. 
Source: Adapted from Saharinen et al. 1996; De Crescenzo et al. 2003; Shi et al. 2011 
e.g. α-SMA 
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1.4 Exosome Biology  
Exosomes are a distinct population of membranous nanovesicles of endocytic origin, 
ranging in a size from 30-150nm in diameter. They used to be regarded as “cellular 
debris” but are now seen as important communicating tools. They were first described 
to be released by rat reticulocytes maturing into red blood cells (Harding et al. 1984, 
1983; Johnston et al. 1987; Pan et al. 1985). Secretion of exosomes were later, noted in 
other cells such as B-cells (Raposo et al. 1996), dendritic cells (Zitvogel et al. 1998), 
platelets (Heijnen et al. 1999), T cells (Peters et al. 1991; Denzer et al. 2000) and tumour 
cells (Wolfers et al. 2001). Over the past few years, exosomes have been demonstrated 
to play roles fundamental to cancer and other diseases and thus study of exosomes has 
become of great interest. 
  
1.4.1 Characteristics of exosomes 
Studying the biology of exosomes is technically challenging due to many reasons such as 
their small size, variation in molecular composition and confusion in their terminology, 
resulting in exosomes being referred to as microvesicles and vice versa. Nevertheless, 
exosomes possess characteristic biophysical and biochemical properties, for example 
they have a diameter of 30-150nm, as shown by immuno-electron microscopy and 
Nanoparticle Tracking Analysis (NTA) (Escola et al. 1998; Sokolova et al. 2011; Sharma 
et al. 2010) and have a buoyant density in sucrose of 1.1-1.2g/mL (Raposo et al. 1996). 
 
The protein content of exosomes has been extensively examined from various tumour 
cells such as breast cancer (Koga et al. 2005), colorectal cancer (Choi et al. 2007), 
mammary adenocarcinoma (Wolfers et al. 2001), mesothelioma (Hegmans et al. 2004) 
and brain tumour (Graner et al. 2009). Furthermore, the exosomes studied have been 
isolated from cancer cell supernatants as well as diseased biological fluids, including 
blood-plasma (Caby et al. 2005), urine (Gonzales et al. 2009; Nilsson et al. 2009) and 
pleural effusions (Andre et al. 2002). The exosome composition has been assessed using 
methods such as western blotting, flow cytometry and immuno-electron microscopy but 
mass spectrometry (MS) is the most widely used tool to study the protein content of 
exosomes. In comparison to the early mass spectrometry (MS) used for peptide mapping 
(Théry et al. 1999 and 2001), newer MS-based proteomic tools generate peptide 
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sequence information by time of flight (TOF/TOF) which are better due to their higher 
sensitivity, resolution and mass accuracy and hence assigning a protein identification 
can be done with much greater confidence. Thus the advances in MS has significantly 
improved the depth of exosomal proteome coverage (Simpson et al. 2008). From the 
vast published and unpublished studies the proteins, lipids and RNAs found in exosomes 
have been catalogued in the ExoCarta, an online database (http://www.exocarta.org). 
Additionally, the purification method and characterisation properties are noted on the 
ExoCarta so that the researchers can assess the quality of the exosome preparations to 
that of their corresponding data shown (Mathivanan et al. 2012).  
 
From the ExoCarta database, exosomes in general have been revealed to contain 
membrane and cytosol components associated with their endosomal origin and 
exosome biogenesis. Some of which are illustrated in figure 1.5, such as the Rab 
proteins, annexins (Mears et al. 2004), tetraspanins (CD9, CD81 and CD63) (Théry et al. 
2002; Escola et al. 1998), ALIX, TSG101 and heat shock proteins (HSC70 and HSP90) 
(Théry et al. 2002). Most exosomes also contain MHC Class I molecules (Blanchard et al. 
2002; Wolfers et al. 2001) and lysosomal markers LAMP1 and LAMP2 (Denzer et al. 
2000). Some cancer cell-derived exosomes express certain cytokines and growth factors, 
such as TNFα in melanoma derived exosomes (Soderberg et al. 2007) and TGF-β in brain, 
mesothelioma and prostate cancer exosomes (Graner et al. 2009; Clayton et al. 2007; 
Webber et al. 2010). Apart from proteins, constituents of lipidic membrane like 
cholesterol and ceramide are also enriched in exosomes (Trajkovic et al. 2008; Subra et 
al. 2007; Wubbolts et al. 2003). Studies have also shown exosomes to contain both 
mRNA and miRNA (Valadi et al. 2007; Taylor and Gercel-Taylor 2008; Skog et al. 2008). 
The most common proteins found amongst exosomes are ALIX, TSG101 and 
tetraspanins (CD9, CD63 and CD81) and are routinely used as positive markers for 
exosome identification using antibody based techniques such as ELISA and western blot. 
 
Exosomes also possess some distinct sets of proteins associated with their cell of origin. 
For example, antigen presenting cells such as dendritic cells and B-lymphocytes are 
enriched in MHC Class I and II, tetraspanins (CD9, CD63 and CD81) and co-stimulatory 
molecules CD80 and CD86, indicating exosomes from antigen presenting cells contain 
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the cellular machinery required to induce a potent T-cell response (Raposo et al. 1996; 
Zitvogel et al. 1998; Théry et al. 1999, 2001; Clayton et al. 2001; Heijnen et al. 1999). In 
numerous cancer cell studies, the tumour-associated proteins and miRNA content in the 
cells were similarly expressed in their corresponding exosomes, thus exosomes may 
provide a cell-type signature for diagnostic purposes (Mathivanan et al. 2010; Skog et 
al. 2008; Rabinowits et al. 2009; Taylor and Gercel-Taylor 2008; Andre et al. 2002; Huber 
et al. 2005). All these studies, demonstrate the complexity of exosomal vesicles and 
hence their potential diverse roles as mechanistic component involved in cell-to-cell 
communication. 
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Molecular composition of exosomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Schematic representation of the some of the components found on an exosome. 
Exosomes are membrane-bounded vesicles containing various transmembrane proteins 
including integrins, tetraspanins (CD9, CD81, CD63), MHC molecules, heat shock proteins, 
growth factors and cytokines. Exosomes also encapsulate MVB-associated proteins (ALIX and 
TSG101), enzymes, Rab proteins, cytoskeletal components as well as mRNA and miRNA. 
Source: Adapted from Raposo et al 1996; Zitvogel et al 1998; Thery et al 1999; Clayton et al 2001; 
Wolfers et al. 2001; Graner et al. 2009; Clayton et al. 2007; Subra et al. 2007; Wubbolts et al. 
2003; Valadi et al. 2007 Webber et al. 2010 
Introduction 
 
24 
 
1.4.2 Exosome biogenesis and the endogenous control of their secretion 
The biogenesis and secretion of exosomes involves various molecules and is 
schematically summarised in figure 1.6. Early studies using pulse chase and immuno-
electron microscopy revealed exosomes to be contained within endosomal 
compartments, known as multivesicular bodies (MVBs) (also referred to as 
multivesicular endosomes) which then fuse to the plasma membrane to release pre-
formed vesicles as exosomes. The generation of exosomes, corresponding to the 
intraluminal vesicles (ILVs) in the MVBs involves the cargo clustering at the endosomal 
limiting membrane, the formation of inward budding of the vesicle and its release into 
the MVB. Many studies carried out in yeast revealed the endosomal sorting complex 
required for transport (ESCRT) family to be involved in the formation of MVBs. The 
ESCRTs proteins are grouped into 4 complexes (ESCRT-0, -I, -II and -III) plus accessory 
proteins and are recruited to the endosome in an ordered manner. The ESCRT-0 is 
responsible for the cargo recognition and clustering in an ubiquitin-dependent manner 
(Katzmann et al. 2003). ESCRT-0 also recruits ESCRT-I components (such as TSG101), 
which in turn recruits members of the ESCRT-II. Both the ESCRT-I and ESCRT-II induce 
the inward budding of vesicles (Katzmann et al. 2001). ESCRT-III is then recruited along 
with the accessory proteins which drive vesicular scission, as well as the disassembly and 
recycling of the ESCRT complexes (Babst et al. 2002; Katzmann et al. 2001; Jouvenet et 
al. 2011).  
 
Likewise, in eukaryotic cells such as MHC class II expressing HeLa cells, RNA interference 
(RNAi) was used to target different components of the ESCRT machinery, revealing 
exosome biogenesis and secretion to be dependent on various components of the 
ESCRT. For example, silencing of HRS and STAM (ESCRT-0 members) reduced exosome 
secretion as noted by reduction of MHC class II, CD63 and particle concentration, 
measured by fluorescence-activated cell sorting (FACS), western blotting and 
Nanoparticle Tracking Analysis (NTA) (Colombo et al. 2013). Similarly, silencing of 
TSG101 (ESCRT-I member) reduced exosome secretion and modified protein content of 
exosomes as evidenced by increased number of exosomes being negative for CD63 and 
MHC class II, suggesting TSG101 is required for targeting these cargos into exosomes in 
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HeLa cells. Thus interfering with the components of the ESCRT machinery lowers 
exosome secretion and modifies their protein composition. 
 
The ESCRT-III accessory protein, ALIX has been reported to promote the inward budding 
of vesicles in MVBs by its interaction with heparan sulphate proteoglycan (HSPG) 
syndecan-1 and the cytoplasmic adaptor syntenin (Baietti et al. 2012). Depletion of ALIX 
using siRNA, did not affect exosome secretion but increased the amount of MHC class II 
expressed on the cells and subsequently on their exosomes. Silencing of ALIX, also 
lowered the level of CD63 and HSP70, indicating that ALIX may also control the protein 
composition of the exosomes (Colombo et al. 2013). Once inward budding of vesicles is 
complete, the ESCRT complexes require energy to dissociate from the endosomal 
membrane and this energy is provided by the ESCRT-III accessory protein ATPase Vps4 
(Babst et al. 2011).  
 
Inhibiting ESCRT components does not completely block the formation MVBs (Stuffers 
et al. 2009) thus other molecules independent of the ESCRT machinery maybe involved 
such as lipids and tetraspanins. Sphingolipids such as ceramide, are synthesised by an 
enzyme called neutral sphingomyelinase (nSMase) which converts sphingomyelin to 
ceramide. Ceramide is proposed to facilitate membrane invagination of exosomes into 
MVBs and exosome secretion, as the inhibition of nSMase attenuated the biogenesis 
and the release of exosomes from glial cells (Trojkovic et al. 2008). Other studies have 
also reported the release of miRNA containing vesicles (presumed to be exosomes) to 
be dependent on ceramide (Iguchi et al. 2010; Kosaka et al. 2010). Specific lipids such as 
cholesterol are also enriched in exosomes from human dendritic cells (Laulagnier et al. 
2004) and oligodendroglia cells (Strauss et al. 2010). Drug-induced inhibition of 
cholesterol reduced the secretion of exosomes, thus cholesterol may be involved in 
exosome release. Tetraspanins expressed on exosomes may also play a role in the 
biogenesis and secretion of exosomes. Silencing CD63 using siRNA impaired vesicle 
formation by melanocytes, as noted by reduction of ILV numbers within the MVBs in 
comparison to the control melanocytes (Van Niel et al. 2011). CD81 is also enriched in 
internal vesicles of MVBs (Escola et al. 1998) and the depletion of CD81 using RNAi did 
not affect the size nor the amount of exosomes released from lymphoblasts, as 
Introduction 
 
26 
 
determined by electron microscopy and the Nanoparticle Tracking Analysis (Perez-
Hernandez 2013). However, proteomics analysis of exosomes from CD81 deficient cells, 
revealed an altered protein profile with reduced CD19 and CD20 in comparison to 
exosomes from the wild type cells. Therefore, CD81 plays a role in regulating the protein 
composition of exosomes (Perez-Hernandez 2013), emphasising exosome biogenesis 
and secretion are regulated by both ESCRT-dependent and independent components. 
 
Mechanisms that drive trafficking of MVBs to the plasma membrane involves the Rab 
family of small GTPase proteins. In a leukaemia cell line (K562), time-lapse confocal 
microscopy revealed GFP-labelled Rab11 to dock MVBs containing transferrin receptor 
and HSC70 expressing exosomes to the plasma membrane in a Ca2+-dependent manner 
(Savina et al. 2005). Furthermore, screening for GTPase in proteolipid protein (PLP)-rich 
exosomes from oligodendroglia cells revealed Rab35 to be the most abundant GTPase 
and the knock down of Rab35 impaired the secretion of exosomes-containing PLP and 
ALIX, resulting in the accumulation of PLP within the endosomes (Hsu et al. 2010; 
Frühbeis et al. 2013). Furthermore, Rab27a and Rab27b were observed to regulate 
exosome secretion in HeLa cells, in particular Rab27a, where knock down of Rab27a 
resulted in accumulation of endosomes within the cells (Ostrowski et al. 2010). The 
involvement of Rab27a in exosome secretion was later confirmed in other cancer cell 
lines such as melanoma (Peinado et al. 2012), breast cancer (Zheng et al. 2013) and 
prostate cancer (Webber et al. 2014). In these studies, depletion of Rab27a resulted in 
a reduction of exosomes within the conditioned media as determined by NTA, 
immunoblotting and protein quantification. 
 
The fusion of the MVBs with the plasma membrane to release vesicles may require 
soluble NSF Attachment Protein Receptor (SNARE) complexes, as shown in various 
models of lysosome secretion (Rao et al. 2004; Proux-Gillardeaux 2004). 
Immunofluorescence revealed, the vesicle-SNARE (v-SNARE) protein, VAMP-7 localised 
on the lysosomes, to interact with the target-SNARE (t-SNARES) such as syntaxin-4 and 
SNAP-23 on the plasma membrane, inducing fusion of the vesicle to the cell membrane 
(Rao et al. 2004). Additionally, the inhibition of VAMP-7 or SNAP-23, reduced the 
secretion of lysosomes, thus lysosome secretion is dependent on SNARE complexes 
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(Proux-Gillardeaux 2004). Whether the same interaction occurs with MVBs containing 
exosomes has not been thoroughly explored. Nevertheless, a study using a leukaemia 
cell line noted depletion of VAMP-7 to cause accumulation of enlarged MVBs containing 
acetylcholinesterase-exosomes close to the cell membrane, suggesting the fusion of 
MVB with the plasma membrane was abrogated (Fader et al. 2009). Thus the SNARE 
proteins are important for the release of exosomes. 
 
An alternate view of exosome release in certain cell types such as T cells is the direct 
budding of nanovesicles, referred to as exosome-like vesicles from the plasma 
membrane (Booth et al. 2006). The co-localisation of exosomal and endosomal 
molecules such as CD81, CD63, TSG101 and ATPase Vps4 at certain locations of the 
plasma membrane of Jurkat T cells were capable of outward vesicular budding. This 
indicates that certain regions of the plasma membrane contain elements which can 
permit exosome biogenesis and the outward budding of vesicles. Taken together, the 
biogenesis and secretion of exosomes is complex and the mechanism involved may 
differ among different cell types. 
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Biogenesis and secretion of exosomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.6: Schematic representation of the origin and secretion of exosomes. 
Exosomes are endosomal in origin (1), as they are generated in multivesicular bodies (MVBs) (2). 
The formation of MVBs has been shown to require ESCRT proteins, lipids (ceramide) and 
tetraspanins, but the role of these molecules in exosome biogenesis are unclear. The MVBs can 
either fuse with the lysosomes for degradation (3) or fuse with the plasma membrane to secrete 
exosomes into the extracellular milieu (4). Several Rab proteins (Rab11, Rab27 and Rab25) are 
known to be involved in trafficking MVB to the plasma membrane. The final step of exosome 
secretion, i.e the fusion of MVBs with the plasma membrane most probably requires the SNARE 
proteins, but is still unclear. Large vesicles such as microvesicles bud directly from the plasma 
membrane (5). Some studies report nanovesicles referred to as exosome-like vesicles to also 
possess the capacity to bud directly from the plasma membrane (6). 
Source: Adapted from Kowal et al. 2014 and Booth et al. 2006 
(1) 
(2) 
(3) 
(4) 
(5) 
(6) 
Exosome-like vesicles 
 Microvesicles 
Exosomes 
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1.4.3 Exogenous regulators of exosome secretion 
The secretion of exosomes is found to be up-regulated in cancer. For example, women 
with ovarian cancer have a greater level of circulating tumour-derived exosomes, in 
comparison to those with benign or age-matched healthy volunteers. Additionally, 
exosome concentration was found to increase with a more aggressive stage of ovarian 
cancer (Taylor and Gercel Taylor 2008). Similarly, circulating tumour exosomes were 
significantly increased in patients with adenocarcinoma in comparison to those without 
adenocarcinoma (control) (Rabinowits et al. 2009). There are many factors involved in 
the regulation of exosome secretion. Environmental factors such as stress can enhance 
exosome secretion via activation of p53 (Yu et al. 2006). Furthermore, a hypoxic tumour 
phenotype in breast cancer cell lines enhanced the release of exosomes (King et al. 
2012). This hypoxic response may be driven by hypoxia-induced factor (HIF-1α) as 
manipulating the cancer cells with HIFα siRNA attenuated the enhanced release of 
exosomes, when the cells were cultured under hypoxic conditions in vitro. 
 
Various agents can also regulate exosome secretion. The Ca2+ ionophore, A23187 
increased exosome secretion by B lymphoblast cells in a dose-dependent manner 
(Clayton et al. 2001). Other studies also reported exosome release to be induced in a 
Ca2+-dependent manner (Blott et al. 2002; Savina et al. 2003). Another ionophore, 
monensin (an Na2+/H+ exchanger) was also found to increase exosome secretion by the 
cells, possibly in a Ca2+-dependent manner as noted by accumulation of Ca2+ in 
endosomes of leukaemia cells (Savina et al. 2003). Likewise, lymphoblastoid T cells 
treated with monensin or A23187 increased exosome release in a dose-dependent 
manner, as noted by enhanced particle concentration measured by NTA and correlated 
with increased exosome associated proteins ALIX, TSG101, MHC class I (Soo et al. 2012; 
Powis et al. 2011). However, the Ca2+ ionophore, A23187 is known to induce vesicle 
release from the plasma membrane (Heijnen et al. 1999) and these vesicles may also 
express proteins similar to those found on exosomes and so analysis should be taken 
with caution. Nevertheless, some of these studies, analysed exosomal vesicles after 
isolation using a linear sucrose gradient (which will be discussed in more detail later), to 
obtain highly pure exosomal preparations (free from other non-exosomal components) 
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for analysis. This suggests that the response to calcium flux is genuinely exosomal and 
not due to a membrane-blebbing phenomenon. 
 
A recent study reported heparanase, an endoglycosidase to increase exosome secretion 
in myeloma cancer cells. To demonstrate this, the cancer cells were manipulated to 
express high or low levels of heparanase. Cells with abundant heparanase had a 6-fold 
higher amount of total exosomes secreted in the culture media, in comparison to the 
cancer cells with low levels of heparanase, as confirmed by western blotting against 
exosome-associated proteins, NTA and electron microscopy (Thompson et al. 2013). 
Heparanase cleaves heparan sulphate proteoglycan (HSPG) and so exosome secretion 
may be dependent on a specific structural feature of HSPG once exposed after cleavage. 
Furthermore, exosome biogenesis is dependent on the assembly of a complex consisting 
of syndecan-1, cytoplasmic domain syntenin and ALIX as mentioned earlier (Baietti et al. 
2012). The addition of heparanase to glioma cells was found to increase syndecan-1 
within endosomes (Gingis-Velitski et al. 2004). Thus, heparanase may regulate the 
localisation of syndecan-1 and hence promote exosome biogenesis. Lastly, exosomes 
released by cells have been reported to possess a negative feedback loop on exosome 
release by the cell and thus regulating the amount of exosome being secreted. The 
negative feedback regulation was also found to be tissue specific as the addition of 
exosomes from one cell type had no effect on the exosome secretion by another cell 
type (Riches et al. 2014). Collectively, these studies suggest various factors are involved 
in the regulation of exosome secretion by the cell. 
 
1.4.4 Methods for exosome isolation  
Exosomes have been isolated from cell culture medium or biological fluids in several 
ways based on the characteristic properties of exosomes. The most widely used method 
is differential centrifugation involving incremental increase in centrifugal forces, as 
shown in figure 1.7A, to remove cellular debris and large particles. After this 
centrifugation step, some researchers include filtration, using a 0.22μm membrane 
filters (Admyre et al. 2003). This helps remove any fragments and vesicles larger than 
200nm. Very few researchers also use 0.1μm membrane filters (Ji et al. 2008) to 
eliminate large vesicles. However, this is not ideal for viscous fluids, as the filters can 
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become easily blocked, resulting in the loss of exosomes. The final step of 
ultracentrifugation at around 100,000 x g for 1h or longer is used to pellet the exosomal 
vesicles which can then be further washed with PBS at ~100,000 x g to obtain an 
exosomal pellet, relatively free of non-exosomal components (Raposo et al. 1996; Escola 
et al. 1998; Zitvogel et al. 1998). However, an absolute separation of exosomes and non-
exosomal components is impossible by this method alone. 
 
For further purification the exosomal pellet can be centrifuged through flotation on a 
continuous sucrose gradient (0.25M to 2M sucrose) or iodixanol gradient (Opti-PrepTM) 
at 100,000 x g for around 15h or longer (figure 1.7B). This method separates molecules 
based on their density, where the exosomes equilibrate at around 1.1-1.2g/mL (Raposo 
et al. 1996; Tauro et al. 2012; Kalra et al. 2013). This approach results in a homogenous 
size population of vesicles, and eliminates contaminants such as protein aggregates and 
other non-exosomal components. However, the density-gradient is a complex and time-
consuming process. Furthermore, this procedure was found to result in a variable 
recovery of exosomes from the starting amount as measured by the levels of MHC Class 
II expression on biological fluids containing MHC Class II positive exosomes before and 
after isolation using a continuous sucrose gradient (Lamparski et al. 2002). To overcome 
this perceived problem, Lamparski and group (2002) developed a rapid method with 
high exosome recovery, which is based on ultracentrifugation of culture media or 
biological fluids containing exosomes using a 30% sucrose/deuterium oxide (D2O) 
cushion at 100,000 x g for 1h or longer, as shown in figure 1.7C. The cushion has a density 
of 1.210g/cm3, where the exosomes float in. The cushion containing exosomes is 
collected and washed at the same high speed with PBS to obtain a purer exosome 
preparation. Therefore, ultracentrifugation using the sucrose cushion is a suitable 
method of rapid exosome purification and has been used as part of an isolation protocol 
to complete phase 1 clinical trials for melanoma and lung cancer studies (Lamparski et 
al. 2002; Morse et al. 2002). 
 
Even though the density gradient approach obtains exosomes of good purity, it fails to 
isolate exosomes from contaminants such as high density lipoprotein (HDL) which have 
overlapping densities to that of exosomes (Thery et al. 2001). Thus isolation of exosomes 
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from bodily fluids such as the plasma is a challenge due to the highly abundant presence 
of HDL. To overcome this, Size Exclusion Chromatography (SEC) can be used, which 
isolates exosomes based on their size (Böing et al. 2014) and claims to separate 
exosomes from HDL. SEC such as the sepharose CL-2B resin, contains heterogeneous 
sepharose beads with numerous pores of varying sizes, resulting in sequential elution of 
vesicles size fractions which can be collected. This approach, however, is very time-
consuming to complete each run, including the set-up of the column, elution time and 
column washing. This limits the use of SEC for high-throughput exosome isolation and 
makes processing multiple samples difficult. 
 
A more simple and rapid approach for isolating exosomes is the use of immuno-affinity 
capture of exosomes by magnetic beads (Clayton et al. 2001). This involves low speed 
centrifugation at 200 x g and 2000 x g to remove cells and cellular debris. Thereafter, 
culture media or biological fluids containing exosomes are incubated for 24h with Dyna 
beads coated with antibodies directed against proteins exposed on exosomes 
membrane (Clayton et al. 2001; Rabesandratana et al. 1998; Wubbolts et al. 2003). 
Therefore it is a method of isolating exosomes without the need for ultracentrifugation. 
Using this method, antibodies against tumour specific proteins, has been used to isolate 
HER-2 expressing breast cancer exosomes (Koga et al. 2005) and A33-expressing colon 
cancer cell derived exosomes (Ritter et al. 1997; Mathivanan et al. 2010). Since biological 
fluids such as the plasma highly abundant in proteins and lipoproteins, the use of 
affinity-capture magnetic beads for exosomes isolation, lowers the chances of co-
isolation of plasma protein components, which can otherwise co-sediment with 
exosomes at high centrifugation forces using the ultracentrifugation method (Kalra et 
al. 2013). Additionally, the affinity-capture method allows isolation of exosomes from 
culture media containing exosomes from fetal bovine serum (FBS) which can also co-
sediment with exosomes prepared using ultracentrifugation. However, as well as 
benefits of this affinity-capture procedure, there are some disadvantages, such as the 
choice of exosome marker is a key issue. For example, MHC class I can be used to isolate 
MHC class I positive exosomes, however MHC Class I is also shed from plasma 
membrane as a soluble molecule, hence decreasing the efficiency of exosomes being 
captured (Théry et al. 2006). Even though capturing exosomes based on their expression 
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of a chosen protein is advantageous in many ways, it is noted that this approach may 
only isolate a subpopulation exosomes which are positive for the protein selected for 
exosome isolation (Théry et al. 2006). Thus the outcome from this may not represent 
the exosome population as a whole. Taken together, this method is ideal for routine use 
as an analytical tool to assess the phenotype of exosomes. However, this method limits 
the study of the biology of exosomes due to possible loss of function during the release 
of exosomes from the beads. Also many groups claim the method to be poorly efficient 
in the context of biological fluids and is inappropriate for isolation of large amount of 
exosomes as the beads may be fully saturated with exosomes 
 
The most recent methods developed for exosome isolation are commercialised kits of 
polymer-based precipitation, such as the Exo-QuickTM (Systems Biosciences), Total 
Exosome Isolation Kit (LifeTechnologies) and ExoSpin (Cell Guidance Systems). The 
biological sample containing exosomes are added along with the ExoQuickTM solution or 
other commercial reagents and spun at low speed centrifugation (10,000-20,000 x g), 
resulting in an exosome pellet. This method is quick and requires no ultracentrifugation 
or syringes such as those required for density gradient or column chromatography. 
Whilst these kits are less user intensive, the components claimed to be exosomes using 
reagents such as the Exo-QuickTM, however have been poorly characterised and have 
been previously reported to also precipitate non-exosomal contaminants (Oosthuyzen 
et al. 2013). Thus, it may not be an ideal method for studying exosome composition and 
function as these specimens will contain significant contaminants, and potentially alter 
the vesicles structure. 
 
Depending on factors such as source of exosomes, yield of exosome recovery and time 
required for exosome isolation, dictates the methods of choice to use. Ultimately, it is 
the sucrose cushion which is the gold standard for exosome isolation as it can isolate 
large quantities of exosomes over small period of time in comparison to other methods. 
It should also be noted that depending on the exosome isolation procedure, exosome 
preparations may have contaminants to various extent with other extracellular vesicles 
or RNA protein complexes, dramatically affecting the outcome of downstream analysis. 
Therefore, assessing the purity of exosome preparations are of critical importance to 
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demonstrate for example the outcome from experiments are due to properties of 
exosomes and not the contaminants. One way to assess purity is to measure the particle 
to protein ratio (P:P ratio) of the exosomal sample using the nanosight and a 
colourimetric assay for particle and protein concentration measurement, respectively 
(Webber and Clayton 2013). Introduction of contaminants results in a low P:P ratio, 
confirming that a higher P:P ratio, indicates a purer exosome preparation. Using this 
approach, exosomes isolated via the sucrose cushion method exhibited a much higher 
purity of exosomes preparation, in comparison to the traditional simple pellet and wash 
ultracentrifugation method. Therefore, the sucrose cushion method is robust and 
provides isolation of very pure exosomes and this is the approach employed in this 
thesis. 
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Figure 1.7: Diagram illustrates the steps involved for isolating exosomes using simple pellet and wash ultracentrifugation and the continuous sucrose gradient 
method. Flow chart shows the steps (1-5) involved for obtaining a relatively pure exosome pellet (A) which can be further purified by floatation on a continuous 
sucrose gradient at a density range of 1.1-1.2g/mL (B). 
Source: Raposo et al. 1996; Théry et al. 2006 
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Ultracentrifugation methods for isolating exosomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 continued: Diagram illustrates the steps involved for isolating exosomes using the 
30% sucrose/D2O cushion method. Step 1-3 is the same as the simple pellet and wash method 
(A) to remove cellular debris and large particles from the exosome containing sample. The 
exosome containing media is ultracentrifuged with a sucrose cushion to collect exosomes and 
the cushion is washed thereafter to obtain a highly pure exosome pellet (C). 
Source: Lamparski et al. 2002 
~100,000 x g for 1h or longer 
Collect sucrose cushion 
containing exosomes  
 
Step 4: 
Step 3: 
Culture media/bodily fluids 
Step 1-3 are the same as differential centrifugation (figure 1.7A) to 
eliminate cellular debris and large particles 
Supernatants filtered using 0.22μm 
and underlain with 30% sucrose 
cushion. 
 Sucrose 
cushion 
Exosome 
Wash in PBS and ultracentrifuge at 
~ 100,000 x g for 1h or longer 
Pellet= exosomes  
(C) 
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1.4.5 Function of exosomes in cancer 
Exosomes are known to exhibit similar function to that of their parent cell, for example, 
exosomes from antigen presenting cells such as B cells, are enriched in MHC Class II and 
have been demonstrated to be functional in antigen presentation, leading to the 
stimulation of T cell proliferation in vitro (Raposo et al. 1996). In cancer, exosomes can 
play an important role in cell-to-cell communication and appear to effect target cells by 
stimulating them directly by surface expressed ligands or by transferring molecules 
between cells. 
 
Exosomes and immune response 
Cancer derived exosomes are known to present tumour-specific antigens on their 
surface such as HER-2 in breast cancer exosomes and Mart-1 in melanoma derived 
exosomes and so cancer derived exosomes can exert an anti-tumorigenic effect via 
aiding cross-presentation. Melanoma derived exosomes have been reported to deliver 
Mart-1 to antigen presenting dendritic cells for cross-presentation to cytotoxic T 
lymphocytes (CD8+ T cells) via MHC Class I molecules (Andre et al. 2002). The activated 
T cells triggers an anti-tumour response and hence the suppression of tumour growth in 
vivo (Wolfers et al. 2001). In addition, some studies have demonstrated exosomes from 
human pancreas and colon cancer to express heat shock protein 70 (Hsc-70) which 
stimulates the cytotoxic activity of NK cells, resulting in NK-mediated apoptosis of the 
tumour cells (Gastpar et al. 2005; Lv et al. 2012). Taken together, tumour-derived 
exosomes can inhibit tumour progression by promoting both adaptive and innate 
immune responses. 
 
From numerous studies, however, tumour exosomes have been reported to exert 
immunosuppressive functions. The immune escape of tumour cells is one of the critical 
factors in preventing cancer destruction by the immune system. One such way that the 
tumour derived exosomes achieve this is by their induction of apoptosis of CD8+ T cells 
(cytotoxic T-cells). Exosomes from melanoma and prostate cancer cells express Fas-
Ligand (CD95L) which induced apoptosis of Fas positive CD8+ T cells in a dose-dependent 
manner (Andreola et al. 2002; Abusamra et al. 2005). Furthermore, blocking FasL 
abrogated this apoptotic effect by the tumour exosomes (Abusamra et al. 2005). Similar 
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apoptotic property of exosomal vesicles was reported in colorectal cancer cells (Huber 
et al. 2005) and ovarian cancer patients. Another way tumour derived exosomes act on 
the immune system in favour of the tumour cells is by blocking the proliferation and IL-
2 mediated activation of natural killer (NK) cells (Liu et al. 2006). Other studies have 
shown cancer derived exosomes to inhibit myeloid differentiation into dendritic cells 
(DCs) and instead differentiate myeloid cells into immunosuppressive cells (Valenti et al. 
2006; Yu et al. 2007; Xiang et al. 2009). The mechanisms behind this however, are not 
well understood, but exosome driven inhibition of monocyte differentiation into DCs in 
vitro correlated with an increased level of IL-6 and phosphorylated Stat3 in the 
monocyte cells (Yu et al. 2006). Furthermore, in an IL-6 knock out murine model, tumour 
exosomes were less effective at inhibiting monocyte differentiation towards DCs and 
addition of recombinant IL-6 to with tumour exosomes in the IL-6 knockout mice 
restored the tumour exosome mediated inhibition of DC differentiation. Thus exosomes 
may induce enhanced secretion of IL-6 by monocytes, which is partially involved in 
inhibition of DC generation from monocytes (Yu et al. 2006). In addition, the impairment 
of monocyte to DC differentiation has been reported to be mediated by TGF-β and 
prostaglandin-E2 (PGE2) expressed on exosomes (Valenti et al. 2006; Xiang et al. 2009). 
Neutralisation of TGF-β and PGE2 expressed on breast cancer exosomes reverses 
tumour exosome mediated inhibition of DC differentiation and subsequently promotes  
tumour growth in vivo (Xiang et al. 2009). Therefore cancer-derived exosomes direct 
escape from immune surveillance.  
 
From the range of different studies, tumour derived exosomes have therefore been 
revealed to have contradicting roles in cancer; exosomes may exert an anti-tumour 
response as well as triggering an immunosuppressive function. The conflict of the role 
exosomes play in tumour progression may be due to the fact exosomes from various 
cancers possess different phenotypes and hence differences in function are observed.  
 
Drug-resistance 
Cancer exosomes may support drug resistance and in this way help the tumour to 
progress. Ovarian cancer cells which were resistant to the chemotherapy drug cisplatin 
(CDDP) were noted to release significantly more exosomes than cancer cells sensitive to 
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chemotherapy. Thus cancer cells were speculated to release large amounts of exosomes 
in order to export the drug CDDP out of the cell (Safaei et al. 2005). Furthermore, the 
breast cancer cell line MCF-7 was manipulated to become insensitive to the 
chemotherapy agents (adriamycin or docetaxel). These drug-resistance cancer cells 
were found to spread their resistance traits, using exosomes to residual cancer cells 
which were not drug-resistant (Levchenko et al. 2005; Li et al. 2013). Pre-treatment of 
exosomes with RNase failed to make the recipient cancer cells resistant to the drugs, 
therefore the resistance traits may be exosomal RNA dependent (Chen et al. 2014). It 
should be noted however, exosomal RNA content are entrapped within the exosomal 
vesicle (Valadi et al. 2007) and so are protected from degradation by RNase. Hence, in 
these observations, the RNA components being characterised for their role in drug 
resistance are of extracellular RNA and not associated with exosomes (Grange et al. 
2011). Taken together cancer cells can use exosomes to become insensitive to drugs and 
may also use exosomes to transfer their resistance traits to other cells to make them 
resistant too. 
  
Angiogenesis 
Angiogenesis is essential for tumour growth and some studies demonstrate tumour 
derived exosomes to support angiogenesis. Exosomes express tetraspanins which have 
multiple function such as B and T cell activation, adhesion and motility of cells (Levy and 
Shoham 2005; Tarrant et al. 2003; Wright et al. 2004), but the tetraspanin CO-029 
(Tspan8) has also been implicated to play a role in angiogenesis. Tspan8 was found to 
be over-expressed in some tumour cells such as pancreatic cancer cells which correlated 
with significantly increased amount of angiogenesis in mice. Tspan8 positive exosomes 
promoted angiogenesis by favouring endothelial cell branching in vitro (Gesierich et al. 
2006). A study showed fluorescently labelled Tspan8 containing exosomes from rat 
adenocarcinoma cells to be internalised by endothelial cells, resulting in up-regulation 
of several angiogenesis related genes and proteins in endothelial cells such as urokinase 
plasminogen activator (uPA), vascular endothelial growth factor receptor (VEGFR), von 
Willebrand factor (vWF) and other factors. These changes correlated with enhanced 
endothelial proliferation, migration and endothelial branching (Nazarenko et al. 2010). 
Furthermore, exosomal vesicles from glioblastoma were observed to deliver mRNA to 
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endothelial cells which are subsequently translated to protein and promoted tubule 
formation of the endothelial cells (Skog et al. 2008).  Similarly, exosomes from colorectal 
cancer and leukaemia were found to promote endothelial proliferation and tubule 
formation in vitro (Hong et al. 2009). The transfer of miRNA-92a from exosomes to 
endothelial cells in particular, significantly decreased the expression of the adhesion 
molecule integrin α5, resulting in enhancement of endothelial cell migration and tubule 
formation (Umezu et al. 2013). Therefore tumour exosomes can act as a means to 
delivering proteins and genetic information to endothelial cells to promote angiogenesis 
and consequently tumour growth. 
 
1.4.6 Role of cancer secreted exosomes expressing TGF-β1 in reactive stroma generation 
Tumour associated myofibroblasts are known to support the progression of tumours 
(Kalluri and Zeisberg 2006; Kucharzewska et al. 2013; Tuxhorn et al. 2002). Recently TGF-
β positive exosomes secreted from cancer cells such as mesothelioma, and some PCa 
cell lines (DU145 and PC3) have been shown to differentiate normal fibroblasts (lung 
origin) into myofibroblasts, as characterised by de-novo onset of α-SMA expression 
organised into stress fibres, similar to that of an equal dose of exogenous TGF-β1 
(Webber et al. 2010). In contrast exosomes secreted from some cancer cell lines such as 
CaCo2 (a colorectal cancer), MCF-1 (breast cancer) or LnCap (prostate cancer) with low 
or undetectable levels of TGF-β1 failed to differentiate fibroblasts into α-SMA expressing 
myofibroblasts (Webber et al. 2010). Thus exosome-associated TGF-β1 was speculated 
to be involved in the myofibroblastic differentiation. Blocking TGF-β1 signalling revealed 
the differentiation of fibroblast-to-myofibroblasts to be dependent on exosome-
associated TGF-β1 by triggering signalling through the SMAD-dependent pathway 
(Webber et al. 2010) 
 
Further phenotypic analysis revealed major differences in myofibroblasts generated by 
soluble TGF-β1 (sTGF-β1) or TGF-β1 positive exosome induced fibroblasts. Such 
differences are elevation of proteins associated with angiogenesis including HGF, VEGF-
A FGF-2 and uPA in exosomal induced generation of myofibroblasts and these effects 
were inhibited by blocking TGF-β signalling. Additionally, exosome-generated 
myofibroblasts promoted endothelial migration and vessel-like structure formation in a 
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TGF-β1 dependent manner. Soluble TGF-β1 generated myofibroblasts on the other 
hand, failed to produce this pro-angiogenic function. Apart from lung derived 
fibroblasts, exosomes also differentiated non-cancerous stromal cells from the prostate 
to become pro-angiogenic akin to the diseased stroma cells in vitro. Furthermore, 
exosome generated myofibroblasts enhanced tumour growth in vivo in comparison to 
the sTGF-β1 generated myofibroblasts or tumour cells rendered deficient in the 
secretion of exosomes via Rab27aKD (Webber et al. 2014). Thus TGF-β1 associated 
exosomes from cancer cells educate the stromal fibroblasts to become tumour-
promoting, but whether exosomes can influence other precursor cells of myofibroblasts, 
such as mesenchymal stem cells has not been thoroughly explored. 
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1.5 Mesenchymal Stem Cells 
Apart from fibroblasts, another precursor of myofibroblasts are bone-marrow derived 
mesenchymal stem cells (Mishra et al. 2008), which have been reported to home to 
tumour sites and once there, the MSCs may support tumour progression (Shinagawa et 
al. 2010). Thus studying the fate of MSCs differentiation at the tumour sites may help 
understand MSCs contribution to the tumour stroma. 
 
1.5.1 Origin 
The human bone marrow (BM) is a spongy, complex tissue at the centre of bones. Their 
main job is to produce blood cells and is composed of two distinct but independent 
compartments; the hematopoietic and the stromal compartment. The stromal 
compartment consists of a heterogeneous population of cells, such as fibroblasts, 
mesenchymal stem cells (MSCs), macrophages, endothelial cells, adipocytes, 
osteoblasts and osteoclasts which provides the structural and physiological support for 
hematopoietic cells (Krebsbach et al. 1999).  
 
Mesenchymal stem cells (MSCs) are adult stem cells with the capacity of self-renewal 
and trilineage differentiation into adipocytes, chondrocytes and osteoblasts. They were 
first isolated from the bone marrow (BM) of guinea pigs in 1976 by Friedenstein and 
colleagues on the basis of their properties of adherence to plastic, spindle-shaped 
morphology and formation of fibroblasts colonies (Friedenstein et al. 1976). MSCs can 
also be isolated from various tissues such as the umbilical cord blood (Bieback et al. 
2004), synovium (Orbay et al. 2012) and adipose tissue (Fraser et al. 2006). Isolation and 
expansion of BM-MSCs involves the aspiration of BM from the iliac crest and thereafter 
MSCs are isolated by Ficoll-density gradient centrifugation. The cells are seeded on 
plastic plates and MSCs which show plastic adherence expand whilst other cells are 
washed off (Pittenger et al. 1999). Only 0.001 to 0.01% of the cells isolated from the BM 
using the density gradient were in fact MSCs (Pittenger et al. 1999). In contrast, MSCs 
isolated from adipose tissue using liposuction and the gradient method, obtained 500 
times more MSCs in comparison to the BM (Fraser et al. 2006; Kitagawa et al. 2006). 
Thus there are far more MSCs in the adipose tissue but it is the BM-derived MSCs that 
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are the most frequently investigated cell type and are often designated as the gold 
standard MSC source for studying MSC biology. 
 
1.5.2 Classifications of MSCs: lack of stringent MSC definition 
Researchers use different approaches to characterise MSCs, making it difficult to 
compare and contrast study outcomes. To solve this problem, the International Society 
of Cellular Therapy (ISCT) has set a minimal criterion for defining MSCs. Firstly, the MSCs 
must be plastic adherent when maintained in standard culture conditions. Secondly, the 
MSCs must express a varied repertoire of cell surface markers, such as CD44, CD73, 
CD90, CD105 and must be negative for hematopoietic markers CD14 and CD45. Thirdly 
and most importantly, MSCs must differentiate into osteoblasts, adipocytes and 
chondrocytes in vitro when cultured with the appropriate stimuli (Dominici et al. 2006). 
Unfortunately, the current definition suggested by the ISCT is incapable in distinguishing 
MSCs to other stromal cells such as fibroblasts, as they also express similar molecular 
repertoire (Alt et al. 2011; Gang et al. 2007). Fibroblasts do not differentiate into 
osteoblasts, adipocytes and chondroblasts under the same conditions. However, 
fibroblasts are known to have a degree of plasticity and can for example be driven to 
differentiate towards possessing adipocytic features (Feldon et al. 2006; Kuriyan et al. 
2013). Therefore one of the obstacles to MSC research is the lack of unique markers for 
MSC identification. This makes it a challenge to identify MSCs as a contributor within the 
reactive stroma at tumour sites.  
 
Recently, the glycoprotein, stage specific embryonic antigen 4 (SSEA-4) and ganlioside-
2 (GD-2) which are usually found to be expressed in embryonic stem cells have also been 
discovered to be expressed in the BM-derived and adipose-derived MSCs, respectively 
(Gang et al. 2007; Martinez et al. 2007). Additionally, GD-2 expression was absent in 
foreskin fibroblasts. Even though, the function of these antigens are not very well 
understood, SSEA-4 and GD-2 may be associated with a multipotent function and hence 
may be able to distinguish MSCs from other stromal cell types. Furthermore, MSCs 
isolated from different sources share considerable degree of overlap in their surface 
expression profile, but they are known to have variations in the pattern and level of 
expressions at different times of culture. For example, adipose-derived MSCs initially 
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express CD34 but this marker is lost after culturing over time (Djouad et al. 2005). Other 
than variation in expression level of cell surface markers, there are currently no unique 
markers for absolute discrimination of MSCs according to their tissue of origin and from 
other stromal cell types.  
 
1.5.3 Multipotent differentiation capacity 
MSCs can self-renew and have the capacity to differentiate into a variety of tissue types 
of mesodermal lineages such as osteoblasts (Ogura et al. 2004), adipocytes (Qian et al. 
2010) and chondrocytes (Song et al. 2007) when cultured under appropriate conditions. 
The osteogenic differentiation of MSC is divided in three stages. The first is MSC 
proliferation for around 4 days, followed by early cell differentiation which can take up 
to 14 days. The early osteogenic differentiation is characterised by the transcription and 
protein expression of alkaline phosphatase (Aubin et al. 2001) and the expression of 
collagen type I (Quarles et al. 1992). The final stage from days 14-28 results in a full 
osteogenic differentiation as observed by a high expression of osteopontin and 
osteocalcin and the deposition of calcium and phosphate (Huang et al. 2007; Hoemann 
et al. 2009). Similarly the adipogenic differentiation, characterised by the formation of 
lipid droplets and the chondrogenic differentiation identified by cartilage-specific 
extracellular matrix (such as aggrecan and collagen type II), take around 21 days to 
complete (Pittenger et al. 1999; Barry et al. 2001). Therefore the differentiation of MSCs 
into another cell type is a slow process. 
 
The differentiation of MSCs in vitro are totally dependent on culture conditions. Growth 
factors, such as the TGF-β family are essential for chondrogenic differentiation, and TGF-
β along with dexamethasone, an anti-inflammatory steroid molecule are required for 
the osteogenic differentiation (Mackay et al. 1998; Jaiswal et al. 1997; Barry et al. 2001). 
Whereas MSCs differentiate into adipocytes when cultured with dexamethasone, 
isobutyl methyl xanthine, insulin and indomethacin (Pittenger et al. 1999). Thus there 
are some overlaps in culture conditions for the tri-lineage differentiation pathway of 
MSCs. 
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1.5.4 MSCs as a therapeutic tool 
The biological properties of MSCs provides beneficial use as therapeutic tools for 
various medical conditions. 
 
Multi-lineage differentiation capacity 
The multipotent capacity of MSCs has led to their use in regenerative medicine such as 
tissue engineering, where MSCs have been used in bone and cartilage repair, in 
osteogenesis imperfecta (OI) and osteoarthritis, respectively (Horwitz et al. 1999; Gupta 
et al. 2012). Due to their regenerative and their multi-lineage differentiation capacity, 
MSCs are also an attractive candidate for cardiovascular repair. Preclinical trials have 
shown MSCs to engraft and improve cardiac repair after administration (Zhang et al. 
2006; Jiang et al. 2006; Nagaya et al. 2005). Furthermore, a randomized pilot study has 
shown patients with acute myocardial infarction (MI) who received BM-MSCs to have 
an improved cardiac function in comparison to those who received standard saline as 
controls (Chen et al. 2004). Following this study, MSCs have been used to treat both 
acute and chronic MI, with significant improvements in cardiac function (Yang et al. 
2010). 
 
Immunosuppressive property 
MSCs are immunosuppressive, but the mechanisms behind this are still being 
investigated. Many studies report MSC-mediated immunosuppression via inhibition of 
immune cells such as T cells (Di Nicola et al. 2002; Bartholomew et al. 2002; Glennie et 
al. 2005; Augello et al. 2005 and Le Blanc et al. 2003) where increasing the dose of MSCs 
resulted in a greater decline in T-cell proliferation (Bartholomew et al. 2002). 
Furthermore, production of molecules by the MSCs, such as indoleamine 2,3-
dioxygenare (IDO) and nitric oxide were up-regulated following cross-talk with T-cells, 
resulting in the inhibition of T cell proliferation (Meisel et al. 2004; Maby-El Hajjami et 
al. 2009; Sato et al. 2007). Additionally, MSCs secretion of prostaglandin E2 (PGE2) 
suppressed the differentiation of monocytes to dendritic cells, another immune cell type 
which are responsible for antigen presentation to T-cells (Aggarwar and Pittenger 2005; 
Németh et al. 2009; Spaggiari et al. 2009). Therefore various secreted factors by the 
MSCs provide an anti-immune response. 
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Based on the immunosuppressive property of MSCs, they have been proposed as a 
treatment for autoimmune diseases such as graft-versus-host disease (GVHD). GVDH is 
a severe inflammatory condition that results from immune-mediated attack of recipient 
tissues by donor T cells following an allogeneic transplantation for the treatment of 
malignant and non-malignant disorders (Vianello and Dazzi 2008). The clinical efficacy 
of MSCs in acute GVDH was first observed in a 9-year old boy with acute GVHD (Le Blanc 
et al. 2004). The patient, who was unresponsive to other therapies, showed a complete 
response after receiving donor MSCs. Following this pilot study, MSC treatment has 
been studied extensively in steroid-refractory/acute GVDH (Le Blanc et al. 2004; Fang et 
al. 2006; Le Blanc et al. 2008; Wu et al. 2011). 
 
Delivery vehicles 
Gene therapy involves the introduction of functional genes into the body and human 
BM-MSCs has been an attractive cellular vehicle for gene delivery applications because 
of their capacity for multi-lineage differentiation and ex vivo cell expansion. This makes 
it possible to greatly broaden the spectrum of diseases for which MSCs could provide 
therapeutic benefit. Gene therapy has been used to engineer MSCs, by the use of 
lentiviral vectors to enable MSCs to augment their own natural production of a specific 
desired protein or to produce proteins outside of their native repertoire (Morizono et 
al. 2003).  
 
Using such approaches, MSCs can be used for cancer gene therapy due to their inherent 
migratory abilities toward tumours (Wang et al. 2009). MSCs have been genetically 
modified to overexpress various anticancer genes, such as interleukins (ILs), interferons 
(IFNs) and prodrugs which are anti-tumorigenic (Gao et al. 2010; Seo et al. 2011; Studeny 
et al. 2002; Ren et al. 2008; Miletic et al. 2007; Cavarretta et al. 2010). Even though 
preclinical models using gene-modified MSCs for the treatment of cancer have been well 
studied, clinical trials utilising engineered MSCs for cancer therapy have not yet been 
reported. Prior to clinical use the safety of MSC administration needs to be thoroughly 
explored, even though MSC administration has not yet shown any major adverse events. 
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Collectively, the multi-lineage differentiation capacity and immunosuppressive property 
of MSCs provides various beneficial functions in tissue engineering and regenerative 
medicine. 
 
1.5.5. Migratory property: MSCs can migrate at tumour sites 
One of the most remarkable but least understood finding is the ability of MSC to migrate 
from the bone marrow (BM) or peripheral blood into damaged tissues. Systemic 
administration of MSCs in mice and in patients demonstrated that MSCs migrate to sites 
of injury or disease where they enhance wound healing (Fu et al. 2009; Wu et al. 2007) 
or support tissue regeneration, for example in patients with myocardial infarction 
(Kawada et al. 2004). Multiple studies have used fluorescent dyes to show that BM-MSCs 
home to and contribute to the tumour stroma such as the colon, breast and prostate 
cancer (Shinagawa et al. 2010; Quante et al. 2011; Jung et al. 2013). However, for MSCs 
to reach their target tissues, they must be able to cross the endothelial barrier twice: 
once to enter and then again to leave the vascular system.  
 
Transmigration 
One of the first attempts to show transendothelial migration of MSC was by Schmidt et al 
(2006) who utilised isolated mouse heart perfusions with gold-labelled MSCs. Electron 
microscopy detected abolishment of tight cell-cell contacts in-between the endothelial cells 
upon MSC contact. In a later study using human lung and cardiac endothelial cells, time-
lapse and confocal microscopy demonstrated MSCs expressing the cognate receptor very 
late antigen-4 (VLA-4) specifically binds to the adhesion molecule, vascular cell adhesion 
molecule-1 (VCAM-1) on endothelial cells. This resulted in a split between the endothelial 
cells, allowing MSCs to develop cell contacts and integrate across the endothelial layer (Teo 
et al. 2012; Schmidt et al. 2006; Steingen et al. 2008 and Matsushita et al. 2011).  
 
Factors involved in MSC migration and invasion 
Inflammatory cytokines have been suggested to mobilise MSCs from the bone marrow, as 
the concentration of cytokines increases during injury and other disease processes, which 
coincides with increase in MSCs within the circulation (Hong et al. 2009; Wang et al. 2008). 
Tumour-associated myofibroblasts secrete stromal-derived growth factor-1 (SDF-1) and 
matrix metalloproteinase (MMPs) proteolytic enzymes which may be involved in homing of 
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MSCs (Hong et al. 2009; Klopp et al. 2007; Orimo et al. 2005), but have not been investigated 
thoroughly in vitro or in vivo.  
 
The invasion of MSCs into the surrounding tissues requires MSCs to penetrate the basement 
membrane that separates the endothelium from the tumour stroma. The basement 
membrane is a specialised form of extracellular matrix (ECM) consisting of collagen fibres, 
laminin and proteoglycans. For MSCs to overcome this barrier and recruit into the stroma, 
pronounced secretion of MMP-2 by MSCs, in response to inflammatory cytokines (TGF-β1, 
IL-1β and TNF-α), has been reported to play a key role in the degradation of the ECM in vitro 
(Reis et al. 2007). Furthermore, silencing the enzyme using RNA interference, impaired their 
supportive function in promoting MSC invasion. Therefore, MMP-2 supports the invasion of 
MSCs and other MMPs as well as growth factors which have not been investigated as 
thoroughly, may also be involved. 
 
1.5.6 MSCs at the tumour site 
Anti-tumorigenic 
Some studies have shown MSCs which home to the tumour site, have an anti-
tumorigenic effect. For example, intravenously injected MSCs migrated to kaposi’s 
sarcoma (KS) in vivo and inhibited tumour growth in a dose-dependent manner (Khakoo 
et al. 2006). Examination of the interaction between the MSCs and KS were explored in 
a co-culture system in vitro. MSCs were found to inhibit the activation of the protein 
kinase, Akt, which is a critical mediator of KS tumour cell proliferation and survival 
(Khakoo et al. 2006). Similar anti-tumorigenic effect of MSCs were observed with 
hepatoma model in vivo (Qiao et al. 2008), again possibly through an anti-proliferative 
effect on the tumour cells. Furthermore, MSCs in a mouse melanoma model in vivo 
inhibited tumour growth, most likely via inhibition of angiogenesis. Assessment of the 
interaction of MSCs and endothelial cells in vitro revealed MSC-mediated apoptosis of 
the endothelial cells in a dose-dependent manner and hence destruction of capillary 
formation (Otsu et al. 2009). The MSC-mediated apoptosis, was associated with the 
production of MSC-derived reactive oxygen species (ROS), as the anti-oxidant NAC 
attenuated the increased release of MSC-derived ROS and hence reduced the damage 
to the capillary formation. Together, these results indicate that MSCs potentially possess 
cytotoxic properties and can supress angiogenesis and hence inhibit tumour growth. 
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Pro-tumorigenic 
Whether or not MSCs themselves exhibit an anti-tumorigenic effect is still controversial 
as a lot of studies report MSCs to promote tumorigenesis and metastasis in various 
cancer models such as colon, breast, pancreatic and skin cancer in vivo (Djouad et al. 
2003; Karnoub et al. 2007; Zhu et al. 2006; Direkze et al. 2004; Quante et al. 2011). MSCs 
mixed with weakly metastatic human breast carcinoma cells in a mice, increased the 
metastatic abilities of cancer cells into the lung (Karnoub et al. 2007). Inhibition of the 
chemokine, CCL5 protein expression using short hairpin (sh)RNA revealed the MSC-
induced metastasis was dependent on CCL5 released from MSCs and not from the 
cancer cells (Karnoub et al. 2007). Furthermore, MSCs in vitro exhibited 
immunosuppressive property, as shown by their inhibitory effect on T-cell proliferation 
in a dose-dependent manner. This immunosuppressive effect of MSCs was shown to 
increase tumour growth when MSCs were co-injected with melanoma cells in mice, in 
comparison to the administration of tumour cells alone (Djouad et al. 2003). These 
studies, therefore suggest MSCs to provide factors to support migration and escape 
from the immune system and hence aids tumour progression.  
 
Moreover, studies have reported MSCs to contribute to the tumour stroma as α-SMA 
positive myofibroblasts. One such studies revealed approximately 25% of α-SMA 
positive myofibroblasts in pancreatic tumours to be green fluorescent protein (GFP)-
labelled donor-derived BM-MSCs (Direkze et al. 2004). Similar was also observed in a 
gastric cancer mice model (Quante et al. 2011; Gu et al. 2012), confirming that MSCs do 
contribute to the tumour stroma as myofibroblasts. Furthermore, these myofibroblasts 
were found to still hold the capacity to differentiate into adipocytes and osteoblasts 
once isolated from the gastric cancer stroma in vivo and cultured under the appropriate 
conditions (Quante et al. 2011). This indicates that MSCs still retain their multi-potency 
function after myofibroblastic differentiation.  
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1.5.7 Cancer exosomes may be involved in MSC differentiation into myofibroblast-like 
cells 
Human BM-MSCs cultured with breast cancer conditioned media differentiated into α-
SMA positive myofibroblast-like cells and promoted tumour growth in vivo (Mishra et 
al. 2008). However, the molecular factors secreted by the cancer cells, responsible for 
driving this particular differentiation programme remain incompletely understood. 
Similar to our observation with fibroblasts (Webber et al. 2010), some recent studies 
have pointed a potential role of cancer cell secreted exosomes in driving the 
myofibroblastic differentiation of MSCs. Such experiments reveal, exosomes from 
gastric cancer and breast cancer to differentiate human umbilical cord derived and 
adipose derived MSCs into α-SMA positive myofibroblasts, respectively (Gu et al. 2012; 
Cho et al. 2012). However, these experiments failed to successfully show the mechanism 
involved in this exosome-driven differentiation. Exosome treated MSCs were noted to 
have a small increase in phosphorylated SMAD-2/3 in comparison to the untreated MSCs 
and this effect was reduced with the TGF-β receptor inhibitors, indicating a TGFβ-SMAD 
dependent pathway may be involved, similar to that of exosome-mediated fibroblast-
to-myofibroblast differentiation. However, whether the breast and gastric cancer 
exosomes express TGF-β and whether the expression of α-SMA stress fibres in the 
differentiated MSCs are attenuated by the blockage of TGF-β signalling was not shown. 
Thus the mechanism involved in the exosome-mediated generation of myofibroblasts 
from MSCs remains unknown. Furthermore the current studies lack information 
regarding the time and dose of exosome required to differentiate MSCs into α-SMA 
positive myofibroblasts. An important aspect, which has yet to be investigated, is the 
phenotype and function of myofibroblasts derived from MSCs exposed to exosomes. We 
know that α-SMA does not define the tumour promoting features of myofibroblasts, as 
α-SMA positive myofibroblasts generated from fibroblasts induced by cancer exosomes 
or sTGF-β have distinctive functions, in which the exosome generated fibroblasts are 
tumour-promoting (Webber et al. 2014). Thus a lot is unknown regarding the 
differentiation of MSCs into myofibroblasts and subsequently their role, if any in tumour 
progression. 
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1.5.8 Study Aims 
In this thesis, we address the hypothesis that prostate cancer exosomes expressing TGF-
β1 exert an influence on BM-MSCs, capable of modulating their differentiation towards 
tumour-promoting stromal cells. 
 
In order to investigate this, the major aims of the thesis are to: 
1. Assess the phenotype of BM-MSCs, following their exposure to prostate cancer 
exosomes expressing TGF-β1. 
2. Investigate the effect of exosome-differentiated BM-MSCs in modulating the 
behaviours of endothelial and tumour cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
 
52 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Materials and 
methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods and materials 
 
53 
 
2.1. Culture of human cells 
2.1.1 Monolayer culture 
Prostate cancer DU145 or PC3 cell lines were purchased from ATCC and the cells were expanded 
into bioreactor flasks (Integra, Nottingham, UK). The cells were cultured in RPMI 1640 (Lonza, 
Wokingham, UK), supplemented with penicillin (100 U/ml) and streptomycin (100 μg/ml) and 
10% foetal bovine serum (FBS). Bovine derived exosomes were removed from FBS by 
ultracentrifugation at 100,000 g for 24h, followed by filtration through 0.2 μm and then 0.1 μm 
vacuum filters, (Millipore, Watford, UK).  For some experiments DU145 rendered deficient in 
Rab27a using a ribozyme or the lentiviral shRNA knockdown method, were used (Webber et al. 
2014). Human bone marrow MSCs were purchased from Promocell and expanded according to 
the supplier’s instructions using Promocell culture media, with their supplement mixture. For 
differentiation experiments the expansion culture medium was replaced by DMEM-low glucose 
(Lonza) with 10% MSC-optimised FBS (also rendered exosome depleted as above). All 
experiments were conducted with early passage MSC (up to passage 5). Adult lung fibroblasts 
(Coriell Institute for Medical Research, USA) were cultured in DMEM/F12 (Lonza) containing 
penicillin/streptomycin and 10% exosome depleted FBS (Life technologies). Human umbilical 
vein endothelial cells (HUVEC) were purchased from Lonza, and maintained using the EBM2-
bullet kit. For functional assays, these additional growth factor supplements were withdrawn for 
the duration of the experiments. 
 
2.1.2 Bioreactor flasks for prostate cancer cell lines 
DU145 or PC3 cells were seeded into bioreactor flasks (Integra, Nottingham, UK), and 
maintained at high density culture for exosome production. These flasks have two 
compartments; a cellular compartment and a nutrient medium compartment (figure 2.1) which 
are separated by a semi-permeable membrane. The membrane provides exchange of nutrients 
from medium to the cells and removal of waste products from the cells, into the outer 
compartment. The exosomes secreted by the cancer cells are retained in the cellular 
compartment (can hold up to volume of 20ml). Since the cells are maintained at higher density 
compared to T75cm2 flasks, exosomes can therefore be purified from small volumes at high 
yields in comparison to T75cm3 culture flasks. The exosome yields from bioreactor flasks can be 
8-10 times greater than traditional T75cm3 culture flasks (Mitchell et al. 2008).  
 
The culture media (CM) from bioreactor flasks containing prostate cancer cells were removed 
and replaced with fresh media on a weekly basis. The CM from prostate cancer cells containing 
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exosomes (from the cellular compartment) were centrifuged at 400 g, 4oC for 10 min, followed 
by and additional spin at 2000 g for 15 min to remove dead cells and cellular debris. The 
supernatant was collected and filtered using a 0.22μm filter (MILLEX GP Filter), to remove any 
remaining debris and larger vesicles. The supernatant was stored at -80oC until required for 
exosome purification. 
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Bioreactor flask 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Figure 2.1: Bioreactor flask. 
The cell compartment containing exosomes are separated from the medium compartment by a 
10kDa semi-permeable membrane. The membrane allows a continuous diffusion of nutrients and 
waste products between the two compartments. The silicone membrane at the base of the cell 
compartment ensures an efficient gas transfer. 
Source: Adapted from Integra CELLineTM website 
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2.2 Isolation and characterisation of exosomes 
2.2.1 Continuous sucrose gradient 
To characterise exosomes based on their classical density range of 1.1-1.2 g/ml, the 
continuous sucrose gradient was used. To do this, pre-cleared DU145 and PC3 
conditioned media (CM) stored at -80oC were defrosted at 37oC. The CM were 
centrifuged at 120,000 x g for 40 min (4oC) in a fixed-angle TLA110 rotor using Optima 
max ultracentrifugation (Beckman Coulter) to obtain an exosomal pellet. The pellet was 
resuspended in a small volume of PBS (200μl) and overlaid on top of a continuous 
sucrose gradient (0.2M-2.5M) in a polyallomer centrifuge tube (Beckman Coulter). The 
continuous sucrose gradient was produced using a gradient maker, consisting of two 
chambers (Hoefer S614, GE BioScience). One chamber was filled with 0.2M sucrose 
solution and the second chamber with 2.5M sucrose solution. The exosome-loaded 
gradient was ultracentrifuged (using the Optima-Max ultracentrifuge) at 210,000 x g 
with a swing out rotor (MLS-50) for 18h at 4oC. Additionally, a second gradient was made 
to provide a balance during the spin.  
 
Fractions of 330μl were collected carefully from the top to the bottom of the gradient, 
in which a total of 14-15 fractions were obtained. The refractive index of each fraction 
and from this, the density was calculated as described previously (Raposo et al. 1996), 
using the conversion table provided by Beckman Coulter- the relationship between 
density and refractive index is linear. 
 
2.2.2 Sucrose cushion method 
For all experiments, unless otherwise stated, the exosomes were isolated from their 
conditioned medium (CM) using the sucrose cushion method which is a much shorter 
technique for isolating exosome in comparison to using the continuous sucrose gradient. 
The sucrose cushion method involved defrosting the pre-cleared DU145 or PC3 CM 
which were stored at -80oC. The CM underwent ultracentrifugation at 10,000 g for 1.5h 
4oC as an additional clearing step (Optima LE80K Ultracentrifuge, Beckman Coulter, High 
Wycombe, UK). The CM was underlain with a 4ml cushion of 30% Sucrose/ deuterium 
oxide (D2O) (density of 1.2g/ml), and subjected to ultracentrifugation at 100,000 g (with 
a SW32 rotor, Beckman Coulter) for 2h at 4oC. Around 2ml of centre most part of the 
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sucrose cushion was collected and washed by dilution in excess PBS and spinning at an 
additional 100,000 g using a fixed angle rotor to obtain an exosome pellet (70Ti rotor, 
Beckman Coulter). The exosome pellet was resuspended in 50-150μl PBS and stored at 
-80oC until required for experimental use. Thus in total, exosomes have been frozen and 
thawed twice before their use in experimental studies. 
 
The protein concentration of the exosome sample was evaluated using the microBCA 
protein assay (Thermo Scientific, Loughborough, UK). A standard curve was performed 
by serial dilution of 2000μg/ml BSA to 0μg/ml. Exosome samples were diluted 1:8 with 
PBS and absorbance values were extrapolated from the standard curve to calculate the 
protein concentration. Unless stated otherwise, purified DU145 exosomes and PC3 
exosomes were used in BM-MSC differentiation experiments at a dose of 150μg/ml and 
75 μg/ml respectively which is equivalent to a dose of 1ng/ml sTGF-β1 as described 
previously (Clayton et al. 2007; Webber et al. 2010). 
 
2.2.3 Nanoparticle Tracking Analysis 
The Nanoparticle Tracking Analysis (NTA) visualises and analyses nanometre particles in 
liquids from 10-2000nm. The size of the particles are related to the rate of Brownian 
motion, temperature and the viscosity of the liquid. Each exosome preparation was 
taken and particle counts and size distribution was determined using NTA (NanoSight 
Ltd, Amesbury, UK). The instrument was configured with a 488nm LM14 laser module 
and a high sensitivity digital camera system (OrcaFlash2.8, Hamamatsu C11440, 
NanoSight Ltd, Amesbury, UK). Six replicate videos of 30s were taken at 25oC, with 
samples under controlled flow (with the syringe pump speed set to 80), and batch-
analysed using NTA-software (version 2.3), with the minimal expected particle size set 
to automatic, and camera sensitivity set at 14-16 and detection thresholds set to 1-3, to 
reveal small particles. Samples were diluted in clinical water, free of particles (Fresenius 
Kabi, Runcorn, UK) to a concentration between 2x108 and 9x108 particles/ml within the 
linear range of the instrument. Prior to analysis of exosomal samples, 100nm standard 
latex beads were tested as a control to confirm the NTA measurements are accurate. 
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The estimated purity of exosomal samples was determined using particle to protein ratio 
(P:P) (P/μg) as described previously (Webber and Clayton 2013). The protein and particle 
concentration were measured by the BCA assay and Nanosight, respectively and used 
to calculate the P:P ratio. Webber and Clayton’s study (2013) involved the isolation of 
exosomes using different methods with or without incremental doses of contamination. 
 
This led them to propose an arbitrary threshold, in which ratios greater than 3x1010 P/μg 
are of high purity, ratios of 2 x 109 to 2 x 1010 P/μg represent low purity and ratios below 
1.5 x 109 P/μg are unpure. In this thesis, these arbitrary thresholds were used to 
estimate the purity of exosomal preparations. 
 
2.2.4 Cryo-Transmission Electron Microscopy  
The morphology of exosomes were examined using a cryo-transmission electron 
microscopy (cryo-TEM) in collaboration with Dr. Georgi Lalev (Cardiff University). DU145 
and PC3 exosome pellets purified using the 30% sucrose/D2O cushion method were 
resuspended in PBS (at a dilution of 1:10,000). 1μl of the exosomal sample was applied 
onto a carbon grid (JEOL) and blotted with filter paper to remove excess fluid. The 
specimen grid was then rapidly plunged into liquid ethane that has been pre-cooled to 
liquid nitrogen temperature (-175oC) to prevent the formation of ice crystals. The 
specimen grid was transferred into a cryo holder and inserted into the JEM-2100 LaB 6 
cryo-TEM (JEOL, Peabody, MA, USA) to view nano-sized particles present within the 
sample using the JEOL TEMographyTM software system. This method currently remains 
incompletely optimised at Cardiff University, and this is ongoing and being undertaken 
by the group. 
 
2.2.5 Microplate-immuno-phenotype assay 
Purified exosomes were diluted in PBS and immobilised onto high protein binding ELISA 
strips (Fisher) at a dose of 1μg/well and incubated overnight at 4oC. The exosome wells 
were washed 3 times using PBS, to remove unbound particles. Following 2h blocking (1% 
BSA/PBS w/v), primary monoclonal antibodies (mAbs) were added at 2µg/ml, for 1h at 
RT, including; anti-CD9 (R&D Systems), CD81, CD63 (Serotec), MHC Class-I (eBioscience), 
PSCA (Santa Cruz), GAPDH and isotype (IgG1 and IgG2b) control (eBiosystems). After 
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washing wells with 0.1% BSA/PBS (w/v) the primary mAbs were detected by goat anti-
mouse biotinylated antibody (Perkin Elmer) (diluted in 0.1% BSA/PBS (w/v) in a 1:5000 
dilution) for 1h RT. Signal was assessed by adding Europium-streptavidin conjugate 
(Perkin Elmer), for 40min at RT. The wells were washed 6 times and enhancement 
solution (Perkin Elmer) added for 10min and signal assessed by time-resolved 
fluorimetry on a Wallac Victor-II multi-label plate reader (Perkin Elmer). 
 
2.2.6 Cell lysates and western blotting 
Lysates of exosomes (purified from the sucrose cushion) or whole cells (1x106 cells) were 
prepared by resuspending in RIPA buffer containing 1X protease inhibitor cocktail (Santa 
Cruz). To remove insoluble materials, the samples were centrifuged at 10,000 g for 10 
min (4oC), split into aliquots and stored at -80oC. Protein concentration was determined 
by Bradford protein assay (BioRad, Hertfordshire, UK). 
 
Cell lysates (10μg) and exosomes (10μg) were boiled in SDS sample buffer (Invitrogen), 
either reducing with the addition of 20mM Dithiothreitol (DTT) or under non-reducing 
conditions. Samples as well as molecular weight markers (Precision Plus ProteinTM 
Standards, Invitrogen) were subjected to electrophoresis for 1h on NuPAGE precast 4%-
20% Bis-Tris gradient gels (Invitrogen). The gels were run using 1x NuPAGE MOPS SDS 
running buffer (Invitrogen) and Invitrogen PowerEaseTM 500 power supply. Proteins 
were transferred to a methanol-activated PVDF membrane (GE Healthcare) using 25mM 
Tris, 192mM glycine (both Sigma) and a BioRad Mini Trans-Blot Electrophoretic Transfer 
Cell (BioRad Laboratories Inc, Hemel Hempstead, UK). The tank was kept cool by placing 
on ice with BioIce cooling unit in the tank and the blots were run for 1.5h at a constant 
80V. The membranes were blocked in PBS containing 0.5% (w/v) Tween-20 (Sigma) and 
3% (w/v) non-fat powdered milk. Membranes were probed with antibodies including 
TSG101, ALIX, LAMP-1, Calnexin (Santa Cruz), 5T4 (gift from Oxford Biomedica UK 
Limited), MHC Class I (Clone HC-10; gift from Dr E Wang from Cardiff University) and 
GAPDH (Bio Chain) at 1μg/ml for 1h at RT. After membranes were washed 3x for 5min 
in 0.5% Tween20 in PBS and incubated with goat anti-mouse-HRP conjugate (Santa 
Cruz), bands were detected using X-ray film (GE Healthcare, Buckinghamshire, UK) and 
a chemiluminescence reagent (Super Signal West Pico, Thermo Scientific). 
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2.2.7 TGF-β1 ELISA 
Quantification of TGF-β1 was performed using the DuoSet ELISA Development System 
(R&D Systems). A serial dilution of TGF-β1 standard from 2000pg/ml to 0pg/ml was 
prepared in 0.1% BSA in PBS to generate a seven point standard curve. Different doses 
of prostate cancer exosomes (1μg, 5μg, 10μg and 15μg) were prepared in 0.1% BSA in 
PBS. To activate latent TGF-β1 to the immunoreactive form detectable by the Quantikine 
TGF-β1 immunoassay, the exosome samples (100ul each sample) were acid activated 
using 20μl of 1N HCL, vortexed and incubated for 10min at RT. The acidified samples 
were then neutralised by adding equal volume (20μl) of 1.2N NaOH/0.5M HEPES. 1N 
HCL (100mL) was prepared by adding 8.33mL of 12N HCL to 91.67mL deionised water. 
1.2N NaOH/0.5M HEPES (100mL) was prepared by adding 12mL of 10N NaOH and 11.9g 
of HEPES to 75mL deionised water. The pH was measured after neutralisation to ensure 
pH was within 7.2-7.6. Once neutralised the standards and samples were added to the 
96 microplate strips (100ul/well), covered with adhesive strips and incubated for 2h at 
RT (The samples were run in triplicates). The wells were aspirated and washed three 
times using 1x Delfia buffer (PerkinElmer) and TGF-β detection antibody (biotinylated 
goat anti-human at 300ng/ml) diluted in 0.1% BSA in PBS, was added to the wells, 
covered and incubated for another 2h at RT. 
 
The plate was aspirated and washed again using Delifa buffer x 3 and streptavidin- 
conjugated europium in Delfia assay buffer (PerkinElmer) (1:1000) was added to the 
wells and incubated for 45 min at RT. The microplate was aspirated and washed x6 using 
Delfia wash buffer and enhancement solution (PerkinElmer) added for 5 min and signal 
measured using time resolved fluorimetry on the Wallac Victor 2 (PerkinElmer). The 
absorbance values were extrapolated from the standard curve to calculate the TGF-β1 
concentration of the sample. 
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2.3 BM-MSC Differentiation 
2.3.1 Growth Arrest 
Prior to all experiments, BM-MSCs were growth-arrested in serum-free medium for 24h 
to allow cell cycle synchronisation. To do this, the Promocell culture media with 
supplement mix was removed via aspiration and the cells were washed using serum-
free DMEM-low glucose to remove any residual FBS. Fresh serum-free medium (DMEM-
low glucose) was then added to the cells for 24h. In all experiments, unless otherwise 
stated, the cells were cultured in DMEM (low-glucose) with 1% FBS, as BM-MSCs 
become senescent with long term serum deprivation. 
 
2.3.2 Adipogenic Differentiation 
6 x 104 BM-MSCs or lung fibroblasts were cultured in wells of a 24 well plate and once 
confluent the cells were given adipogenic induction medium (DMEM containing insulin, 
dexamethasone, indomethacin and IBMX) as described (Pittenger et al. 1999). In 
addition soluble recombinant human TGF-β1 (1ng/ml) or DU145 exosomes (150µg/ml) 
was added along with the induction medium to some wells. Fresh adipogenic induction 
medium was given every 2-3 days over a period of 21 days, with the exception of day 7 
and day 15, in which maintenance medium (DMEM with only insulin and FBS) was given. 
After 21 days of differentiation, adipocytes were fixed in 4% (w/v) paraformaldehyde 
(ebioscience) and lipid droplets stained with Oil Red O Solution and counterstained with 
haematoxylin solution (both from Chemicon International, Ternecula, US). 
 
2.3.3 Myofibroblastic Differentiation 
BM-MSCs were cultured in 8 well chamber slides or 24 well plates with Promocell culture 
media with supplement mixture and once 70% confluent, the cells were growth-arrested 
for 24h. The cells were then stimulated with 150μg/ml of DU145 exosomes or 75μg/ml 
of PC3 exosomes or the equivalent of sTGF-β1 (1ng/ml) (added in DMEM 1% exosome-
depleted FBS) for 14 days. In some experiments this was done in the presence of a 
neutralising TGF-β antibody at 10μg/ml (R&D Systems), or an inhibitor of the Alk-5 TGF-
β receptor-1 (SB431542) at 10μM (Sigma, Dorset, UK). In other experiments, BM-MSCs 
were also cultured in conditioned media of normal or exosome-deficient DU145 cells (by 
either ultracentrifugation or Rab27a knock down using the ribozyme silencing method). 
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For kinetics and dose experiments, BM-MSCs were exposed to 150μg/ml over different 
time points (day 0, 3, 6, 9 and 14) or BM-MSCs exposed to variable exosome doses (0-
300μg/ml). The cells were stained for α-SMA and the proportion of positive cells were 
manually counted across 6 microscopic fields and triplicate treatments unless stated 
otherwise. 
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2.4 Characterisation and phenotyping of cells 
2.4.1 Light microscopy and immunohistochemistry 
Light microscopy was used to examine the general morphology of cells in vitro. DU145, 
PC3, fibroblasts, myofibroblasts and BM-MSCs in 75cm3 or 25cm3 culture flasks, at 70-
100% confluence were viewed under phase-contrast using a Zeiss AxoiVert 40 CFL 
microscope (Carl Zeiss Ltd, Welwyn Garden City, UK).  Images were captured using the 
Canon Powershot G6 digital camera and Canon utilities remote capture (v.2.7.5.27). 
 
For indirect immunofluorescence analysis, the monolayer of DU145 and PC3 cells were 
seeded at 20,000 cells/well in the wells of 8 chambered cover glass slides (Fisher) and 
incubated until ~70% confluent. Similarly, stromal cells such as fibroblasts, 
myofibroblasts, as well as untreated, TGF-β1 or exosome treated BM-MSCs were 
cultured in chamber slides. The cells were gently washed 3x in pre-warmed phosphate 
buffered saline (PBS) (Lonza) and fixed in fresh ice-cold acetone: methanol (1:1 v/v) 
(Fisher Scientific) for 5 min and allowed to completely air dry at room temperature. The 
cells were washed with PBS and blocked for 1.5h at room temperature (RT) in 1% Bovine 
serum albumin (BSA) (R&D Systems) in Hanks’ balanced salt solution (HBSS) (Sigma). The 
cells were washed 3 times using 0.1% BSA/HBSS (w/v) and were then stained with 
unconjugated anti-mouse monoclonal antibodies (shown in table 2.1) at 1μg/ml (in 0.1% 
BSA/HBSS w/v) for 1h at RT. The cells were washed 3 times again and goat- anti mouse 
secondary antibody (Alexa-488) at 10μg/ml was applied (Invitrogen) for 40 min at RT, in 
the dark. Following another 3 washes, the cells were counterstained with 4’,6-
diamidino-2-phenylindole (DAPI) (14.3mM) (Invitrogen) diluted 1:50,000 in 0.1% 
BSA/HBSS (w/v) for 10 min, followed by 3 further washes and the cells were  visualised 
by wide-field fluorescence (AxioVert, Zeiss). 
 
2.4.2 Phenotypic assessment by flow cytometry 
Stromal cells were seeded in 6-well plates at 80,000 cells/well. Once confluent, cells 
were harvested using accutase (Promocell) and centrifuged to obtain cell pellets which 
was then resuspended in PBS to form a homogenous suspension. The resuspended cell 
pellets were incubated on ice with directly conjugated antibodies (Table 2.2) at doses of 
5-20μl/test (as recommended by the supplier) for 1h. Matched isotype controls included 
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as negative controls. Resuspended cell pellets which were incubated with unconjugated 
antibodies for 1 hr such as GD-2 (BD Bioscience) were detected using Alexa-488 labelled 
goat-anti-mouse secondary antibody (1:200 from Invitrogen) for 40 min and then 
washed in PBS. Cells were analysed using a FACScanto cytometer (Beckton Dickinson, 
Oxford, UK). 
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Antibodies used for immunohistochemistry 
 
 
 
 
Table 2.1: List of antibodies used to assess phenotype of cells by indirect immunohistochemistry. 
Matched isotype controls were included as negative controls. 
Primary antibody 
against: 
Target protein 
details 
Source Final 
concentration 
CK-7 (IgG1) Epithelial 
cytoskeletal protein 
Santa Cruz 1μg/ml 
CK-8 (IgG1) Epithelial 
cytoskeletal protein 
Santa Cruz 1μg/ml 
CK-19 (IgG1) Epithelial 
cytoskeletal protein 
Santa Cruz 1μg/ml 
α-Tubulin (IgG2a) Cytoskeletal 
component 
Santa Cruz 1μg/ml 
CD9 (IgG2b) Tetraspanin R&D Systems 1μg/ml 
CD81 (IgG1) Tetraspanin R&D Systems 1μg/ml 
CD63 (IgG1) Tetraspanin R&D Systems 1μg/ml 
PSCA (IgG1) Prostate stem cell 
antigen 
Santa Cruz 1μg/ml 
MUC-1 (IgG1) Tumour-associated 
antigen 
Santa Cruz 1μg/ml 
α-SMA (IgG2a) Myofibroblast 
marker 
Santa Cruz 1μg/ml 
EEA-1 (IgG1) Early endosome 
marker 
Santa Cruz 1μg/ml 
LAMP-2 (IgG1) Glycoprotein Santa Cruz 1μg/ml 
MMP-1 (IgG1) Enzyme Santa Cruz 1μg/ml 
MMP-3 (IgG1) Enzyme Santa Cruz 1μg/ml 
MMP-13 (IgG1) Enzyme Santa Cruz 1μg/ml 
SerpinA-1 (IgG1) Serine protease 
Inhibitor 
Santa Cruz 1μg/ml 
CD31 (IgG1) Endothelial cell 
marker 
Santa Cruz 1μg/ml 
IgG1  Isotype control ebioscience 1μg/ml 
IgG2a  Isotype control ebioscience 1μg/ml 
IgG2b  Isotype control ebioscience 1μg/ml 
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Antibodies for phenotypic analysis by flow cytometry 
 
 
 
 
 
  
  
Primary antibody 
against: 
Target protein 
details 
Source Final 
concentration 
SSEA-4 FITC (IgG3) Cell surface 
glycosphingolipids 
R&D Systems 10μl/test 
Unconjugated GD-2 
(IgG2a) 
Disganglioside BD Bioscience 10μg/ml 
CD146 FITC (IgG2a) Cell adhesion 
molecule 
Biolegend 10μg/ml 
CD44 PE (IgG1) Cell surface 
glycoprotein 
BD 20μl/test 
CD90 PE (IgG1) (Thy-1) cell surface 
molecule 
eBioscience 20μl/test 
CD105 APC (IgG1) (Endoglin) Cell 
surface glycoprotein 
eBioscience 5μl/test 
CD73 PE (IgG1) Cell surface molecule BD Pharmingen 20μl/test 
CD14 APC (IgG1) Haematopoietic 
marker 
eBioscience 5μl/test 
CD45 PE-Cy5 (IgG1) Haematopoietic 
marker 
eBioscience 20μl/test 
FITC (IgG2a) Isotype control BD Phosflow 20μl/test 
APC (IgG1) Isotype control eBioscience 20μl/test 
PE (IgG1) Isotype control eBioscience 5μl/test 
PE Cy5 (IgG1) Isotype control BD Pharmingen 5μl/test 
FITC (IgG3) Isotype control eBioscience 10μl/test 
Table 2:2: List of antibodies used to assess phenotype of cells by fluorescence-activated cell 
sorting (FACS). Matched isotype controls were included as negative controls. 
Methods and materials 
 
67 
 
2.4.3 Enzyme-Linked Immunosorbent Assay (ELISA) 
The quantity of VEGF-A or HGF present in cell conditioned media (CM) of BM-MSCs was 
assayed using the DuoSet ELISA system (R&D Systems). The manufacturer’s instructions 
were followed, in which the VEGF-A or HGF capture antibody at a dose of 1μg/ml (mouse 
anti-human against VEGF-A or HGF) were added to a 96-well microplate (Greiner) at 
100μl per well and incubated overnight at room temperature (RT). Unbound antibody 
was removed by aspiration and the wells were washed 3 times with Delfia wash buffer 
(1X diluted in water) (Perkin Elmer, Cambridge, UK). Thereafter, blocking buffer was 
added to the wells (1% BSA in PBS) for 1 hour, followed by the addition of a serial dilution 
of recombinant human VEGF-A and HGF standards (diluted in 0.1% BSA in PBS) starting 
from 2000pg/ml or 8000pg/ml, respectively to 0pg/ml, to create a seven point standard 
curve.  
 
Secondly, the CM from the BM-MSCs was normalised for cell count and lightly spun 
using the bench centrifuge to remove any large cellular debris. Since the protein 
concentration is unknown, the CM was diluted at a high and low range (1:2 and 1:6) in 
0.1% BSA in PBS and applied to the wells and incubated for 2h at RT.  The wells were 
aspirated and washed and VEGF-A or HGF detection antibody (biotinylated goat anti-
human antibody against VEGF-A or HGF) at 50ng/ml or 200ng/ml, was added 
respectively for 2h at RT. After another aspiration and wash step, the colourimetric HRP-
based detection antibody recommended by the manufacturer was substituted for 
streptavidin-conjugated Europium diluted in Delfia assay buffer in a 1:1000 dilution 
(both from PerkinElmer) and applied to wells for 45 min, at RT. Lastly, the microplate 
was washed 6x using the Delfia wash buffer and enhancement solution (PerkinElmer) 
added for 5 min and signal measured using time resolved fluorimetry on the Wallac 
Victor 2 (PerkinElmer). The absorbance values were extrapolated from the standard 
curve to calculate the VEGF-A or HGF protein concentration of the sample. 
 
2.4.4 PCR Fibrosis Array 
RNA Extraction 
In order to examine potential differences in the phenotype of differentiated BM-MSCs 
following exosome or sTGF-β1 treatment, a PCR fibrosis array was used. To do this, firstly 
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the cellular RNA of the untreated or treated BM-MSCs cultured in 6-well plates was 
extracted at day 3 using 1ml Tri-Reagent per well (Sigma-Aldrich). Thereafter 200μl 
chloroform was added to the samples and was mixed by inverting the sample several 
times in eppendorf tubes. The samples were incubated on ice for 5 min to allow 
separation of the aqueous and phenol phases and centrifuged at 12,000 x g for 20min 
at 40C. The colourless aqueous layer containing RNA was removed and mixed with an 
equal volume of ice-cold isopropanol and incubated at -200C for 24h. The samples were 
again centrifuged at 12,000 x g for 20min at 4oC, to wash away the isopropanol and the 
pellets were washed in ice-cold 75% ethanol (v/v) by inversion and centrifuged again at 
12,000 x g for 20min at 40C. This step was repeated again and thereafter, the RNA pellets 
were air dried at RT and dissolved in 20μl H2O.  
 
Determining the RNA concentration 
The RNA sample was diluted (1:50) in RNAse free H2O (1μl RNA in 49μl H2O) and the 
Nanodrop 2000 Spectrophotometer (Thermo Scientific, Loughborough, UK) was used to 
obtain a ratio of absorbance measured at 260nm and 280nm. A ratio ≥1.7 was 
considered sufficiently pure RNA and used for analysis. The absorbance at 260 was used 
to calculate the RNA concentration as shown below. The extinction coefficient for RNA 
is 40 and the dilution factor of samples were 1:50.  
 
[RNA] (μg/ml)= Absorbance260 x dilution factor x extinction coefficient 
 
Reverse Transcription  
Total RNA (0.5μg) was reverse transcribed using the RT2 First Strand Kit (Qiagen, 
Manchester, UK) to generate complementary DNA (cDNA). Reverse transcription was 
carried out in a final volume of 10ul per reaction containing 0.5μg of RNA, 4μl of 5x 
Buffer BC3, 1μl Control P2, 2μl PE3 Reverse Transcriptase Mix and 3μl RNAse- free H2O. 
10μl genomic DNA elimination mix was added to each RNA sample (each reaction) and 
samples were then reverse transcribed using the StepOne Plus Real-Time PCR System 
thermocycler (Life Technologies). This involved sample incubation at 420C for 15min, 
followed by incubation at 950C for 5 min. 91μl RNase-free H2O was added to the cDNA 
sample and stored at -200C. 
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Quantitative Polymerase Chain Reaction (q-PCR) 
The Polymerase Chain Reaction (PCR) component mix contained cDNA synthesis 
reaction (102μl), RNase-free water (1248μl) and 2x RT2 SYBR Green Mastermix 
containing the HotStart DNA Taq Polymerase (1350μl) which was required for 
amplification. The mixture was prepared in a 5ml tube and vortexed. 25μl of the PCR 
mix was added per well of a RT2 Profiler 96-well plate array covering 84 transcripts of 
known association with fibrosis (table 2.3) (Qiagen). The RT2 Profiler Array was 
performed as biological triplicates for each treatment condition; the untreated, TGF-β1 
treated and exosome treated BM-MSCs (9 arrays in total). The array also contained 5 
housekeeping genes (β-actin, β-2-microglobulin, GAPDH, HPRT1 and RPLP0), a genomic 
DNA control, reverse-transcription controls and positive PCR controls. The PCR array 
plates were sealed with an Optical adhesive film (Qiagen) and centrifuged at 1000 g for 
1 min at room temperature to remove bubbles. Amplification was carried out using the 
StepOne Plus Real-Time PCR System thermocycler (Life Technologies) which involved a 
cycle at 950C for 10min, so that the HotStart DNA Taq polymerase is activated, followed 
by 40 cycles at 950C for 15s and 600C for 1min. 
 
The comparative Ct method was used for relative transcript quantification against the 
average ΔCt derived from the internal controls (β-actin, β-2-microglobulin, GAPDH, 
HPRT1 and RPLP0). Data was analysed using the ABI StepOnePlus software (Version 2.0 
supplied by Applied Biosystems) and the data as presented as volcano plots with a p-
value threshold of <0.05 and a fold-change threshold of ±3. 
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Human Fibrosis PCR Array 
 
Pro-Fibrotic: ACTA2 (α-SMA), AGT, CCL11 (Eotaxin), CCL2 
(MCP-1), CCL3 (MIP-1a), CTGF, GREM1, IL13, 
IL13RA2, IL4, IL5, SNAI1 (Snail) 
Anti-Fibrotic: BMP7, HGF, IFNG, IL10, IL13RA2 
Extracellular Matrix & Cell Adhesion:  
ECM Components; COL1A2, COL3A1 
Remodelling Enzymes; 
 
LOX, MMP1 (Collagenase 1), MMP13, 
MMP14, MMP2 (Gelatinase A), MMP3, 
MMP8, MMP9 (Gelatinase B), PLAT (tPA), 
PLAU (uPA), PLG, SERPINA1 (a1-antitrysin), 
SERPINE1 (PAI-1), SERPINH1, TIMP1, TIMP2, 
TIMP3,TIMP4 
Cellular Adhesion; ITGA1, ITGA2, ITGA3, ITGAV, ITGB1, ITGB3, 
ITGB5, ITGB6, ITGB8 
Inflammatory Cytokines & Chemokines: CCL11 (Eotaxin), CCL2 (MCP-1), CCL3 (MIP-
1a), CCR2, CXCR4, IFNG, IL10, IL13, IL13RA2, 
IL1A, IL1B, IL4, IL5, ILK, TNF 
Growth Factors: AGT, CTGF, EDN1, EGF, HGF, PDGFA, PDGFB, 
VEGFA 
Signal Transduction:  
TGF-β Superfamily; BMP7, CAV1, DCN, ENG (EVI-1), GREM1, 
INHBE, LTBP1, SMAD2, SMAD3, SAMD4, 
SMAD6, SMAD7, TGFB1, TGFB2, TGFB3, 
TGFBR1 (ALK5), TGFBR2, TGIF1, THBS1, 
THBS2 
Transcription Factors; CEBPB, JUN, MYC, NFKB1, SP1, STAT1, STAT6 
Epithelial-to-Mesenchymal Transition: AKT1, BMP7, COL1A2, COL3A1, ILK, ITGAV, 
ITGB1, MMP2 (Gelatinase A), 
MMP3,MMP9,SERPINE1 (PAI-1), SMAD2, 
SNAI1 (Snail), TGFB1, TGFB2, TGFB3, TIMP1 
Others:  BCL2, FASLG (TNFSF6) 
Table 2:3: The Human Fibrosis PCR Array profiles the expression of 84 key genes involved in 
dysregulation tissue remodelling during repair and healing of wounds or at tumour sites. The 
array contains genes encoding ECM remodelling enzymes, TGFβ signalling molecules and 
inflammatory cytokines as well as additional genes important for fibrosis. 
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2.4.5 TaqMan gene PCR 
The selected transcripts (MMP-1, MMP-3, MMP-13, SerpinA-1, AGT) from the PCR 
fibrosis array were verified using TaqMan PCR gene expression assays. In addition, the 
mRNA level of Rab27a in PCa cells was also evaluated using this method. Firstly the RNA 
was extracted and measured the same way as mentioned above, but the RT and 
amplification step were different and explained below. 
 
Reverse Transcription 
Reverse transcription was performed using the random primer method in a final volume 
of 20μl per reaction containing 1μg of RNA of the sample, 2μl of 10x reverse 
transcription buffer, 0.8μl of 25mM deoxynucleotide triphosphate (dNTPs) (mixed 
nucleotides of dATP, dCTP, dGTP and dTTP), 2μl of 10x reverse transciption random 
primers, 1μl of MultiscribeTM reverse transcriptase and 1μl of RNase Inhibitor. A negative 
control was included, which was H2O substituted for the MultiscribeTM reverse 
transcriptase (all from Applied Biosystems). The samples were reverse transcribed using 
the StepOne Plus Real-Time PCR System thermocycler which involved incubation at 250C 
for 10min to allow the primers to anneal to the RNA. The primers were then extended 
using the reverse transcriptase in the presence of dNTPs at 370C for 2hr, generating 
cDNA. The cDNA was then heated at 850C for 5s to deactivate the RT. The cDNA samples 
were stored at -200C. 
 
Quantitative Polymerase Chain Reaction (q-PCR) 
The q-PCR was carried out in a final volume of 20μl per reaction containing 1μl of sample 
cDNA, 10μl x2 of PCR TaqMan Master Mix, 8μl H2O, 1μl primer + probe (primer of MMP-
1, MMP-3, MMP-13, SerpinA-1, AGT, Rab27a and GAPDH) (Qiagen). A negative control 
was prepared using H2O substituted for the cDNA. The PCR amplification was performed 
using the Step One Plus Thermocycler, involving a cycle of 95oC for 1s, and 60oC for 20s 
for 40 cycles. 
 
The comparative CT method was used for relative quantification of gene expression. The 
CT (threshold cycle where amplification is in the linear range of the amplification curve) 
for the standard reference gene (GAPDH) was subtracted from the target gene CT to 
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obtain the ΔCT for each sample. The expression of the target gene in experimental 
samples relative to expression in control samples was calculated: 
 
Relative expression =  2 - (ΔCT 1)-ΔCT(2)) 
 
The ΔCT(1) is the mean ΔCT value calculated for the experimental samples, and ΔCT(2) is 
the mean ΔCT value calculated for the control samples (GAPDH). The data was analysed 
using the ABI StepOnePlus software (Version 2.0 supplied by Applied Biosystems). 
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2.5 Rab27a knock down 
Exosomes secretion is regulated by Rab27a GTPase (Ostrowski et al. 2010) and hence 
the knock down of Rab27a in DU145 cells, is expected to negatively influence exosome 
secretion. Our Rab27aKD was achieved through collaboration with Prof Wen Jiang 
(Department of surgery and tumour biology, Cardiff University) who have routinely 
established the ribozyme method for gene silencing and the DU145Control Vector and 
DU145Rab27aKD cells were used for some experiments in this thesis (Oncotarget, 2014). 
However during my study the more stable lentiviral approach was developed by our 
group and cells obtained by this approach were used in the later part of the studies. The 
two different methods for Rab27aKD are described below. 
 
2.5.1 Ribozyme silencing method 
One way to silence genes is by the use of ribozymes. Ribozymes are catalytic RNA 
molecules used to inhibit gene expression by cleaving to the mRNA molecules via 
Watson-Crick base pairing, and so silencing the genes by preventing translation, as 
shown in figure 2.2A (Xiet et al. 1997; Dorsett and Tuschl 2004). Cleavage by ribozyme 
also requires divalent ions, such as magnesium and ribozymes are short enough to be 
chemically synthesised or transcribed from a vector, allowing a continuous production 
of ribozymes within the transfected cells (Dorsett and Tuschl 2004). 
 
Rab27a knock down using the ribozyme silencing method was carried out by a 
collaborator, Prof Wen Jiang (Jiang et al. 2006). This involved designing a hammerhead 
ribozyme transgene targeting human Rab27a using Zukers RNA mfold programme 
(Zuker et al. 2003) and synthesised by Sigma-Aldrich. These were subsequently cloned 
in mammalian pEF6/V5 vector, amplified in E.coli and uptake of vector verified by their 
resistance of ampicillin (100μg/ml). 1 x 106 DU145 cells were transfected with the 
vectors using electroporation and cells which had taken up the vector were selected 
based on their resistant to blasticidin (5μg/ml). DU145Control Vector (carrying the empty 
vector pEF6/V5) and two DU145Rab27aKD attempts were made, named Rab27aKD2 and 
Rab27aKD3. The cells were cultured in RPMI 10% FBS containing blasticidin at a high 
dose of 5μg/ml for 1 week and thereafter the dose of blasticidin was reduced to 
0.5μg/ml. The knockdown of Rab27a was confirmed by qPCR. For functional 
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experiments, blasticidin was not used. Such experiments included the collection of 
conditioned media from the DU145Control Vector or DU145Rab27aKD cells to treat BM-MSCs 
and the use of these mutated cells for the xenograft experiment to assess tumour 
growth. 
 
2.5.2 shRNA lentiviral method 
Gene silencing was also carried out using a short hairpin RNA (shRNA) which is a 
sequence of RNA that makes a tight hairpin turn that can be used to silence target gene 
expression via RNA interference (RNAi). RNAi is a biological process in which RNA 
molecules inhibits gene expression by causing destruction of specific mRNA molecules. 
shRNA was in these studies delivered using lentiviral vectors as shown in figure 2.2B. 
Once the vector has integrated into the host genome, the shRNA are transcribed in the 
nucleus and the resulting shRNA are exported out of the nucleus and processed by Dicer 
(ribonuclease) and loaded into the RNA-induced silencing complex (RISC). This complex 
cleaves the target mRNA and thus represses translation of the mRNA, resulting in target 
gene silencing.  
 
For my studies, the DU145NM Control (transduced with a non-mammalian control shRNA) 
and DU145Rab27aKD cells used, were previously generated by Dr Jason Webber. The 
DU145 cells were plated in a 48-well flat-bottomed plates at 18,000 cells/well, in 
exosome-depleted media. At day 1, the cells were infected with lentiviral particles 
(MOI=10) in the presence of Hexadimethrine bromide (8mg/ml). At day 2, Puromycin 
(1.25mg/ml) was added and media was changed at day 5 and Rab27a knockdown was 
verified using qPCR. The cells were cultured in the presence of Puromycin for a further 
6 passages prior to experimental use, such as the spheroid models to assess cellular 
invasion and growth. 
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Gene Silencing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.2: Rab27a knockdown via the ribozyme silencing and the lentivrival shRNA method. 
Ribozymes can be directly introduced into the cell using the mammalian pEF6/V5 vector. The 
hammerhead ribozyme has two arms which bind to and degrade the mRNA by cleaving via 
hydrolysis of the phosphodiester backbone of the mRNA and thus prevent mRNA translation 
into a protein (A). Lentiviral vectors can be used to stably deliver viral genome into the 
cytoplasm where they are reverse-transcribed (2). The DNA intermediate is imported into the 
nucleus (3) where it is stably integrated into the host genome (4). The silencing construct is then 
constitutively expressed and processed into shRNAs that forms a complex using Dicer and 
cleaves target mRNA, preventing its translation into proteins (5) (B). 
Source: Adapted from Dorsett and Tuschl 2004 and ThermoScientic website 
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2.6 Functional experiments 
2.6.1 Proliferation 
Endothelial cells or prostate cancer (PCa) cells were seeded at 1x104 cells/ml and 
cultured for 24h in growth-factor free conditions prior to stimulations. BM-MSCs were 
pre-treated for 4d with exosomes (150μg/ml) or sTGF-β1 (1ng/ml) and conditioned 
media (CM) was harvested and centrifuged at 400 g to remove cellular debris. BM-MSCs 
CM normalised for cell count was added to endothelial cells or PCa cells at a ratio of 1:1 
(v:v) with EBM2-medium or RPMI media, and incubated for 6 or 3 days respectively. 
Endothelial and PCa cells were harvested using accutase or trypsin, respectively (Lonza) 
and the cellular pellet obtained after centrifugation at 400 g for 7min was resuspended 
in 100μl PBS (original volume) and diluted in Guava ViaCount reagent (at 1:3 and 1:10 
dilutions) for 5 min at RT and cell number and viability was measured using the Guava 
EasyCyte flow cytometer (Millipore). The ViaCount assay distinguishes viable and non-
viable cells based on differential permeabilities of two DNA-binding dyes in the Viacount 
reagent; the nuclear dye which only stains nucleated cells and a viability dye which 
brightly stains dying cells. Debris are excluded from the results based on negative 
staining with the nuclear dye. The cell counts and viability measurements of the original 
sample (corrected for dilution) were performed in triplicates. 
 
2.6.2 Motility 
Prior to the assessment of cell motility, a confluent monolayer of endothelial cells or 
tumour cells in 24 well plates were cultured for 24h in growth-factor free conditions. 
The confluent monolayer was subject to a single vertical scratch using a 200μl pipette 
tip. The wells were gently washed with PBS and BM-MSC CM was added as above, and 
wells were microscopically monitored up to 24hr. The width of the scratch in duplicate 
wells was measured at 4 points for each well, using Image-J (National Institutes of Health, 
Bethesda, MD, USA) and the rate of monolayer recovery plotted as relative to the original 
scratch width (% closure), as described previously (Webber et al. 2014). 
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2.6.3 Tubule formation assay 
Formation of endothelial tubules was performed as described previously (Webber et al. 
2014), with endothelial cells (20,000/well) added in triplicate to monolayers of BM-MSCs 
that had been previously treated with exosomes or sTGF-β1 for 4 days. After a further 6 
days of culture, structures formed by endothelial cells were visualised by 
immunofluorescent labelling of CD31 (SantaCruz). The total area occupied by CD31-
positive structures was quantified using the free-hand selection tool in Image-J to 
calculate the area occupied by stained cells in each well. Data shows the average from 
triplicate wells per treatment, and are representative of three such experiments. 
 
2.6.4 Spheroid generation for invasion and growth assessment 
Spheroids were generated in poly (2-hydroxyethyl methacrylate) (poly-HEMA) (Sigma, 
Dorset, UK) coated 96-well “u”-bottom plates. To do this, 20mg/ml poly-HEMA solution 
was made in pre-warmed 95% ethanol (diluted in H2O) and the mixture was vortexed to 
solubilise the poly-HEMA. 150μl of the solution was added to the wells of a 96-well plate 
and allowed to evaporate in the hood overnight. A second coat was applied and again 
evaporated for 24h. To generate tumour cell and BM-MSC heterotypic spheroids, 
tumour cells (DU145NM or DU145Rab27aKD using the shRNA lentiviral knockdown method) 
were incubated alone or together with BM-MSCs at a ratio of 4 tumour cells: 1 MSC in 
the poly-HEMA plates and was centrifuged at 1000rpm for 10min (15 spheroids were 
generated for each condition). The total cell seeding was of 1x104 cells per well and the 
medium used consisted of 1:1 ratio (v/v) or RPMI and DMEM (low glucose) in 10% FBS. 
After 4 days, the cells had established 3D-spheroidal structures. 
 
Growth assessment 
The spheroids were cultured in a 1:1 ratio of RPMI: DMEM 10% FBS and every other day, 
50% of the culture media was replaced by fresh media. Over a 20d period, spheroid 
volume was measured every 4 days. Image J was used to measure the radius of the 
spheroid as shown below; 
 
 
 
r1 
r2 
r3 
The radius measurement was used to estimate spheroid 
volume using the formula: (4/3)r1r2r3.  
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Invasion assay 
To evaluate potential changes in invasive behaviour of the cells, spheroids were 
transferred to fresh uncoated 96 well plates and MatrigelTM (Corning, Flintshire, UK) was 
added (100μl/well). The matrigel basement membrane matrix consists of laminin, 
collagen type IV, heparan sulphate proteoglycan and entactin. After setting of the 
MatrigelTM at 370C for 30min, medium was added and the wells monitored 
microscopically for 4 days thereafter. To estimate the magnitude of invasion out from 
the spheroid, the free-hand selection tool in Image-J was used to draw the 
circumference of the central sphere. This was subtracted from the circumference of the 
region occupied by invading cells. This gives an approximation of the area of the 
MatrigelTM invaded by cells, as it does not take account of the volume aspect of the 3D 
culture, and is likely therefore to underestimate the true differences across the 
treatments. 
 
2.6.5 Xenotransplantation for tumour growth assessment 
With the aid of Dr Jason Webber and collaboration with Prof Wen Jiang and group (Cardiff 
University), tumour growth was assessed in vivo, in the presence of BM-MSCs with exosome 
proficient or exosome deficient DU154 tumour cells (using ribozyme method of Rab27a 
knockdown). Suspensions (100ml) containing 600,000 DU145 cells and 150,000 BM-MSCs in 
3mg/ml Matrigel were sub-cutaneously injected into both flanks of 4 to 6 week old athymic 
nude mice (CD-1; Charles River Laboratories, Kent, UK). There were a total 5 groups 
(DU145Control Vector only, DU145Rab27aKD only, DU145Control Vector with BM-MSCs, DU145Rab27aKD 
with BM-MSCs and BM-MSCs only). There were 6 mice per group, except the BM-MSC only 
controls (the negative control), where only 3 mice were used. Tumour size was measured 
weekly over 28 days, using an external caliper to measure the height and width of the 
tumour. Tumour volume was calculated; tumour volume (mm3) = 0.523 x width2 x length. 
Animals were treated humanely in accordance with UK Home Office code of practice and 
the United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines 
(Workman et al. 2010). At the experimental end point or severity limits, the mice were 
dispatched humanely under the schedule 1 (Scientific Procedures) Act 1986, involving the 
exposure to carbon dioxide.  
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3.1 Isolation and characterisation of prostate cancer exosomes 
The prostate cancer (PCa) cell lines chosen for this study are DU145 and PC3 because 
they are commonly used for the study of prostate cancer as these are well characterised 
(Alimirah et al. 2006; Clayton et al. 2007; Webber et al. 2010; Tai et al. 2011; Perkel et 
al. 1990). In addition, unlike LnCap (a PCa cell line), DU145 and PC3 cells are known to 
produce TGF-β1 bearing exosomes (Webber et al. 2010) which are under investigation 
in this thesis for their role in BM-MSC differentiation. 
 
A high quality isolation method for exosomes, followed by characterisation and 
identification of these vesicles are crucial, to enable one to distinguish exosomes from 
other non-exosomal vesicles or cellular debris from within the cell secretome. This will 
also demonstrate that the experimental outcome are due to exosomes and not the 
contaminants. I will describe two gold standard methods to isolate exosomes form 
prostate cancer cells, based on their biophysical properties. These are the continuous 
sucrose gradient (Raposo et al. 1996; Caby et al. 2005; Nilsson et al. 2009) and the 30% 
sucrose cushion method (Lamparski et al. 2002), both of which utilise the floatation 
property of exosomes to isolate them. 
 
To characterise the exosomes isolated from PCa cell lines (DU145 and PC3), we assessed 
the biophysical and phenotypic nature of the vesicles. The morphology of PCa exosomes 
was examined using cryo-Transmission Electron Microscopy. Validation of exosomal 
markers was performed on purified exosomes using a microplate-immuno-phenotype 
assay or western blotting for a range of exosomal related proteins including 
tetraspanins, ALIX, TSG101 as well as for proteins not expressed on exosomes, such as 
calnexin, an endoplasmic reticulum marker. The purity of exosomes was assessed based 
on the particle to protein ratio using the Nanosight and a colourimetric (BCA) assay for 
particle and protein concentration measurement, respectively (Webber and Clayton 
2013). PCa derived exosomes have been shown to express TGF-β1 which is involved in 
the differentiation of fibroblasts into myofibroblasts (Webber et al. 2010). To test if 
exosomal TGF-β1 have an effect on MSC differentiation, TGF-β1 expression on 
exosomes from DU145 and PC3 will be quantified here using TGF-β1 ELISA. 
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3.1.1 Characterisation of prostate cancer cell lines 
For my studies, PCa cell lines (DU145 and PC3) were bought new from ATCC, in which 
the DU145 and PC3 cells were derived from the brain and bone metastatic site, 
respectively. The prostatic epithelium consist mainly of luminal and basal cells (Wang et 
al. 2001) and hence the morphology and phenotype of the carcinoma cells were 
evaluated to confirm if they appeared as epithelial cells prior to their expansion in 
bioreactor flasks. In addition the expression of tumour associated proteins and proteins 
commonly enriched in exosomes were examined. 
 
The monolayer of DU145 and PC3 epithelial cells were evaluated by phase contrast 
microscopy (figure 3.1), revealing both cell lines to be plastic adherent and exhibiting 
polygonal shape in appearance. This morphology agreed with other reports of prostate 
epithelial cells (Hayward et al. 2001; Lang et al. 2001). The PCa cell lines also appeared 
to grow without contact inhibition and formed overlapping cell layers after reaching 
confluence. 
 
The phenotype of PCa cell lines was assessed by immunofluorescence staining for a 
variety of epithelial markers. Cytokeratins (CKs) such as CK-7, CK-8 and CK-19 are 
intermediate filaments used to characterise epithelial cells (Wang et al. 2001; Lang et al. 
2001). Other common characteristics of epithelial cells are the presence of 
microtubules, such as α-tubulin (Soucek et al. 2006; Husain and Harrod 2011). Here, 
both the DU145 and PC3 cells were strongly positive for CK-7, CK-8 and α-tubulin (figure 
3.2A). Therefore, the epithelial phenotype of DU145 and PC3 here agreed with the 
published literature (Nagle et al. 1987; Wang et al. 2001). 
 
The expression of tetraspanins (CD9, CD81 and CD63) which are commonly found in 
exosomes (Lamparski et al. 2002; Rapaso et al. 1996; Escola et al. 1998; Heijnen et al. 
1999) were assessed among the PCa cell lines using immunofluorescence. 
Heterogeneous population of DU145 and PC3 cells were positive for CD9. Additionally, 
the majority of the PCa cells were positive for CD81 and CD63 (figure 3.2B). These 
findings were similar to published literature on the expression of tetraspanins in PCa 
cells (Zvereff et al. 2007; Liu 2000). As a negative control, DU145 and PC3 cells were 
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stained for the non-epithelial marker, α-SMA, and as expected both PCa cell lines were 
negative for this cytoskeletal protein (figure 3.2B). This suggests the DU145 and PC3 cells 
are epithelial in nature with no mixed population containing myofibroblast or smooth 
muscle cells, from the stromal compartment of the prostate. 
 
DU145 and PC3 cell lines were also assessed for the presence of tumour-associated 
Mucin-1 (MUC-1) and prostate stem cell antigen (PSCA). The expression of the 
glycoprotein, MUC-1 is usually found on the apical surface of epithelial cells (Brayman 
et al. 2004), but is overexpressed in many carcinomas such as breast and lung cancer 
(Lacunza et al. 2010; Yao et al. 2011). In the context of prostate cancer, MUC-1 was 
expressed in DU145 and to a lesser extent in PC3 cells (Joshi et al. 2009). Here, a 
heterogeneous population of DU145 and PC3 cells were also positive for MUC-1 (figure 
3.2C). Furthermore, the name of PSCA is inaccurate as it is not a stem cell marker nor is 
it expressed exclusively by the prostate cells but is found to be overexpressed in prostate 
carcinoma cells (Reiter et al. 1998; Bargäo Santos and Patel 2014; Taeb et al. 2014). In 
agreement with these reports, DU145 and PC3 cells were strongly positive for PSCA 
(figure 3.2C). In summary, the morphology and phenotype of PCa cell lines are indeed 
epithelial cells in nature consistent with the literature. They also express proteins that 
are found to be overexpressed by many cancer cells, giving us an indication of what we 
might expect to find on PCa exosomes. 
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Morphology of PCa cell lines  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: DU145 and PC3 have a cobblestone morphology. 
Monolayer of live-prostate cancer cells (DU145 and PC3) were imaged using phase-contrast 
microscopy to confirm the cobblestone morphology of the epithelial cells. Scale bar 100μm. 
 DU145 PC3 
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Phenotype of prostate cancer cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: DU145 and PC3 cells have an epithelial phenotype. DU145 and PC3 cells were fixed and stained with antibodies against cytokeratin-7,   -19 and -8 and 
α-tubulin followed by goat anti-mouse FITC secondary antibody (green). The cells were additionally stained with DAPI (blue). Scale bar 100μm (A). 
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Phenotype of prostate cancer cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.2 Continued: DU145 and PC3 cells were fixed and stained with antibodies against tetraspanins (CD9, CD81 and CD63) and α-SMA followed by goat anti-mouse 
FITC secondary antibody (green). The cells were additionally stained with DAPI (blue). Scale bar 100μm (B). 
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Phenotype of PCa epithelial cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Continued: DU145 and PC3 cells were fixed and stained with antibodies against MUC-1 and PSCA followed by goat anti-mouse FITC secondary antibody 
(green). The cells were additionally stained with DAPI (blue). IgG isotype controls were also included. Scale bar 100μm (C). 
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3.1.2 Flotation of vesicles on continuous sucrose gradient 
Spinning exosomal samples on a continuous sucrose gradient as mentioned in materials 
and methods, is a commonly used analytical tool to isolate exosomes, based on their 
flotation property (Raposo et al. 1996; Escola et al. 1998). A total of fifteen fractions was 
collected from a continuous sucrose gradient overlaid with DU145-exosome and 
fourteen fractions collected from gradient overlaid with PC3-exosomes. The refractive 
index (RI) of the individual fractions was measured using an automatic refractometer 
and the RI was then used to calculate the density of the fractions using a conversion 
table provided by Beckman Coulter. A serial increase in density with increasing fraction 
number was revealed (figure 3.3A and 3.3D). DU145 exosomes were predicted to be 
present at fractions 7-10 and PC3 exosomes were predicted to be present in fractions 5-
10, as these fractions span the classical density range for exosomes at 1.1-1.2g/ml 
(Raposo et al. 1996).  
 
The Nanoparticle Tracking Analysis (NTA) revealed the number of nanoparticles per 
fractions (figure 3.3B and 3.3E), in which the early DU145 fractions (1-4) and PC3 
fractions (1-3) was extremely low in particle count (<3x1011 counts/ml) and so were no 
longer subjected to any further analysis. With regard to the continuous sucrose gradient 
containing DU145 exosomes, the numbers of particles were found to increase by 28 fold 
from fraction 5 to fraction 9 and thereafter the particle count gradually decreased to 
low levels. Similarly with the continuous sucrose gradient containing PC3 exosomes, the 
particles increased from fraction 4 to fraction 8 by 13-fold and particle counts decreased 
thereafter. Thus, the majority of nanoparticles were concentrated within the density 
range of 1.1-1.2g/ml, agreeing with the literature (Raposo et al. 1996; Escola et al. 1998). 
 
To characterise purified vesicles as exosomes, the fractions were subjected to western 
blotting using antibodies against the multivesicular endosome associated proteins 
(TSG101 and ALIX). Positive staining for the TSG101 in fractions spanning the exosomal 
density range was observed, with no staining at the hypo or hyper dense region of the 
gradient. Maximal staining was found within fractions 8 and fraction 9 from the DU145-
continuous sucrose gradient (figure 3.3C) which contained the most particles. ALIX was 
found to be only expressed within fraction 9 and 10. Similarly with the PC3-continous 
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sucrose gradient, positive staining for TSG101 was found in fractions 5-9 and positive 
ALIX staining at fractions 5-10, with maximal staining at fractions 8 where the highest 
particle counts resided (figure 3.3F). Therefore the commonly used proteins for defining 
a vesicle as exosomes, ALIX and TSG101 are only found to stain fractions at exosomal 
density range of 1.1-1.2g/ml and so exosomes must be present in these fractions. 
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DU145 exosomes isolated using a continuous sucrose gradient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: DU145 exosomes float at density of 1.1-1.2g/ml. 
DU145 exosomal pellet centrifuged at 120,000 x g was overlaid on a sucrose gradient (0.2M-2M) and 
spun at 210,000 x g at 40C overnight. Fractions (1-15) were collected and density of each fraction 
calculated using refractometry and density conversion table. Fractions 7-10 are predicted to contain 
exosomes (A). Fractions (1-15) were analysed by nanoparticle tracking analysis (NTA), showing peak 
nanoparticle concentration at fraction 9 (B). Fractions 5-15 was analysed by western blot for exosomal 
markers (TSG101 and ALIX). Marker lane (ML) included for identifying the molecular weight of the 
antibody (C). 
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PC3 exosomes isolated using a continuous sucrose gradient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 continued: PC3 exosomes float at density of 1.1-1.2g/ml. 
PC3 exosomal pellet was overlaid on a sucrose gradient, in the same manner as with the DU145 
exosomes. Fractions (1-14) were collected and density of each fraction was calculated, in which 
fractions 5-10 are predicted to contain exosomes (D). Fractions (1-14) were analysed by NTA, 
showing peak nanoparticle concentration at fraction 8 (E). Fractions 4-14 were analysed by western 
blot for exosomal markers (TSG101 and ALIX). Marker lane (ML) included for identifying the 
molecular weight of the antibody (F). 
D) 
E) 
F) 
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3.1.3 Exosomes purified by the sucrose cushion method. 
Isolation of exosomes using a continuous sucrose gradient is a good method to 
characterise exosomes but it is a long process (>18h) and results in variable recovery of 
the starting amount of exosomes (Lamparski et al. 2002). Thus it is not ideal as a routine 
use of isolating exosomes for experimental use. Instead the sucrose cushion is a rapid 
method for isolating exosomes of high yield (Lamparski et al. 2002). This method 
involves ultracentrifugation of cell conditioned media (CM) with a 30% sucrose/D2O 
cushion to capture exosomes based on their buoyant density in sucrose of 1.1-1.2g/ml. 
The cushion containing exosomes was collected and underwent a PBS wash at high 
speed, resulting in an exosomal pellet which was then characterised. 
 
Firstly, the morphology of DU145 and PC3 exosome pellets were examined using cryo-
transmission electron microscopy (TEM) in collaboration with Dr. Georgi Lalev (Cardiff 
University). To do this, the exosomal pellets were resuspended in PBS and placed onto 
carbon grids and were then rapidly plunged into liquid ethane at liquid nitrogen 
temperature to prevent formation of ice crystals. The grid containing exosomal sample 
was viewed under cryo-TEM, revealing rounded structure of vesicles with thick outer 
boundary, suggesting the possibility of the lipid bilayer (figure 3.4). The diameter of the 
DU145 and PC3 exosomes agrees with the classical diameter range of exosomes at 30-
100nm found by others (Raposo et al. 1996; Escola et al. 1998; Sokolova et al. 2011; 
Sharma et al. 2010; Welton et al. 2010). 
 
Secondly, the phenotype of DU145 and PC3 exosomes was examined using a microplate-
immuno-phenotype assay, in which the exosomes were coated on plates overnight and 
were assessed for their surface expression of proteins commonly found in exosomes, 
such as the tetraspanins (CD9, CD81 and CD63). Our data demonstrated, exosomes from 
both PCa cell lines express tetraspanins (figure 3.5A), in which the DU145 exosomes 
have a 2-fold greater expression of CD9 and CD81 in comparison to the PC3 exosomes 
(P<0.001). Furthermore, DU145 and PC3 derived exosomes express CD63 but to a lesser 
extent than that of the other tetraspanins. The expression of cytosolic protein, 
glyceraldehyde-3-phosphatedehrogenase (GAPDH) and PSCA was also assessed, 
revealing DU145 and PC3 exosomes to exhibit positive expression of GAPDH and a low 
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expression level (<7 x105 TRF) for PSCA. Therefore the PCa exosomes express proteins 
commonly found to be present in exosomes by other researchers (Lamparski et al. 2002; 
Théry et al. 1999; Escola et al. 1998) as well as proteins that are found in cells they 
originate from. 
 
To ensure that a particular protein is specifically enriched in exosomes, one successful 
approach is to compare proteins from exosomes and from whole cell lysates (CL) 
prepared from the parent cells on the same gel. Cell lysates and exosomes from DU145 
and PC3 were compared by western blotting with a range of antibodies. This allowed us 
to compare the relative expression of known exosome markers, such as MVE markers 
(TSG101 and ALIX), 5T4 a tumour associated marker and MHC Class I, in exosomes 
compared to whole cell lysates (figure 3.5B). These were highly enriched in exosomes 
from both PCa cell lines. LAMP-1 (lysosomal-associated membrane protein-1), a 
glycoprotein expressed within the lysosomal compartment was found to be positively 
expressed in DU145 and PC3 exosomes, at a similar level to that of their parent cell.  In 
contrast, the endoplasmic reticulum protein, calnexin was only stained in cell lysates. 
The expression of the cytosolic marker, GAPDH were found in both exosomes and cell 
lysates, as expected. The phenotype of exosomes analysed here agree with the 
literature (Raposo et al. 1996; Lamparski et al. 2002; Escola et al. 1998). 
 
Using Nanoparticle Tracking Analysis (NTA), the majority of the nanovesicles within the 
PCa vesicular pellet isolated from the sucrose cushion had a diameter of 79nm and 
85nm, from the DU145 and PC3 cells respectively (figure 3.6 and 3.7). This finding agrees 
with the cryo-TEM data presented here and by previous studies, in that exosome have 
a diameter within the range of 30-100nm (Raposo et al. 1996; Sokolova et al. 2011; 
Escola et al. 1998). Furthermore, there are no large particles present (>400nm), 
concluding that there are no microvesicles or other large form of cellular participate 
present.  
 
Estimating the purity of exosomes isolated, aids researchers to carry out routine quality 
control tests. The purity of exosomes can be measured based on the particle to protein 
ratio (P:P) using the nanosight and a colourimetric (BCA) assay for particle 
Isolation and characterisation of prostate cancer exosomes 
 
94 
 
(nanovescicles) and protein concentration measurement respectively, as described by 
Webber and Clayton (2013). A recent study has shown that introducing protein 
contaminants into the exosome preparation, resulted in a reduced P:P ratio in 
comparison to the exosome sample with no contamination. The decrease in P:P ratio 
correlated with increased dose of protein contamination. Thus pure exosome 
preparations exhibit higher particle to protein ratio (Webber and Clayton 2013). 
 
Furthermore, their study showed conditioned media (CM) containing exosomes from 
PCa bioreactor flasks had a low P:P ratio (3.7 x 108 P/μg). Whereas pelleting and wash 
purification of exosomes increased the P:P ratio (2 x 1010P/μg). Isolating purer 
exosomes, using the sucrose cushion method further enhanced this P:P ratio (3.4 x 1010 
P/μg). From these outcomes, Webber and Clayton (2013) proposed arbitrary thresholds, 
in which ratios greater than 3 x1010 P/μg are of high purity, ratios of 2 x 109 to 2 x 1010 
P/μg represent low purity and ratios below 1.5 x 109 P/μg are unpure. Using these 
thresholds, in this particular exosome preparation, the DU145 and PC3 exosomes 
isolated using the sucrose cushion had a P:P ratio of 4.00 x 1010 and 2.97 x 1010 P/μg 
respectively, and are therefore of high purity (figure 3.6 and 3.7). The quality control 
threshold has been used routinely on exosomes prepared from the 30% sucrose cushion, 
some of which are shown in table 3.1. The majority of exosomes passed the quality 
threshold and are used for experimental studies. The exosomal vesicles that are unpure 
(<1.5 x 109 P/μg), due to issues during the purification (i.e. not collecting the sucrose 
cushion in a clean manner) are discarded. In summary, exosomes isolated from PCa cells 
using the sucrose cushion method are of good purity and largely free from non-exosomal 
proteins.  
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Morphology of exosomal vesicles from prostate cancer cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3.4: DU145 and PC3 exosomes are circular and less than 100nm in diameter. DU145 and PC3 
exosome pellet was resuspended in PBS (1:10000) and applied to a holey carbon grid. The exosomal 
specimen grid was then rapidly plunged into liquid ethane at (-196oC to -210oC) and viewed under 
cryo-transmission electron microscopy (Cryo-TEM), confirming the rounded structure of exosomal 
vesicles with a diameter <100nm. Scale bar; 100nm. 
 DU145 PC3 
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Characterisation of DU145 and PC3 derived exosomes from the sucrose 
cushion method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3.5: Exosomes from DU145 and PC3 cells express exosome-associated proteins. 
Exosomes from DU145 and PC3 cells were captured onto high protein binding ELISA plates 
(1μg/well) and analysed for the expression of tetraspanins (CD9, CD81, CD63) as well as 
expression of prostate stem cell antigen (PSCA) and GAPDH. Time resolved fluorescence (TRF) 
of the staining is shown with isotype subtraction (A). One-Way ANOVA with Tukey’s multiple 
comparison test ***=P≤0.001. Cell lysates (10μg) and exosomes (10μg) from DU145 and PC3 
were compared by western blot using a range of antibodies (TSG101, ALIX, 5T4, MHC Class I, 
Calnexin and GAPDH (B). 
A) B) 
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Figure 3.6: Exosomes isolated from DU145 cells using the sucrose cushion are of high purity. The particle concentration (P/ml) and diameter of DU145-exosomes isolated 
using the 30% sucrose cushion was measured using Nanoparticle Tracking Analysis (NTA). 6 replicate measurements were carried out and overlaid to show the consistency 
across the repeat measurements (A). BCA assay was used to calculate the protein concentration (μg/ml) of the exosomes. The purity of exosomes were assessed by the 
particle: protein ratio (B). 
Protein concentration= 174μg/ml 
Particle concentration = 6.92 x 1012 P/ml 
Ratio (P/μg) = Particle conc. / Protein conc. 
Ratio (P/μg) = 4.00 x 1010 P/μg 
A) 
B) 
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Figure 3.7: Exosomes isolated from PC3 cells using the sucrose cushion are of high purity. The particle concentration (P/ml) and diameter of PC3-exosomes isolated using the 
30% sucrose cushion was measured using Nanoparticle Tracking Analysis (NTA). 6 replicate measurements were carried out and overlaid to show the consistency across the 
repeat measurements (A). BCA assay was used to calculate the protein concentration (μg/ml) of the exosomes. The purity of exosomes were assessed by the particle: protein 
ratio (B). 
Protein concentration= 5606μg/ml 
Particle concentration = 1.665 x 1014 P/ml 
Ratio (P/μg) = Particle conc. / Protein conc. 
Ratio (P/μg) = 2.97 x 1010 P/μg 
A) 
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Routine quality control of exosome preparations 
 
Date Exosome 
source 
Protein 
concentration 
(μg/ml) 
Particle 
concentration 
(Particles/ml) 
Ratio 
(P/μg) 
Quality 
Control 
07/03/12 DU145 605 7.27 x 1012 1.20 x 1010 PASS 
30/7/13 PC3 2271 2.33 x 1012 1.03 x 109 FAIL 
20/08/12 DU145 1097 3.95 x 1013 3.6 x 1010 PASS 
08/09/13 DU145 3696 3.25 x 1013 8.79 x 109 PASS 
02/06/13 PC3 513 4.8 x 1012 9.36 x 109 PASS 
03/10/13 PC3 4301 1.64 x 1014 3.8 x 1010 PASS 
11/09/13 DU145 6390 1.86 x 1013 2.91 x 109 PASS 
09/10/13 PC3 4006 3.18 x 1013 9.43 x 109 PASS 
09/10/13 DU145 2372 3.95 X 1011 1.66 X 108 FAIL 
10/10/13 DU145 1905 1.2 x 1014 6.30 x 1010 PASS 
18/10/13 Du145 10273 2.51 x 1014 2.44 x 1010 PASS 
01/11/13 DU145 1927 6.73 x 1013 3.49 x 1010 PASS 
16/11/13 DU145 689 4.23 x 1012 6.14 x 109 PASS 
17/11/13 DU145 4549 1.78 x 1013 3.91 X 109 PASS 
30/01/14 PC3 1393 1.71 x 1013 1.23 x 1010 PASS 
14/03/14 DU145 3518 3.86 x 1013 1.09 x 1010 PASS 
11/02/14 DU145 6875.7 1.05 x 1014 1.53 x 1010 PASS 
17/01/14 DU145 1762 4.25 x 1013 2.41 x 1010 PASS 
30/01/14 PC3 1404 1.71 x 1013 1.22 x 1010 PASS 
14/02/14 DU145 3518 3.86 x 1013 1.09 x 1010 PASS 
26/03/14 DU145 4240 1.48 x 1014 3.49 x 1010 PASS 
23/7/14 DU145 13898 8.24 x 1011 5.93 x 107 FAIL 
30/07/14 PC3 2271 2.33 x 1012 1.09 x 109 FAIL 
13/8/14 DU145 7281 2.20 x 1012 3.02 x 108 FAIL 
30/06/14 PC3 4322 1.53 x 1014 3.54 x 1010 PASS 
Table 3.1: Quality of exosomes prepared from the sucrose cushion. Protein and particle 
concentration of exosomes were measured using Nanoparticle Tracking Analysis and BCA assay, 
respectively, to calculate the particle: protein ratio. Exosomal samples isolated with a particle: 
protein ratio of ≥2 x 109 (P/μg) passes the arbitrary quality threshold (as proposed by Webber 
and Clayton 2013). 
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3.1.4 Quantification of exosomal TGF-β1 expression 
My thesis will be focusing on the biological function of exosomal TGF-β1 on the fate of 
bone marrow mesenchymal stem cell (BM-MSC) differentiation. The focus on TGF-β1 
was brought about from its importance in the induction of fibroblast differentiation into 
myofibroblasts (Tuxhorn et al. 2002). Furthermore, exosomes from mesothelioma and 
PCa cells have been shown to express TGF-β1 (Clayton et al. 2007; Webber et al. 2010). 
Here, different doses of exosomes from DU145 and PC3 cells were evaluated for the 
expression of TGF-β1 using the TGF-β1 ELISA (figure 3.8). The exosomal samples were 
prepared prior to running the assay by acid-activating the latent TGF-β1 to the 
immunoreactive form (using HCL) which can be detected by the TGF-β1 immunoassay. 
A good linear response was observed with increasing dose of exosomes and the TGF-β1 
levels. A consistent expression of the active form of TGF-β1 was observed among the 
exosome samples, in which 7pg of TGF-β1 was expressed per μg of DU145 exosomes 
and 14pg of TGF-β1 expressed per μg of PC3 exosomes. Therefore, TGF-β1 is found to 
be expressed on the exosome surface, with PC3-derived exosomes expressing double 
the amount of TGF-β1 in comparison to the DU145 derived exosomes. Knowing the 
quantity of TGF-β1 expressed on exosomes will allow equivalent dose of both exosomal 
TGF- β1 and soluble TGF-β1 to be used for comparison when assessing their effects on 
fate of MSC differentiation. 
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Exosomal expression of TGF-β1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.8: TGF-β1 are expressed more in PC3 exosomes than the DU145 exosomes  
Different doses of DU145 and PC3 exosomes (1μg, 5μg, 10μg and 15μg) in triplicates were 
subjected to acid activation and the expression of active TGF-β1 were measured using TGF-β1 
ELISA (A). From these multiple preparations, the TGF-β1 concentration per μg of exosomes was 
plotted (B). 
 
Figure 4.1: BM-MSCs, fibroblasts and myofibroblasts are spindle-shaped but only the 
myofibroblasts express α-SMA. The spindle-shaped appearance of BM-MSCs, fibroblasts and 
myofibroblasts (generated by treating fibroblasts with 1.5ng/ml sTGF-β1 for 72h) were imaged 
live in vitro using light microscopy under phase contrast. Scale bar 100μm (A). The stromal cells 
were fixed and immunohistochemically stained with monoclonal antibody against α-SMA, 
followed by goat anti-mouse FITC secondary antibody (green). The cell were additionally stained 
with DAPI (blue). IgG2a isotype control were also included. Scale bar 100μm (B).Figure 3.2: TGF-
β1 are expressed more in PC3 exosomes than the DU145 exosomes  
Different doses of DU145 and PC3 exosomes (1μg, 5μg, 10μg and 15μg) were subjected to acid 
activation and the expression of active TGF-β1 were measured using TGF-β1 ELISA. n=3 (A). From 
this, the TGF-β1 concentration per μg of exosomes was plotted (B). 
DU145= 7pg TGF-β1/μg exosomes 
PC3= 14pg TGF-β1/μg exosomes 
A) B) 
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3.2 Discussion  
In this chapter, the PCa cell lines, DU145 and PC3 have been confirmed to be epithelial 
by their cobblestone appearance, and the repertoire of CK expression revealed the 
DU145 and PC3 cells to exhibit classical luminal epithelial features, such as the 
expression of CK-7, CK-8 and CK-19. The PCa cells lacked the expression of α-SMA and 
so there was no stromal cells such as myofibroblasts or smooth muscle cells. In addition 
the DU145 and PC3 are heterogeneously positive for tumour-associated proteins MUC-
1, which are found to be overexpressed in many cancers such as breast, lung and also 
prostate cancer (Lacunza et al. 2010; Yao et al. 2011). DU145 and PC3 also exhibit 
prostate specific marker, PSCA, which is known to be specifically expressed in prostate 
epithelial cells and overexpressed in PCa cells (Reiter et al. 1998; Bargão Santos et al. 
2014; Taeb et al. 2014). Tetraspanins are commonly found in exosomes from various cell 
types (Lamparski et al. 2002; Rapaso et al. 1996; Escola et al. 1998; Heijnen et al. 1999). 
Our data has shown DU145 and PC3 cells to heterogeneously express tetraspanins CD9, 
CD81 and CD63. These findings were akin to other reports of expression of tetraspanins 
found in PCa cells (Zvereff et al. 2007; Liu et al. 2000). Some studies demonstrate 
exosomes to be akin to their parental cells (Bharathiraja et al. 2014) and if so, assessing 
the phenotype of PCa cells here, may indicate the phenotypic nature of their respective 
exosomes. 
 
PCa exosomes can be isolated using the continuous sucrose gradient method, where 
PCa cells have been demonstrated to secrete exosomes which float in fractions which 
span the classical exosomal densities of 1.1-1.2g/ml. These fractions contained the 
greatest number of nanoparticles and the strongest staining for exosome-associated 
proteins such as ALIX and TSG101. Thus the biophysical and biochemical properties of 
PCa exosomes agree with that of exosomes from other cancer cell lines (Raposa et al. 
1996; Escola et al. 1998; Heijnen et al. 1999). 
 
Exosomes purified from DU145 and PC3 cells using the sucrose cushion method revealed 
them to be rounded. However, the structural features of the vesicles, such as the lipid 
bilayer could not be visualised clearly. This is due to the lack of optimisation of factors 
such as sample preparation, sample loading onto the carbon grid, surface charge on 
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carbon support films and thickness of ice, all of which affects the performance and 
resolution of imaging (Cho et al. 2013; Grassucci et al. 2007). We couldn’t yet optimise 
the procedure as the Cryo-TEM is a new instrument at the School of Optometry (Cardiff 
University). PCa exosomes were a monodisperse population, in which the majority of 
the vesicles were less than 100nm in diameter, as shown by the cryo-TEM and the NTA, 
which agrees with most publications (Webber and Clayton 2013; Sheldon et al. 2010). 
The Nanosight performs a size analysis of particles in fluid phase, as opposed to fixed 
and dehydrated samples used in other methods such as traditional (non-cryo) electron 
microscopy and hence may give a truer representation of exosomes in their natural 
state. There were no large particles of more than 400nm, demonstrating an absence of 
non-exosomal components, such as apoptotic cellular material, in the size range of 
500nm in diameter or more. Microplate-immuno-phenotype assay revealed exosomes 
express tetraspanins and low levels of PSCA and so have some resemblance to their 
parental cells. Western blot demonstrated exosomes to be of good quality as they were 
enriched in exosomal markers with respect to whole cell lysates and levels of non 
exosomal calnexin was barely detectable. Furthermore, using the particle to protein 
ratio as proposed by Webber and Clayton (2013) showed the majority of exosomes 
isolated using the sucrose cushion method to be of high purity. More recent methods 
have been established for exosome isolation, such as the use of sepharose 2B column 
(Rabinowits et al. 2009; Sokolova et al. 2011) and exosome immunocapture plates. In 
addition, commercial methods such as the Exo-spin (Cell Guidance), exosome isolation 
kit (Life Technologies) and the ExoQuick method which utilises the total exosome 
isolation reagent, claim to precipitate exosomes from cell culture CM (System 
Biosciences). However, these methods are still yet to be standardized, and do not always 
generate exosomes of typical characteristics and purity, and the methods have not been 
thoroughly tested, especially in the context of P:P ratio. Therefore utilising the sucrose 
cushion method was justified by their results and we kept to this method for the 
remainder of the thesis, as this is a more rapid method than the continuous sucrose 
gradient technique for isolating exosomes. 
 
Lastly, in this chapter TGF-β1 has been demonstrated to be expressed on the surface of 
both DU145 and PC3 exosomes, with PC3 expressing double the amount of TGF-β1 to 
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that of PC3 exosomes. Previous studies report TGF-β1 to be expressed on exosomes by 
various cell types (Clayton et al. 2007; Cai et al. 2012; Xiang et al. 2009) and in agreement 
with the data presented here, similar levels of TGF-β1 expression were reported on 
DU145 and PC3 cells (Webber et al. 2010). Furthermore, TGF-β1 expression on 
exosomes do differ among the different PCa cell lines. For example, PC3 and DU145 were 
both found to express TGF-β1 whereas LnCap, (another PCa cell line) had very low levels 
of TGF-β1 (Webber et al. 2010). Since soluble TGF-β1, as well as exosomal TGF-β1 are 
known to be involved in the myofibroblastic differentiation of stromal cells (Tuxhorn et 
al. 2002; Webber et al. 2010), PCa exosomes expressing TGF-β1 are hypothesised to 
differentiate BM-MSCs into myofibroblast-like cells. By knowing the quantity of TGF-β1 
on exosomes, equivalent dose of exosomes, matched to the sTGF-β dose can be used to 
investigate the effect they have on the fate of BM-MSC differentiation.  
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4.1 Characterisation of MSC, fibroblasts and myofibroblasts 
Bone-marrow derived MSCs (BM-MSCs) are well-known to possess powerful tissue 
reparative and protective mechanisms, such as their capacity to differentiate into 
various mesenchymal tissues and their immunosuppressive property. This makes BM-
MSCs attractive for treatment of different diseases (Fujita et al. 2015; Fortier and Smith 
2008). Despite these advantageous MSC traits, BM-MSCs have been recently 
demonstrated to migrate to tumour stroma sites (Shinagawa et al. 2010; Khakoo et al. 
2006) and conflicting reports exist, demonstrating MSCs to either promote (Djouad et 
al. 2003; Zhu et al. 2006; Karnoub et al. 2007) or suppress tumour growth (Qiao et al. 
2008; Khakoo et al. 2006). BM-MSCs under the influence of cancer cells CM have been 
noted to differentiate into myofibroblast-like cells (Mishra et al. 2008). Recently TGF-β1 
positive exosomes from cancer cells have been shown to differentiate fibroblasts into 
tumour-promoting myofibroblasts (Webber et al. 2014). Thus, in this thesis we will be 
focusing on the fate of BM-MSC differentiation in response to PCa derived TGF-β1 
bearing exosomes. 
 
Before using BM-MSCs in our experimental studies, BM-MSCs have been rigorously 
characterised to confirm they are genuine MSCs and not a mixed population of other 
stromal cell types, such as macrophages, endothelial cells, hematopoietic cells and 
fibroblasts found within the BM. Freidenstein (1976) was the first to isolate and expand 
BM-MSCs and noted them to be plastic adherent with an elongated spindle-shaped 
morphology. Further adaptation from this, the International Society for Cellular Therapy 
(ISCT) set a minimal criteria for defining MSC, which state that in addition to MSCs being 
plastic adherent, they must express surface antigens; CD73, CD105, CD90 and must be 
negative for hematopoietic antigens (CD14 and CD45). The function of these molecules 
on BM-MSCs are not well defined, but CD73 is an ecto-5’-nucleotidase known to support 
MSC migration (Ode et al. 2011), whereas CD105, is a TGF-β receptor III, which plays a 
role in TGF-β signalling during MSC chondrogenic differentiation (Barry et al. 1999). In 
contrast, the exact function of CD90 is less well defined and has been proposed to have 
a role in the stromal adherence of CD34+ cells (Craig et al. 1993). The last criteria set by 
the ISCT, is that MSCs must also be able to differentiate into multi-lineage pathways, 
such as adipocytes, chondrocytes and osteocytes when cultured under appropriate 
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conditions (Dominici et al. 2006). This criteria is followed by scientists carrying out MSC 
research, but unfortunately, one of the obstacles with MSC research remains to be the 
lack of unique markers for MSC identification. The cell surface markers suggested by the 
ISCT is incapable in distinguishing MSCs from stromal cells such as fibroblasts 
(Kundrotas, 2012), and so identifying MSC as a contributor to the activated stroma at 
cancer sites is a challenge.  
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4.1.1 Morphology and phenotypic characterisation of BM-MSCs, fibroblasts and 
myofibroblasts 
The morphology and phenotype of BM-MSCs were compared to other stromal cell types 
that are found within the tumour stroma such as fibroblasts and myofibroblasts. Any 
differences will help define BM-MSCs and may potentially aid in demonstrating their 
relative proportion within the activated stroma. Commercially purchased naïve BM-
MSCs from healthy donors were used.  With regard to fibroblasts, and myofibroblasts, 
normal adult diploid fibroblasts (AG02262 from Coriell Institute) of lung origin were used 
as they represent a typical fibroblasts exhibiting appropriate mesenchymal markers and 
are non-transformed and become senescent after approximately ten population 
doubling. In addition, the majority of these fibroblasts can differentiate into 
myofibroblasts under the control of TGF-β1 and have been widely used in the study of 
exosome controlled differentiation (Webber et al. 2010; Webber et al. 2014).  
 
The BM-MSCs were plastic adherent and morphological evaluation by phase-contrast 
microscopy revealed the cells to possess a rounded cell body with long and thin cell 
processes (figure 4.1A) which agree with published literature (Martinez et al. 2007). 
However, evaluation of fibroblasts and myofibroblasts (generated from fibroblasts 
treated with sTGF-β1 over 72h) also exhibited a similar cell shape. Therefore 
morphology fails to distinguish the BM-MSCs from fibroblasts and myofibroblasts. This 
led us to assess the phenotype of the cells by immunofluorescence staining for alpha 
smooth muscle actin (α-SMA), a well-known myofibroblast marker. Unlike 
myofibroblasts, BM-MSCs and fibroblasts do not constitutively express α-SMA (Figure 
4.1B) thus α-SMA cannot distinguish between these two cell types. 
 
The surface-phenotype of BM-MSCs was analysed according to the classical ISCT criteria 
using flow cytometry. The majority of the BM-MSCs positively expressed the markers 
CD73, CD90 and CD105 and were negative for haematopoietic markers CD14 and CD45 
(figure 4.2A). Thus the BM-MSCs well satisfied characteristics suggested by the ISCT. The 
phenotype of BM-MSCs was explored a little deeper, by evaluating the expression of 
other surface proteins such as CD44, CD146, SSEA-4 and GD-2. Previous studies have 
reported BM-MSCs to express CD44 (Spaeth et al. 2013; Yang et al. 2010), CD146 
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(Espagnolle et al. 2014) and the glycoprotein, stage-specific embryonic antigen-4 (SSEA-
4) which are usually found in undifferentiated pluripotent human embryonic stem cells 
(Gang et al. 2007). Furthermore a study has reported ganglioside-2 (GD-2) a protein 
commonly found in embryonic stem cells to be expressed in adipose derived MSCs and 
absent in foreskin fibroblasts (Martinez et al. 2007), making it a potential marker to 
distinguish MSCs from fibroblasts. Here, we revealed all the BM-MSCs to highly express 
CD44 and likewise the majority of all the cells positively expressed SSEA-4 and GD-2 and 
to a lesser extent, CD146 (figure 4.2B). Fibroblasts and myofibroblasts were compared 
to this panel and found to display similar characteristics to the BM-MSCs (figure 4.2C). 
However, staining for SSEA-4 and GD-2 was absent or low in both fibroblasts and 
myofibroblasts (P≤0.001), demonstrating BM-MSCs are phenotypically distinct from 
other stromal cell types. 
 
In our hands, SSEA-4 was exclusively expressed in BM-MSCs and not fibroblasts and 
myofibroblasts and so this antigen raised the possibility of detecting MSCs within the 
tumour stroma as well as tumour associated myofibroblasts of MSC origin. To test this, 
normal and prostate cancer stromal cells were obtained from the Wales Cancer Bank 
and the stromal cells were evaluated for the expression of SSEA-4 (figure 4.3). There was 
a 2% higher population of SSEA-4 positive cells found within the tumour stromal cells, in 
comparison to the normal prostatic stroma. This observation was not significant, but the 
data still indicates the presence of SSEA-4 positive cells within the prostate stroma, may 
indeed be MSCs 
 
In summary, the morphology and phenotype of BM-MSCs to other stromal cells are 
similar, but α-SMA can identify myofibroblasts whilst SSEA-4 can uniquely distinguish 
BM-MSCs from fibroblasts and myofibroblasts and so this marker may enable us to track 
BM-MSCs as contributors to the tumour stroma. In this particular case, however, there 
is an insignificant increase in SSEA-4 positive cells in tumour stroma, suggesting little 
MSC contribution in the tumour stroma. 
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Morphology and α-SMA phenotype of the stromal cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Figure 4.1: BM-MSCs, fibroblasts and myofibroblasts are spindle-shaped but only the myofibroblasts 
express α-SMA. The spindle-shaped appearance of BM-MSCs, fibroblasts and myofibroblasts (generated by 
treating fibroblasts with 1.5ng/ml sTGF-β1 for 72h) were imaged live in vitro using light microscopy under 
phase contrast. Scale bar 100μm (A). The stromal cells were fixed and immunofluorescently stained with 
monoclonal antibody against α-SMA, followed by goat anti-mouse FITC secondary antibody (green). The cell 
were additionally stained with DAPI (blue). IgG2a isotype control were also included. Scale bar 100μm (B). 
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Surface Phenotype of BM-MSCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: BM-MSCs express surface antigen suggested by the ISCT and also express CD44, CD146, SSEA-4 and GD-2. BM-MSCs were fixed and stained with 
conjugated antibodies against the ISCT suggested molecules; CD73, CD90, CD105, CD14, CD45, CD44 (A), as well as other cell surface molecules; CD146, SSEA-4, and 
GD-2 (B). Flow cytometric histograms show a positive shift in the cell surface molecules expression (black) from the isotype control (grey). No shift in CD14 and CD45 
(black) are seen from the isotype (grey). Dot blot show the percentage of cells positive (black) for the specified marker (CD73, CD90, CD105, CD14, CD45, CD44, 
CD146, SSEA-4, and GD-2) in relation to the isotype control (grey). 
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Comparison of the BM-MSCs, fibroblasts and myofibroblasts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.2 continued: BM-MSCs, fibroblasts and myofibroblast express similar cell surface molecules. Fibroblasts and myofibroblasts (fibroblasts treated with 
1ng/ml sTGFb1 for 72h) were treated in the same manner as BM-MSC and summary data (bar) to compare various cell surface antigen expression among the three 
cell types; BM-MSCs (black), fibroblasts (blue) and myofibroblasts (green). Median Fluorescence Intensity (MFI) plotted after isotype subtraction (above) and 
percentage positive cells (below) are recorded ± SD of duplicates (C). Students T-test *P≤ 0.005, **P≤ 0.01 and ***P≤ 0.001.  
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SSEA-4 positive cells in primary prostate stromal cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.3: SSEA-4 positive stromal cells are found in the prostate. Normal and prostate cancer stromal 
cells were fixed and stained with FITC-conjugated monoclonal antibody against SSEA-4. Median 
Fluorescence Intensity (MFI) of cell surface expression of SSEA-4 plotted after isotype subtraction (right) 
and percentage positive cells (left) are shown with ± SD of duplicates. T-test: not significant.  
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4.1.2 Adipogenic differentiation of BM-MSCs and the response to DU145 exosomes 
BM-MSCs have already been shown to differentiate into adipocytes, osteoblasts and 
chondrocytes according to the supplier. Nevertheless, we wanted to be certain this 
property of cells was real in our hands, by examining the ability of BM-MSCs to undergo 
at least one of the classical programmes of differentiation, focusing on adipogenesis in 
this case. BM-MSCs were cultured in the adipogenesis media (containing 
dexamethasone, IBMX, insulin and indomethacin) for a period of 21 days as described 
by Pittenger (1999). The BM-MSCs developed multiple lipid droplets within the cytosol, 
which stained intensely with Oil red O (figure 4.4A). Fibroblasts treated identically 
showed no signs of adipogenic differentiation. Therefore we have genuine MSCs that 
can be used for our planned investigations. 
 
Since this thesis intends to examine the effect of PCa exosomes upon the fate of BM-
MSC differentiation, we explored the impact of adding exogenous sTGF-β1 or TGF-β1 
bearing exosomes from PCa cells to this adipogenic system. A dose of 1ng/ml of sTGF-
β1 was used, as this is a common concentration known to induce MSC differentiation 
into various mesenchymal cell types such as vascular smooth muscle cells and 
chondrocytes (Guerrero et al. 2014; Motoyama et al. 2010). Furthermore, exosomes in 
the previous chapter were shown to contain around 7pg of TGF-β1 per μg of DU145 
exosomes and this agreed with published literature (Webber et al. 2010; Clayton et al. 
2007). Thus sTGF-β1 (at 1ng/ml) or DU145-exosomal TGF-β1 (150μg/ml) at a dose 
approximately equivalent to 1ng/ml TGF-β1 were added to some wells together with 
the adipogenic differentiation factors every 3 days throughout the 21 day experiment 
and the effect on adipogenesis was compared (figure 4.4B). To obtain quantification of 
the adipogenic differentiation, adipocyte were counted from a total of 10 microscopic 
fields from the different conditions (figure 4.4C). Evaluation under microscopy revealed 
either treatment of sTGF-β1 or exosomal TGF-β1 to result in significant (P<0.001) 
inhibition of the differentiation into adipocytes, by 96% and 87% respectively in 
comparison to the untreated adipogenic differentiation of BM-MSCs.  
 
In addition, we examined whether BM-MSCs under the influence of PCa exosomes, 
differentiate to a myofibroblast-like phenotype. The BM-MSCs under the same 
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conditions as mentioned above were evaluated for the myofibroblastic marker, α-SMA 
by immunohistochemistry and proportion of α-SMA positive cells were quantified. BM-
MSCs in standard (DMEM with 10% FBS) or adipogenesis media exhibited a low 
proportion of α-SMA positive cells (<7%) and this was not altered following sTGF-β1 
treatment (figure 4.5A and B). In contrast more than 50% of the cells exhibited strong 
α-SMA expression following treatment with exosomes at a matched TGF-β1 dose as 
observed by filamentous stress fibres, which are not seen in other conditions. In 
summary BM-MSCs possess the ability to differentiate into adipocytes when cultured 
under appropriate conditions. However, this differentiation pathway is attenuated 
when either sTGF-β1 or PCa exosomes were added, indicating the potent strength of 
these factors, being able to override this differentiation programme. By evaluating α-
SMA expression, it is clear that exosomes drive MSC differentiation into myofibroblast-
like cells, although the response was heterogeneous. In contrast, α-SMA expression was 
not apparent with sTGF-β1 along with the adipogenesis media, therefore differentiation 
of BM-MSCs into myofibroblast-like cells may not be possible when stimulated with the 
soluble form of TGF-β1. 
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Adipogenic differentiation of BM-MSCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 4.4: BM-MSCs have the capacity to differentiate into adipocytes and this differentiation is inhibited by 
either sTGF-β1 or PCa exosomes. BM-MSCs and fibroblasts cultured in standard media (top) or with the 
addition of adipogenic stimulants (bottom) for 21 days was stained for adipocytes using Oil Red O solution and 
nuclei was stained using haematoxylin (A). Selection from image showing clusters of Oil Red O-stained fat 
droplets in adipocytes (A, inset). During adipogenic differentiation, sTGF-β1 (1ng/ml) or DU145 exosomes 
(150μg/ml) were repeatedly added along with the adipogenic stimulants and the formation of Oil Red O positive 
adipocytes (black arrows) examined at day 21. Scale bar 100μm (B). Bars show the mean (±SD) number of 
adipocytes per field of view, from a total of 10 microscopic fields examined in duplicate wells per treatment 
and are representative of two independent experiments (C).***P≤0.001 One-way ANOVA with Tukey’s post-
test. 
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Myofibroblast-like phenotype 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4.5: Presence of DU145 exosomes in the adipogenesis media trigger enhanced α-SMA expression 
in BM-MSCs. BM-MSCs were cultured in standard media or adipogenesis media (with or without sTGF-β1 
(1ng/ml) or DU145 exosomes (150μg/ml) as depicted) over 21 days. The cells were stained for α-SMA 
(green) and DAPI (blue). Scale 100μm (A). Quantification of the proportion of α-SMA positive cells, from a 
total of 6 microscopic fields examined in duplicate wells per treatment, is shown (B). Representative of 
two independent experiments. ***P≤0.001 One-way ANOVA with Tukey’s post-test. 
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4.2 Discussion 
Our data fulfils ISCTs criteria for defining MSCs, as the cells were plastic adherent, 
spindle-shaped in appearance, expressed the cell surface molecules CD73, CD90, CD105 
and were negative for the hematopoietic markers. Therefore, we have genuine MSCs 
which are not contaminated with hematopoietic cells or other stromal cells. In addition, 
we also demonstrated the expression of the protein CD44 on BM-MSCs, in agreement 
with previous studies (Spaeth et al. 2013; Yang et al. 2010). CD44 was demonstrated to 
facilitate MSC migration in vitro through the interaction with extracellular hyaluronan 
(Zhu et al. 2006), which may be crucial for recruitment of MSCs into wound and tumour 
sites. BM-MSCs also expressed GD-2, similar to that of adipose-derived MSCs (Martinez 
et al. 2007), but the function of GD-2 on MSCs is unknown. In addition, our data revealed 
a subpopulation of BM-MSCs to express CD146 and this heterogeneity was also noted 
by others (Tomin et al. 2011; Espagnolle et al. 2014; Russell et al. 2013). CD146 positive 
and negative BM-MSCs were found to express similar levels of CD73, CD90 and CD105 
but under appropriate conditions, only the CD146 positive MSCs were committed 
towards a vascular smooth muscle lineage characterised by up-regulation of calponin-1 
and the ability to contract collagen matrix (Espagnolle et al. 2014). Therefore there are 
subpopulations of BM-MSCs that are more prone to differentiate into certain cell types.  
 
The panel of cell surface molecules used to characterise MSCs do not distinguish MSCs 
from fibroblasts and myofibroblasts as they also display similar characteristics. The 
presence of α-SMA stress fibres was able to distinguish myofibroblasts from the other 
two stromal cell types, but it remained difficult to discriminate between fibroblasts and 
BM-MSCs. Based on this reason, some researchers argue that MSCs and fibroblasts are 
identical (Hematti 2012). However, the SSEA-4 glycoprotein usually expressed in 
embryonic stem cells was also expressed on BM-MSCs (Gang et al. 2007) and here we 
confirm the value of SSEA-4 in distinguishing MSCs from fibroblasts and myofibroblasts 
in an unequivocal manner. SSEA-4 does not play critical roles in maintaining the 
pluripotency of embryonic cells (Brimble et al. 2007), but instead is related to the 
multipotency function, as only the MSCs expressing SSEA-4 exclusively exhibited the 
capacity to differentiate into the classical multi-lineage pathways in vitro (Rosu-Myles et 
al. 2013). Therefore the SSEA-4 subpopulation within the MSCs is indicated to truly 
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exhibit the multi-lineage capacity. Overall, it is a challenge to define MSCs in tissues, but 
SSEA-4 may be a definitive marker for MSCs which can help identify these cells in situ. 
Our data demonstrated an insignificance difference in SSEA-4 positive cells among the 
normal and prostatic stromal cell populations (taken from prostatectomy tissue). This 
may have been partly affected by the small sample size used for assessment which is 
taken into account by the t-test, resulting in a bigger p-value. Nevertheless, there was a 
small percentage of stromal cells from both normal and tumour prostate to be SSEA-4 
positive, suggesting the presence of MSCs in prostatic stromal cell populations. 
However, the origin of SSEA-4 positive MSCs within the prostate stroma are unknown. 
It may be that SSEA-4 is also expressed on MSCs from other sources such as adipose 
tissue and SSEA-4 may also be expressed on cancer stem cells. In addition, whether 
SSEA-4 expression decreases once MSCs have migrated or differentiated requires 
investigation. A marker unique to BM-MSC, will enable us to track BM-MSCs as 
contributors to the tumour stroma. 
 
The last criteria and arguably the most important for defining MSCs, is their functional 
multi-lineage differentiation capacity. Here we confirm that BM-MSCs can differentiate 
into adipocytes and the addition of sTGF-β1 or DU145 exosomes along with the 
adipogenesis media had the capacity to override the potent adipogenic differentiation 
programme. However, it was only the PCa exosomes that imposed a switch towards 
generating myofibroblast-like cells. TGF-β1 is a key cytokine driving the differentiation 
of MSCs into various mesenchymal cell types at the dose used in this study (1ng/ml). For 
example, MSCs treated with sTGF-β1 over 14 days can differentiate into vascular smooth 
muscle cells (Guerrero et al. 2014). In addition the presence of sTGF-β1 along with the 
adipogenic stimulants, dexamethasone can halt MSC differentiation towards adipocytes 
and drive the MSCs to differentiate into osteoblasts (Jaiswal et al. 1997; Bruder et al. 
1997). Furthermore, 3-dimensional conformation of MSC aggregates with sTGF-β1, 
dexamethasone and insulin will undergo chondrogenic differentiation (Johnstone et al. 
1998; Mackay et al. 1998; Lee et al. 2004b). Therefore sTGF-β1 within the adipogenesis 
media may drive MSCs to differentiate into mesenchymal cell types, other than the 
adipocytes or myofibroblasts. 
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Our data show that PCa exosomes can differentiate MSCs into myofibroblast-like cells, 
but whether this effect is solely dependent on PCa exosomes and not observed as a 
synergistic effect with other hormones present within the adipogenesis media requires 
investigation. DU145 and PC3 exosomes have been demonstrated to express high levels 
of latent TGF-β1, which can be presented to recipient cells in a biologically active manner 
(Webber et al. 2010). In addition, a distinct phenotype and function of myofibroblasts 
generated from fibroblasts using exosomes, in comparison to using sTGF-β1 has been 
shown (Webber et al. 2014). Thus, even though the interaction between exosomes and 
MSCs are not well understood, exosomal-TGFβ1 is believed to play a role in this 
myofibroblastic differentiation, and can be a focus for a mechanistic investigation. In 
addition the function of exosome-modified MSC in promoting tumour progression 
warrants further investigation. 
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5.1 Direct effect of exosomes on MSC phenotype 
In the previous chapter, prostate cancer exosomes within the adipogenesis media were 
shown to drive BM-MSC differentiation away from adipogenesis and towards a 
myofibroblast-like cells. Here, the direct effect of PCa exosomes on BM-MSCs 
differentiation will be explored.  
 
5.1.1 Phenotypic changes of BM-MSCs in response to exosomes 
To assess the fate of BM-MSC differentiation in response to PCa exosomes, the BM-
MSCs were firstly growth arrested overnight once 70% confluent. Thereafter BM-MSCs 
were cultured in standard media (DMEM 1% exosome depleted FBS) alone or with a 
single stimulation with sTGF-β1 (1ng/ml) or exosomes from DU145 or PC3 cell lines at 
equivalent TGF-β1 dosage (150μg/ml or 75μg/ml, respectively) over a 14 day period. The 
BM-MSCs were fixed and phenotypic changes such as the expression of α-SMA were 
explored by immunohistochemistry. In addition, the percentage of positive cells were 
counted over six microscopic fields (figure 5.1 A,B), revealing BM-MSCs treated with 
sTGF-β1 to exhibit negligible change in α-SMA positive cells, compared to that of the 
untreated MSCs. Only the PCa exosomes (DU145 or PC3 derived) drove a significant 
elevation, in α-SMA positive cells, by a 6-fold increase in comparison to the untreated 
MSCs (P≤0.01). Importantly α-SMA protein was not simply elevated in these 
experiments but was present as organised stress-fibres; the onset of which is a key 
characteristic of myofibroblasts. Thus, unlike sTGF-β1, cancer exosomes differentiate 
the majority of BM-MSCs into α-SMA positive myofibroblast-like cells. 
 
The level of pro-angiogenic growth factors such as VEGF-A and HGF secreted by the 
undifferentiated and differentiated BM-MSCs was also investigated, by measuring the 
quantity of these growth factors present within the BM-MSC conditioned medium (CM) 
which has been normalised to their cell number (figure 5.1C). There was around twice 
as much of VEGF-A found in MSC CM in the presence of exosomes (P≤0.05) in 
comparison to untreated MSC CM. Similarly, there was an elevated level of HGF 
(P≤0.001) in exosome-treated MSC CM in comparison to the untreated. In contrast, 
there was less HGF in the CM when BM-MSCs was treated with sTGF-β1. From this we 
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can conclude that exosomes and sTGF-β1 differentiate MSCs but towards different end 
points, as shown by the striking difference in phenotype and secretory profile.  
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Myofibroblastic differentiation of BM-MSCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.1: DU145 and PC3 exosomes differentiate BM-MSCs to a myofibroblast-like 
phenotype. BM-MSCs at passage 3 were growth arrested overnight and were either left 
untreated, or cultured in the presence of sTGFβ (1ng/ml) or DU145 exosomes (150ug/ml) 
or PC3 exosomes (75μg/ml) in DMEM with 1% exosome depleted FBS over 14 days. BM-
MSCs were examined by immunohistochemistry for the expression of α-SMA (green) and 
DAPI (blue). Selected region (grey box) show the presence of α-SMA positive stress fibres. 
Scale bar 100μm (A). The proportion of α-SMA positive cells over 6 microscopic fields were 
examined in duplicates per treatment. Representative for three such experiments (B). 
Conditioned media (normalised for cell number) from the undifferentiated and 
differentiated BM-MSCs was analysed by ELISA for VEGF-A and HGF levels (C). One-way 
ANOVA with Tukey’s multiple comparison test.* P≤0.05, **P≤0.01 and ***P≤0.001 and 
****P≤0.0001 
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5.1.2 Dose and kinetics of MSC differentiation in response to DU145 exosomes 
So far we know that PCa exosomes can differentiate BM-MSCs into myofibroblast-like 
cells. However the optimal dose and time of exosome exposure needed to generate 
myofibroblasts from BM-MSCs is not yet known. Most researchers use sTGFβ-1 at a dose 
of 1-1.5ng/ml to differentiate cells into myofibroblasts (Lewis et al. 2004; Lijnen et al. 
2003; Jester et al. 1999). Likewise a single dose of 200µg/ml of PCa exosomes which was 
a matched-TGF-β1 dose to 1.5ng/ml sTGF-β1 induced fibroblasts to differentiate into α-
SMA positive myofibroblasts after 72h (Webber et al. 2010). With regard to MSCs, Gu et 
al. (2012) treated umbilical cord derived MSCs with 800μg/mL of gastric cancer 
exosomes repeatedly every 3 days, over a 14 day period, resulting in α-SMA positive 
myofibroblast-like cells. In contrast to this high dose, as little as 4 or 20µg of breast 
cancer exosomes was used to investigate if adipose-derived MSCs differentiate into 
myofibroblasts, they did not however mention how long the MSCs were treated for. 
Nevertheless, low levels of α-SMA positive cells were observed but the actin stress fibres 
were not detected (Cho et al. 2012). Thus, exosomes at a very low dose was probably 
too weak to have an effect on MSC differentiation towards myofibroblast-like cells. In 
addition, in these cases, the expression level of TGF-β1 on exosomes was not known and 
even though both low and high range of exosome dose have been used to study 
myofibroblastic differentiation, the optimal dose and time of exosome exposure needed 
to generate myofibroblasts from BM-MSCs are not yet known. 
 
Here, the kinetics of BM-MSC differentiation in response to PCa exosomes was tested 
by treating the BM-MSCs with a single dose of 150μg/ml DU145 exosomes over different 
time points (3d, 6d, 9d and 14d period). After each time point, α-SMA expression was 
assessed by immunohistochemistry and the proportion of α-SMA positive cells were 
counted. There was no spontaneous elevation of α-SMA in the untreated BM-MSCs. The 
kinetics of α-SMA onset was slower than we had expected, certainly slower than that 
for fibroblasts in which α-SMA peaks at around 3 days post-exosome stimulation 
(Webber et al. 2010). Here, there was no change in α-SMA status by day 3 for BM-MSCs, 
with changes only becoming apparent 6 days post exosome treatment but continuing 
steadily thereafter approaching 70% positivity with α-SMA stress fibres by day 14 (figure 
5.2 A,B). The level of pro-angiogenic factors, VEGF-A and HGF secreted by the 
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exosomally-differentiated BM-MSCs were also measured using ELISA and compared to 
untreated and sTGF-β1 treated BM-MSCs. As expected, the secretion of these growth 
factors by the untreated BM-MSCs was low over 14 days and the VEGF-A level remained 
unchanged with sTGF-β1 treatment (figure 5.2C), agreeing with earlier observations. In 
contrast, elevated secretion of VEGF-A and HGF by exosome-treated BM-MSCs 
occurred, with peak elevation of VEGF and HGF secretion (P≤0.001) observed at day 8 
and 6 respectively. Therefore, there was notable changes in the cells at time point’s 
preceding the changes in the cytoskeleton (α-SMA), and so the response to exosomes is 
actually quick but takes two weeks to fully generate into myofibroblasts. 
 
The impact of exosome dose on BM-MSC differentiation was examined, by treating BM-
MSCs with DU145 exosomes at 75μg/ml, 150μg/ml or 300μg/ml for 14 days. The 
response to exosome treatment was dose dependent, with an approximately 3 fold 
elevation to around 30% of the population becoming α-SMA positive at 75µg/ml. This 
increased to around 75% with very high exosome doses of 300µg/ml (figure 5.3 A,B). 
When evaluating levels of pro-angiogenic factors secreted by the MSCs, there was no 
significant difference in VEGF-A concentration between the untreated and 75μg/ml 
exosome treated MSCs. However, a 4 fold increase in VEGF-A secretion was observed 
with 150μg/ml and this incremented further with 300μg/ml exosomes (P≤0.0001) 
(figure 5.3C). Similarly, HGF secretion by exosome-treated BM-MSCs was dose-
dependent, as HGF secretion was elevated with increasing exosome-dose. In summary, 
our data show exosome-mediated MSC differentiation is time and dose-dependent. 
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Kinetics of MSC differentiation by DU145 exosomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.2: MSC differentiate into myofibroblast-like cells in a time-dependent manner. BM-MSCs were growth arrested overnight 
and cultured in standard media (DMEM 1% exosome depleted FBS) alone or with DU145 exosomes (150µg/ml) over different time 
points (3d, 6d, 9d and 14d). The MSCs were examined by immunohistochemistry for the expression of α-SMA (green) and DAPI (blue). 
Scale bar; 200μm (A).The proportion of α-SMA positive cells were counted from 6 microscopic fields of view across duplicate wells 
and plotted as bar graph (B). One-way ANOVA with Tukey’s post-test. ***P≤0.001 and ****P≤0.0001. 
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Kinetics of MSC differentiation by DU145 exosomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 continued: MSC differentiate into myofibroblast-like cells in a time-dependent 
manner. Conditioned media (normalised for cell number) taken from BM-MSCs treated with 
sTGF-β1 or DU145 exosomes at specified time point, were analysed by ELISA for levels of VEGF-
A or HGF (C). Two-way ANOVA with Benferroni post-test.  * P≤0.05, **P≤0.01 and ***P≤0.001 
(n=3). 
(C) 
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Dose-dependence of MSC differentiation by DU145 exosomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
BM-MSC + 75µg/ml exosome + 150µg/ml exosome + 300µg/ml exosome 
(A) 
Ø Ø Ø 
(B) (C) 
Figure 5.3: Exosome generate α-SMA positive cells in a dose-dependent 
manner. BM-MSCs were growth-arrested (DMEM 1% exosome-depleted FBS) 
for 24h and thereafter stimulated for 14d with increasing doses of exosomes 
(0-300µg/ml). The MSCs were examined for the expression of α-SMA (green) 
and DAPI (blue) by immunohistochemistry. Scale bar; 200μm (A). 
Quantification of the proportion of α-SMA positive cells from a total of 6 
microscopic fields were examined in duplicate wells per treatment, are shown 
(B) One-Way ANOVA, Tukey’s multiple comparison test. Conditioned media 
(normalised for cell number) taken from BM-MSCs treated with differentiate 
exosome dosage were analysed by ELISA for levels of VEGF-A or HGF (C). Two-
way ANOVA with Benforri post-test.  * P≤0.05, **P≤0.01, ***P≤0.001 and 
****P≤0.0001. 
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5.2 The relative importance of exosomes, as a component of the cancer 
secretome, in driving MSC differentiation 
The secretion of exosomes is regulated by Rab27a; a GTPase involved in the fusion of 
multivesicular endosomes containing exosomes to the plasma membrane, resulting in 
the release of exosomes (Ostrowski et al. 2010; Bobrie et al. 2012). Blockade of Rab27a 
has been shown to decrease the secretion of exosomes in many studies (Li et al. 2014; 
Bobrie et al. 2012; Ostrowski et al. 2010). Here, the secretion pathway of exosomes was 
interfered by Rab27a knock down in DU145 cells using the ribozyme silencing method, 
carried out by our group in collaboration with Prof Wen Jiang (Cardiff University). These 
DU145 Rab27aKD cells were then used to test the exosome-dependency of BM-MSC 
differentiation. 
 
5.2.1 Characterisation of Rab27aKD DU145 cells 
Two RAB27aKD DU145 cell lines were generated using the ribozyme silencing method, 
referred to as RAB27aKD2 and RAB27aKD3. Confirmation of the knock down of RAB27a 
was carried out using qPCR to show the relative quantitation (RQ) of the RAB27a mRNA 
(figure 5.4). In comparison to the DU145Control Vector cells, RAB27a mRNA level was 
reduced by 53% and 65% in DU145RAB27aKD2 and DU145RAB27aKD3, respectively. Therefore 
DU145RAB27aKD3 had the lowest mRNA level of RAB27a. To investigate the effects of 
RAB27a silencing upon the endocytic tract, the DU145Control Vector and DU145RAB27aKD3 cells 
were stained for the early endosome antigen-1 (EEA-1) and lysosome associated 
membrane protein-2 (LAMP-2) and evaluated using immunohistochemistry. Given the 
association of exosomes with the late endocytic tract, it was predicted that there will be 
very little impact in the distribution of EEA-1 due to the silencing of RAB27a. As expected 
the knock down of RAB27a did not affect the localisation of EEA-1, as in both the control 
vector and RAB27aKD cells, EEA-1 protein was found to be spread throughout the cell 
(figure 5.5A). Conversely, expression of LAMP-2, a marker of lysosomes and endosomes, 
became concentrated near the nuclei (principally where the late endosomes are 
located) (figure 5.5B). This cytopathic effect was also reported by Ostowski et al. (2010) 
when silencing RAB27a, and is suggestive of a failure to secrete LAMP-2 positive 
exosomes, with the cell having to concentrate this molecule into lysosomes possibly for 
degradation. 
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To observe whether knock down of RAB27a mRNA affected exosome secretion, the 
particle concentration was quantified. To do this, the conditioned media from the 
DU145 control vector and both the RAB27aKD DU145 cells were collected, spun at 400g 
and 2000g to remove cells and cellular debris, and filtered to remove large non-
exosomal particles. The media was normalised to cell count and then subjected to 
Nanoparticle Tracking Analysis, as mentioned in materials and methods. In comparison 
to the DU145Control Vector CM, the particle concentration within the DU145RAB27aKD2 CM and 
DU145RAB27aKD3 CM was reduced by 16.8% (P<0.01) and 67.3% (P<0.0001), respectively 
(figure 5.6A). This agreed well with the aforementioned decrease in cellular mRNA for 
RAB27a. Because the NTA method does not discriminate exosomes from other nano-
particles, it was important to use other approaches to confirm these data. To confirm 
the loss of exosomes from RAB27a knock down, the CM from the control and RAB27aKD 
cells were normalised to cell count and subjected to high speed ultracentrifugation 
(120,000g) to obtain a pellet, which should contain exosomes if any present. The 
resuspended pellet was stained for the exosome-associated proteins ALIX and GAPDH 
(figure 5.6B). As expected, DU145RAB27aKD2 had reduced ALIX staining in comparison to 
the control, whereas negligible amount of ALIX and GAPDH staining were seen in the 
DU145RAB27aKD3 sample. Our conclusion is that DU145RAB27aKD3 is the better knockdown 
and attenuates exosome secretion the most. From hereafter, DU145RAB27aKD2 was no 
longer used for analysis. 
 
Another way to deplete exosomes from tumour cell conditioned media is by high speed 
ultracentrifugation at 120,000g as mentioned in materials and methods and as 
described above. Nanoparticle Tracking Analysis of the conditioned media revealed 91% 
reduction in nanoparticle concentration by this method, in comparison to the control 
tumour cell CM (pre-spin CM)  (figure 5.7), indicating that the majority of the exosome 
particles can be removed by high speed ultracentrifugation. Therefore exosome 
deficient DU145 conditioned media can be produced by gene manipulation or directly 
by physical manipulation, respectively.  
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Confirmation of Rab27a knock down 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Ribozyme silencing method of Rab27aKD cells have reduced Rab27a mRNA expression. 
Relative quantitation (RQ) of Rab27a mRNA among the low passage of DU145Control Vector, DU145Rab27aKD2 
and DU145Rab27aKD3 were evaluated using qPCR with GAPDH marker as the internal control (housekeeping 
gene). 
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Location of EEA1 and LAMP-2 within the DU145 control vector and 
RAB27aKD cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: RAB27aKD does not affect the location of EEA-1 but affects the location of LAMP-2. 
DU145control vector and DU145Rab27aKD3 cells were fixed and expression of EEA-1 (green) (A) and 
LAMP-2 (green) (B) were assessed by immunohistochemistry. DAPI (blue) was used to stain 
nuclei. The spread-out and concentrated location of LAMP-2, in the DU145Control vector and 
DU145Rab27aKD are shown, respectively in the grey box. Scale bar 100μm. 
DU145Control vector DU145Rab27aKD 
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RAB27a knock down attenuates exosome secretion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: RAB27aKD attenuate exosome secretion.  
Conditioned media from the DU145Control Vector, DU145Rab27aKD2 and DU145Rab27aKD3 cells were 
collected, normalised to cell count and particle count was measured using Nanoparticle Tracking 
Analysis and percentage of particle concentration by the different cells plotted as a bar graph. 
6 measurements were taken per sample. One-way ANOVA with Tukey’s post-test **P≤0.01, 
***P≤0.001 and ****P≤0.0001 (A). Exosome pellet from the different cell types were stained 
for the antibodies against ALIX and GAPDH and evaluated by western blotting blot (B). 
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High speed ultracentrifugation removes exosomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 5.7: Exosomes can be removed by high speed ultracentrifugation.  
Normal DU145 conditioned media pre-spin (black) and post-spinning (green) by high speed 
ultracentrifugation were subjected to Nanoparticle Tracking Analysis for quantifying exosome 
particle concentration. Six measurements were obtained from each sample. One-way ANOVA 
with Tukey’s post-test * P<0.05, **P<0.01 and ***P<0.001. 
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5.2.2 MSC cultured in exosomes depleted DU145 culture media do not differentiate into 
myofibroblasts 
To investigate whether BM-MSC differentiation was solely dependent on prostate 
cancer exosomes, BM-MSCs were cultured in culture media (CM) from exosome-
proficient and exosome-deficient DU145 cells. DU145 cancer cells had been rendered 
exosome-deficient by Rab27a knockdown, or alternatively the exosomes were depleted 
from the CM using ultracentrifugation at 120,000 x g. In addition, the exosome 
containing pellet generated by the spin was resuspended in the original volume and 
used to culture the BM-MSCs. After 14 days, α-SMA expression was assessed by 
immunohistochemistry and the proportion of α-SMA positive cells were examined. 
 
Untreated BM-MSCs exhibited negligible levels of α-SMA positive cells, as expected and 
in the presence of non-manipulated DU145 CM, the majority of BM-MSCs differentiated 
into α-SMA positive myofibroblasts (figure 5.8 A,B). This myofibroblastic differentiation 
failed to occur when the BM-MSCs were cultured with exosome-depleted DU145 CM, in 
which the DU145Rab27aKD CM or exosome depleted DU145 CM post-spin revealed a 6-fold 
and 5-fold reduction in α-SMA positive cells, respectively (figure 5.8B), akin to the 
findings with untreated BM-MSCs in standard media. The exosome containing pellet 
however was sufficient to fully restore myofibroblastic differentiation to that of the 
DU145 control CM. Therefore our data show that cancer exosomes and not other 
soluble factors within the cancer cell secretome are chiefly responsible for controlling 
the differentiation of BM-MSCs into myofibroblasts. 
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(A) 
Myofibroblastic differentiation of BM-MSCs is dependent on PCa-derived exosomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.8: Myofibroblastic differentiation of BM-MSCs is PCa exosome dependent. BM-MSCs were growth arrested overnight 
and thereafter cultured in standard media (DMEM 1% FBS) alone or with DU145 culture media (CM) at a 1:1 ratio. CM used was 
normalised for cell number and was taken from DU145Control or DU145Rab27aKD cells, or from DU145Control cells following 
ultracentrifugation to pellet exosomes (120,000g supernatant), or the exosome containing pellet from this spin (120,000g pellet) 
which was resuspended in the original volume. After 14 days, cells were assessed for the expression of α-SMA (green) and DAPI 
(blue) by immunohistochemistry. Scale bar 200µm (A). Quantification of the proportion of α-SMA positive cells from a total of 6 
microscopic fields were examined in duplicate wells per treatment, and mean (±SD) proportion of α-SMA positive cells are shown. 
Representative of two experiments (B). Students T-test ***P≤0.001. 
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5.3 The role of exosomal TGF-β1 in MSC differentiation 
The mechanism by which exosomes trigger alterations in recipient cells are not well 
understood. PCa exosomes have been shown to express TGF-β1 in the previous chapter 
and is hypothesised to be chiefly responsible for BM-MSC differentiation into 
myofibroblast-like cells. 
 
5.3.1 Blocking exosomal TGF-β1 partially inhibits a-SMA expression 
To test the role of exosomal TGF-β1 on BM-MSC differentiation, TGFβ signalling was 
blocked using either an inhibitor of the ALK5 TGFβ-receptor I, SB431542 (10µM) or using 
a neutralising antibody (10µg/ml) against TGF-β that will bind to and inhibit exosomally-
delivered TGF-β1 as described by others (Webber et al. 2010; Webber et al. 2014). The 
proportion of α-SMA positive cells, arising following stimulation was assessed by 
immunohistochemistry and quantified, revealing a 6 fold increase in α-SMA positive cells 
forming stress fibres, in the presence of exosomes. However, exosomes added with 
either inhibitors, failed to trigger differentiation into α-SMA positive cells, as the 
percentage α-SMA positive cells remained low, similar to that of the untreated or sTGF-
β1 treated BM-MSCs (figure 5.9 A,B). Therefore, the mechanism by which prostate 
cancer cells modulate BM-MSC fate requires exosomes and exosomally-delivered TGF-
β1. 
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α-SMA expression in BM-MSCs after abrogating exosomal TGF-β 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.9: Myofibroblastic differentiation of MSC is DU145 exosome dependent.  
BM-MSCs were growth arrested for 24h and then cultured in standard media (DMEM 1% FBS) 
alone or with sTGFβ (1ng/ml), or DU145 exosome (150µg/ml) in the absence or presence of the 
Alk-5 inhibitor SB431542 (10µM) or neutralising antibody against TGFβ (10µg/ml). At day 14, the 
cells were assessed for the expression of α-SMA (green) and DAPI (blue) by 
immunohistochemistry. Filamentous stress fibres are observed with exosome treatment (grey 
box). Scale bar; 200μm (A). Quantification of the proportion of α-SMA positive cells from a total 
of 6 microscopic fields were examined in duplicate wells per treatment are shown (B). Bars, Mean 
±SD. One-Way ANOVA with Tukey’s post test ***P≤0.001 and ****P≤0.0001. 
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5.4 Discussion 
Soluble TGF-β1 is a well-known cytokine involved in the myofibroblastic differentiation of 
fibroblasts (Thannickal et al. 2003; Midgley et al. 2013).  In this chapter, the phenotype of BM-
MSCs differentiated by sTGF-β1 or TGF-β1 positive PCa exosomes was shown to differ. 
Treatment with sTGF-β1 resulted in low levels of α-SMA positive cells and VEGF-A secretion, 
similar to that of the untreated BM-MSCs and a decreased level of HGF secretion. Therefore, 
unlike with fibroblasts, sTGF-β1 fails to differentiate BM-MSCs into myofibroblast-like cells 
and the reasons for this are not well understood. However, MSCs can clearly respond to sTGF-
β1 as they have the TGF-β receptor and intracellular signalling machinery to do so (Shangguan 
et al. 2012) and sTGF-β1 is known to play an important role in directing fate decisions for 
MSCs. For example, sTGF-β1 is a key requirement for stimulating the initial stages of 
chondrogenic differentiation of MSCs (Tuli et al. 2003; Niger et al. 2013), by supporting MSC 
condensation, chondrocyte proliferation, extracellular matrix deposition of type II collagen 
and aggrecan, and finally terminal differentiation which is required for chondrogenesis. For 
example, MSC condensation is strongly stimulated by TGF-β1 induced elevation of N-cadherin 
expression, which in turn enhances cell adhesion. TGF-β1 signalling via Smad 1/5/8 is required 
for chondrocyte hypertrophy, a part of the differentiation process (Tuli et al. 2003; Song et al. 
2007). Likewise, TGF-β1 can provide support for osteoblast (Zhou, 2011) and smooth muscle 
cell differentiation (Alimperti et al. 2014), but inhibits adipogenesis (Choy et al. 2003) and 
myogenesis (Liu et al. 2001). Therefore, under the influence of sTGF-β1, MSCs maybe more 
prone to differentiate into cell types other than myofibroblasts. 
 
In contrast, PCa exosomes had the potent capacity to differentiate BM-MSCs into 
myofibroblasts, as noted by the onset of α-SMA stress-fibres. This finding agrees with recent 
observations in umbilical cord and adipose tissue derived MSCs using gastric cancer and 
breast cancer exosome, respectively (Gu et al. 2012; Cho et al. 2012). Furthermore, we have 
shown that exosome treated BM-MSCs secrete elevated levels of the pro-angiogenic factors; 
VEGF and HGF, which are consistent with features of prostate cancer-associated 
myofibroblasts, as shown by previous studies (Webber et al. 2014). Our data demonstrates 
the response to exosome treatment is dose and time-dependent, where exosomes had a 
remarkable effect on BM-MSCs with a single treatment of 150µg/ml, giving a dramatic 
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differentiation towards α-SMA stress fibres myofibroblasts-like cells at day 14. This differed 
to Gu et al. (2012) study, where umbilical cord-MSCs required 800μg/ml gastric cancer-
exosomes, with repetitive exposure every 3 days over a 14 day period. The difference may be 
because the expression of TGF-β1 from PCa exosomes may significantly differ from exosomes 
of gastric cancer cells. Also, these studies isolate exosomes using crude pelleting with no 
sucrose cushion, which results in pelleting exosomes along with a lot of contaminants as 
shown by Webber et al. (2012). These contaminants which contribute to the dose of 
exosomes used may have no effect on BM-MSCs. Unlike these studies, I have isolated 
exosomes using the sucrose cushion, which obtains exosomes with much less contaminates 
as shown by Webber (2012). Thus it is likely that the exosomes isolated from the sucrose 
cushion are more pure, and so a much more apparent effect is seen with lower dose of 
exosomes. 
 
The kinetics of α-SMA in MSCs takes longer, up to 14 days, in comparison to fibroblasts 
(Webber et al. 2010) in which α-SMA peaks at around 72h post exosome stimulation. In 
general, BM-MSCs take longer to differentiate, for example 21 days are required for 
differentiation into adipocytes and chondrocytes and osteoblasts to occur (Pittenger et al. 
1999; Solchaga et al. 2011; Birmingham et al. 2012). 
 
Next, in this chapter, we investigated whether BM-MSC differentiation was solely dependent 
on cancer exosomes and to address this, exosome-deficient cancer cells were used by knock 
down of Rab27a. This manipulation attenuated exosome secretion from the cells, significantly 
as shown by loss of exosome associated protein (ALIX) within the exosome containing pellet 
and a reduction in particle concentration, in agreement with the similar reduction of Rab27a 
mRNA. Knock down of Rab27a also accumulated LAMP-2 around the nuclei, suggesting an 
accumulation of exosomes in the cell. This observation agreed with previous studies (Webber 
et al. 2014; Ostrowski et al. 2010) and additionally Ostrowski (2010) noted Rab27aKD to result 
in an enlarged MVE, most possibly from the accumulation of exosomes. Inhibition of Rab27a, 
however, for assessing exosome function is flawed as inhibition of Rab27a also effects 
secretion of soluble factors such as placenta growth factor and platelet-derived growth 
factors in melanoma cells (Peinado et al. 2012). Similarly, in breast cancer cells, secretion of 
other non-exosome associated proteins such as MMP-9 was decreased, with Rab27a knock 
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down (Bobrie et al. 2012). This makes the Rab27aKD approach inadequate for the purpose 
intended as it is not entirely exosome-specific and evaluation must be taken with caution. We 
used high speed ultracentrifugation as another approach to remove exosomes and our data 
demonstrated BM-MSCs failed to differentiate into α-SMA positive myofibroblast-like cells, 
when cultured in exosome-deficient cancer CM, by either the genetic manipulation or the 
biophysical approach. Furthermore, the addition of the resuspended exosome rich pellet 
restored the generation of α-SMA positive-myofibroblasts. Therefore, myofibroblastic 
differentiation is predominantly an exosome-mediated effect and not governed by other 
factors derived from the cancer cells. 
 
Lastly, in this chapter, we tried to touch upon the mechanism of interaction between the BM-
MSCs and PCa exosomes, involved in the myofibroblastic differentiation. Previous studies 
have reported fibroblasts and umbilical cord derived MSCs differentiation into myofibroblasts 
to be exosomal TGF-β1 dependent (Webber et al. 2010; Gu et al. 2012). Here, we interfered 
with TGF-β1 signalling by using the ALK5 inhibitor (SB431542), revealing the myofibroblastic 
differentiation of BM-MSCs to be dependent on TGF-β receptor 1 (TGF-βRI). However, other 
factors also bind to TGF-βRI, such as activin (Goumans et al. 2003). Thus the neutralising 
antibody against TGF-β1 was used as a blocking experiment to show that the TGF-β1 and TGF-
βRI interaction is required for BM-MSC differentiation into myofibroblast-like cells. In 
addition, studies have demonstrated exosomal TGF-β1 to trigger phosphorylation of 
SMAD2/3 signalling pathway and inhibition of TGF-β1 on exosomes attenuated SMAD2/3 
phosphorylation and the subsequent differentiation of cells into α-SMA positive 
myofibroblasts (Webber et al. 2010; Gu et al. 2012). Therefore the myofibroblastic 
differentiation of BM-MSCs induced by exosomally expressed TGF-β1 may be SMAD-
dependent, but this has not been investigated here.  
 
The myofibroblastic differentiation cannot be reproduced using a matched-dose of sTGF-β1 
and the reason for this difference may be due to the differences in the interaction between 
the sTGF-β1 and exosome expressing TGF-β1. TGF-β1 is tethered to the exosome surface by 
the transmembrane proteoglycan betaglycan and inhibiting the expression of betaglycan 
using siRNA or releasing betaglycan from exosome surface using pervanadate reagent, both 
reduced exosome TGF-β1 levels. This in turn, reduced the onset of α-SMA stress fibres in 
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fibroblasts (Webber et al. 2010), indicating that betaglycan aids the delivery of exosomal TGF-
β1 to the recipient cell. Furthermore, generating myofibroblasts from fibroblasts using 
exosomes was dependent on herparan sulphate (HS) side chains. Cleavage of HS side chains 
from the exosome surface, resulted in the attenuation of SMAD-dependent signalling, 
therefore the HS side chains are important in delivering efficient SMAD 2/3 signalling to the 
fibroblasts, and the same may occur to BM-MSCs. In contrast, soluble TGF-β1 is known to 
induce SMAD 1/5/8 and the Wnt signalling pathway which drive MSC differentiation towards 
chondrogenesis (Tuli et al. 2003). Whether exosomal TGF-β1 drive SMAD-independent 
pathways such as the Wnt signalling have not been explored. Furthermore exosomes are 
complex vesicles containing various growth factors, mRNA, miRNA (Valadi et al. 2007) which 
can be taken up by recipient cells (Escrevente et al. 2011). Therefore, as well as the interaction 
with exosomal TGF-β1, the possible co-delivery of other growth factors, mRNA and miRNA 
from the cancer exosomes may influence differentiation of BM-MSCs into myofibroblasts. 
Further investigation of the phenotype of exosome-differentiated BM-MSCs may provide us 
with an insight of the potential function of these myofibroblast-like cells. 
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Phenotype of exosome-differentiated BM-MSCs 
The cellular and molecular mechanisms found active in wounds are also found in cancer 
and so these observations led Harold Dvorak in 1986, to postulate that “tumours are 
wounds that do not heal” (Dvorak 1986). These include the presence of αSMA positive 
myofibroblasts (Gabbiani 2003; Orimo et al. 2005; Ueno et al. 2004) and an increase in 
proliferation and invasion of epithelial cells (Sternlicht et al. 1999). In healing wounds, 
myofibroblasts are generated from fibroblasts, by TGF-β signalling and other factors, 
which allows efficient re-epithelialization of the injured site and the myofibroblasts are 
terminated via apoptosis when the wound is fully covered by a new epidermis (Gabbiani 
2003). In carcinoma, however, this process is not self-limiting, and is more akin to 
chronic wounds, resulting in uncontrollable tumour growth and eventually metastasis 
(Schäfer and Werner, 2008).  
 
A key step in prostate cancer (PCa) metastasis is the degradation of the extracellular 
matrix (ECM). Matrix metalloproteinases (MMPs), such as MMP-1 and MMP-13, have 
been found to be expressed by invasive PCa epithelial cells (PC3 cell line) which help 
break down collagen type I and type II within the ECM, respectively (Wu et al. 1991; Daja 
et al. 2003). MMPs and other proteolytic enzymes are also produced by stromal cells, 
such as fibroblasts within breast cancer stroma (Witty et al. 1995) which degrade the 
ECM, allowing the migration and invasion of the cells. We know α-SMA is increased in 
exosome treated BM-MSCs but a more in-depth exploration of the phenotype has not 
been done before. Since the control of the matrix is a major function of stromal cells 
and because this is perturbed in cancer, we predicted that we would discover several 
alterations in relation to this following exosome-mediated differentiation. 
 
To do this, exosome treated BM-MSCs were analysed using a human fibrosis ProliferTM 
PCR array. The array covers transcripts of key genes encoding ECM remodelling 
enzymes, TGF-β signalling molecules and inflammatory cytokines, as well as additional 
genes important for a chronic wound setting. This would give us a focused read-out and 
allow us to rapidly assess their validated factors of release. 
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6.1 Changes in mRNA profile of exosome-differentiated BM-MSCs 
The untreated BM-MSCs, sTGFβ treated and exosome treated BM-MSCs were analysed 
using the PCR fibrosis array to identify any characteristic features of the exosome-
generated myofibroblasts. 
 
6.1.1 RT-qPCR fibrosis array analysis of BM-MSCs and differentiated BM-MSCs 
From the previous chapter, we know that HGF and VEGF-A secreted by exosome treated 
BM-MSCs was elevated at a time point earlier than 14 days. Hence we predicted day 4 
to be the time point most likely to see changes in growth factors such as VEGF and HGF 
as well as other proteins involved in fibrosis. Thus BM-MSCs after 4 days of treatment 
with sTGF-β1 or DU145 exosomes were analysed using the PCR fibrosis array, which 
contained 84 transcripts of known involvement in fibrosis. The mean fold-change of the 
transcripts compared to untreated BM-MSCs are shown in table 6.1 with bold highlights 
to indicate changes considered differentially expressed based on the criteria of ± 3 fold 
change compared to the untreated BM-MSC with a p-value ≤0.05. In addition the mean 
fold change of exosome treated and TGF-β treated BM-MSCs were compared to 
highlight changes unique to the exosome-generated phenotype and the data are 
presented as volcano plots. Treatment with sTGF-β1 was not inert, as we saw elevated 
mRNA for IL-1A and INHBE, whilst there was a decrease in SMAD3, SMAD6, CCL2, IL5, 
ITGB8 and HGF compared to the untreated BM-MSC (figure 6.1, blue circles). Treatment 
with exosomes also elevated INHBE and IL-1A, whilst decreasing ITGB8, but otherwise 
the alterations were dissimilar to those mediated by sTGF-β1. Exosomes strongly 
elevated MMP-3, MMP-13 and SerpinA-1 and less strongly ITGA2, ITGB6 and MMP1 
compared to the untreated BM-MSCs. Exosome treatment also triggered a decrease in 
AGT and BCL2 (figure 6.1, red circles). Unexpectedly, in comparison to the untreated 
BM-MSCs, HGF are found to be down-regulated in exosome-differentiated BM-MSCs 
(fold change ratio of 0.43), which does not agree with our protein data (in the previous 
chapter). The mRNA for VEGF-A was up-regulated in exosome-treated BM-MSCs but was 
not greater than the 3 fold change boundary. In addition there was no change in the 
αSMA expression, but we know the αSMA protein to increase at day 9 or more. Thus the 
array data cannot always be in total agreement with our known protein data. The 
transcripts that could discriminate sTGF-β1 treated BM-MSCs from exosome-treated 
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BM-MSCs are HGF, IL5, CCL2, which were significantly declined by sTGF-β1 treatment.  
Whereas, mRNA for TGF-β3 and metalloproteinase’s such as MMP-1, -3 and -13 were 
significantly up-regulated by exosome treatment (figure 6.1, green circles). Therefore, 
both sTGF-β1 and exosome stimulation of BM-MSCs change the mRNA for various 
fibrosis-related transcripts in comparison to the BM-MSCs. However, it is the exosome-
treated BM-MSCs that have features consistent with matrix turnover and inflammation. 
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PCR-Fibrosis Profiler Array  
 
 
 
 Exosome vs 
Untreated 
TGFβ vs 
Untreated 
Exosome vs 
TGFβ 
mRNA FOLD Change p Value FOLD Change p Value FOLD Change p Value 
ACTA2 0.9834 0.9930 1.9776 0.0123 0.4973 0.0183 
AGT 0.2326 0.0318 0.4236 0.0572 0.5492 0.1434 
AKT1 0.8463 0.2831 0.7163 0.2052 1.1815 0.5812 
BCL2 0.3112 0.0042 0.3901 0.0003 0.7978 0.6274 
BMP7 1.0990 0.6299 1.4227 0.2531 0.7725 0.6699 
CAV1 0.5660 0.0144 0.8912 0.5112 0.6351 0.0334 
CCL11 0.4747 0.1508 0.3332 0.2757 1.4245 0.8367 
CCL2 1.6428 0.1743 0.2161 0.0070 7.6032 0.0185 
CCL3 1.4448 0.4934 0.6953 0.4092 2.0781 0.3863 
CCR2 0.7085 0.5419 0.8021 0.5720 0.8833 0.8901 
CEBPB 1.4727 0.0269 0.5894 0.1547 2.4988 0.0238 
COL1A2 1.4808 0.0005 1.9265 0.0023 0.7686 0.0250 
COL3A1 1.7498 0.0160 1.8150 0.0056 0.9641 0.7933 
CTGF 1.0502 0.6893 1.3088 0.0480 0.8024 0.0813 
CXCR4 2.6848 0.2667 2.5817 0.3556 1.0399 0.8841 
DCN 1.3845 0.1447 0.6306 0.0127 2.1953 0.0196 
EDN1 0.8315 0.0207 1.0616 0.3456 0.7833 0.0137 
EGF 1.6083 0.0991 2.4336 0.0250 0.6609 0.1004 
ENG 1.0461 0.7206 0.6580 0.0692 1.5899 0.1135 
FASLG 0.9232 0.8077 2.2583 0.3459 0.4088 0.3389 
GREM1 1.1101 0.1362 0.7078 0.0145 1.5684 0.0098 
HGF 0.4372 0.0009 0.1219 0.0000 3.5852 0.0125 
IFNG 0.9232 0.8077 1.4227 0.2531 0.6489 0.2473 
IL10 0.6114 0.9924 0.4446 0.1992 1.3751 0.4786 
IL13 1.6605 0.4195 1.5333 0.0908 1.0830 0.5322 
IL13RA2 0.5018 0.0323 0.6284 0.1111 0.7985 0.2892 
IL1A 9.1426 0.0250 22.2091 0.0307 0.4117 0.1334 
IL1B 0.8149 0.6342 0.9906 0.8526 0.8226 0.6590 
IL4 1.6118 0.7286 3.0142 0.3439 0.5347 0.4425 
IL5 0.7856 0.3181 0.1545 0.0124 5.0844 0.0331 
ILK 0.7063 0.0178 0.8300 0.3770 0.8510 0.4203 
INHBE 10.9874 0.0161 26.8968 0.0220 0.4085 0.0848 
ITGA1 8.7288 0.7019 0.8786 0.7089 9.9350 0.3637 
ITGA2 3.9709 0.0024 2.5603 0.0469 1.5509 0.1547 
ITGA3 0.5088 0.0172 0.7562 0.3628 0.6728 0.2717 
ITGAV 0.9610 0.7879 0.8673 0.6429 1.1080 0.7745 
ITGB1 1.4364 0.0299 1.2772 0.0998 1.1246 0.3636 
ITGB3 0.6096 0.0200 0.9124 0.4853 0.6682 0.0716 
ITGB5 1.0796 0.5151 0.9136 0.6991 1.1818 0.4560 
ITGB6 6.5460 0.0017 7.4509 0.2202 0.8786 0.5316 
ITGB8 0.1929 0.0145 0.1179 0.0102 1.6359 0.3754 
JUN 1.0620 0.6512 1.0433 0.7437 1.0179 0.9078 
Table 6.1: The Human Fibrosis RT2 ProfilerTM PCR Array profiles the expression of 84 key genes 
involved in fibrosis, depicting differentially expressed transcripts 
Untreated BM-MSCs or treatment of BM-MSCs with sTGF-β1 or DU145 exosomes (over 4 days) 
were compared using the RT2-ProfilerTM Fibrosis array. Bold text highlights mRNA considered 
differentially expressed according to the criteria of ±3 x fold change and a p-value of <0.05 (t-test 
based on biological triplicates per treatment). 
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PCR-Fibrosis Profiler Array  
 
 
 Exosome vs 
Untreated 
TGFβ vs 
Untreated 
Exosome vs 
TGFβ 
mRNA FOLD Change p Value FOLD Change p Value FOLD Change p Value 
LOX 0.9665 0.8121 1.1998 0.1474 0.8056 0.1798 
LTBP1 1.1981 0.1146 1.1053 0.4087 1.0839 0.4323 
MMP1 3.361 0.0161 0.7416 0.5907 4.5322 0.0147 
MMP13 14.3312 0.0013 1.8575 0.0864 7.7155 0.0018 
MMP14 1.3842 0.1216 0.7739 0.6900 1.7885 0.1908 
MMP2 1.6081 0.0662 1.0982 0.5897 1.4643 0.1878 
MMP3 42.4110 0.0096 0.5927 0.0992 71.5576 0.0093 
MMP8 0.7126 0.2574 1.4758 1.4758 0.4829 0.0273 
MMP9 3.2356 0.3071 0.8412 0.5845 3.8469 0.2139 
MYC 1.8240 0.0150 2.3413 0.0015 0.7791 0.0976 
NFKB1 0.9104 0.5020 0.7172 0.0188 1.2694 0.1947 
PDGFA 0.6840 0.0546 1.1063 0.5935 0.6183 0.1044 
PDGFB 0.9232 0.8077 1.4227 0.2531 0.6489 0.2473 
PLAT 0.9863 0.9482 0.7119 0.1616 1.3854 0.1979 
PLAU 1.2081 0.3322 1.2233 0.2320 0.9876 0.9912 
PLG 0.7913 0.3020 0.4363 0.0443 1.8134 0.0568 
SERPINA1 13.2713 0.0147 0.9513 0.8363 13.005 0.0155 
SERPINE1 1.0189 0.8402 1.7801 0.0849 0.5724 0.0936 
SERPINH1 1.4507 0.0088 2.6688 0.0013 0.5436 0.0039 
SMAD2 0.7627 0.0502 0.8805 0.2932 0.8662 0.3487 
SMAD3 0.3752 0.0483 0.1604 0.0098 2.3392 0.1149 
SMAD4 0.8963 0.5901 0.7615 0.0187 1.1771 0.3504 
SMAD6 0.6809 0.2149 0.3109 0.0045 2.1899 0.0892 
SMAD7 1.3734 0.1058 0.7495 0.3231 1.8326 0.0555 
SNAI1 2.1055 0.0627 0.9437 0.8715 2.2312  0.1779 
SP1 0.9925 0.8698 0.6750 0.3475 1.4703 0.2878 
STAT1 1.5344 0.0957 0.7639 0.2424 2.0086 0.0086 
STAT2 0.6487 0.0662 1.4970 0.8734 0.4334 0.5621 
TGFB1 1.5107 0.0941 1.6242 0.1965 0.9301 0.6896 
TGFB2 1.2627 0.0088 1.9774 0.0003 0.6386 0.0011 
TGFB3 1.0061 0.9888 0.3261 0.0265 3.0848 0.018 
TGFBR1 1.0905 0.6675 0.5638 0.0919 1.9341 0.0711 
TGFBR2 0.6924 0.1494 0.4326 0.0233 1.6007 0.0762 
TGIF1 1.5901 0.0037 1.4112 0.0296 1.1268 0.2588 
THBS1 0.7754 0.0959 0.8742 0.5876 0.8870 0.5287 
THBS2 0.9094 0.6834 0.8009 0.6788 1.1354 0.8971 
TIMP1 2.2392 0.0012 2.7349 0.0000 0.8188 0.0391 
TIMP2 0.5663 0.2508 0.5551 0.2430 1.0201 0.9224 
TIMP3 0.6663 0.1198 1.0161 0.9549 0.6557 0.0841 
TIMP4 0.8829 0.5808 1.2689 0.0813 0.6958 0.0986 
TNF 0.5817 0.3729 2.5033 0.3031 0.2324 0.1517 
VEGFA 1.81 0.0716 2.0893 0.0411 0.8663 0.6159 
Table 6.1 continued: The Human Fibrosis RT2 ProfilerTM PCR Array profiles the expression of 84 key 
genes involved in fibrosis, depicting differentially expressed transcripts 
Untreated BM-MSCs or treatment of BM-MSCs with sTGFβ or DU145 exosomes (over 4 days) were 
compared using the RT2-ProfilerTM Fibrosis array. Bold text highlights mRNA considered differentially 
expressed according to the criteria of ±3 x fold change and a p-value of <0.05 (t-test based on 
biological triplicates per treatment) 
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PCR fibrosis array of untreated, TGF-β1 or exosome treated BM-MSCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 6.1: MP-1, MMP-3, MMP-13 and serpinA-1 are highly expressed in exosome-stimulated 
BM-MSCs 
Volcano plot, depicting results from RT2-Profiler™ fibrosis array comparing day 4 untreated BM-
MSC with sTGF-β1 treated (1ng/ml) (left) or with exosome-treated (150µg/ml) BM-MSC (middle) 
or exosome-treatment vs sTGF-β1 treatment (right). Applied thresholds were a fold change of 
±3 and a p-value of <0.05 (t-test based on biological triplicates per treatment). 
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6.1.2 Verification of mRNA gene expression changes 
The PCR array revealed transcripts for MMP-1, -3, -13, SerpinA-1 and AGT to significantly 
distinguish exosome-treated BM-MSCs from the other BM-MSCs. Thus these transcripts 
were verified among the BM-MSCs using individual primers against these genes using 
TaqMan PCR array. In agreement with the array data, there was a particularly strong 
(p≤0.001) elevation in MMP-3 and also elevated MMP-13 (p≤0.001), MMP-1 (P≤0.05) 
and SerpinA-1 (p≤0.05), with decreased mRNA for AGT (P≤0.001). However sTGF-β1 was 
also shown to decrease AGT (figure 6.2), which differed from the PCR array. Together 
the data show that exosomes impart a phenotype that has some overlap with that of 
sTGF-β1 stimulus, but points some unique features, particularly, the heightened matrix 
regulating proteases such as MMP’s and SerpinA-1.  
  
The phenotype of exosome-differentiated BM-MSCs 
 
152 
 
 
mRNA level of MMPs, SerpinA1 and AGT in BM-MSCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Figure 6.2: MMP-1, MMP-3, MMP-13 and SerpinA-1 are highly expressed in exosome-
stimulated BM-MSCs 
TaqMan-PCR verification of selected transcripts identified by the array (MMP-1, MMP-3, MMP-
13, SerpinA-1 and AGT), revealing reproducible and significant changes in relative mRNA with 
GAPDH as an internal standard, at day 4. Columns represent Log2 (relative expression) ±SD, 
compared to untreated BM-MSC (based on biological triplicates). 
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6.2 Changes in exosome-differentiated BM-MSCs at protein level 
Since, mRNA of MMPs and SerpinA-1 were up-regulated in exosome-treated BM-MSCs, 
the protein of these matrix remodelling enzymes was assessed. 
 
6.2.1 Protein analysis using immunohistochemistry 
For protein detection, the untreated, sTGF-β1 treated or exosome treated BM-MSCs 
after 6 days of stimulation were fixed-permeabilised and then subjected to intracellular 
staining using the antibodies against MMP-1, -3, -13, SerpinA-1 and visualised by 
immunohistochemistry (figure 6.3). MMP-1 was not stained in all three types of BM-
MSCs, whereas, MMP-3 and MMP-13 were positively stained in exosome treated BM-
MSCs, with little or no staining in untreated and sTGF-β1 treated BM-MSCs. SerpinA-1, 
however, was highly elevated in exosome treated BM-MSCs. Therefore, unlike the 
MMP-1 which was not detected under these conditions in BM-MSCs, MMP-3, -13 and 
SerpinA-1 are elevated in exosome-treated BM-MSCs, and may play an important role 
in the function of exosome-treated BM-MSCs. 
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Expression of MMPs and SerpinA-1 in BM-MSCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Exosome-treated BM-MSCs are highly positive for SerpinA-1 and to a lesser extent 
positive for MMP-3 and MMP-13 
BM MSCs were cultured in untreated DMEM 1% MSC-FBS or with the addition of sTGFβ (1ng/ml) 
or DU154 exosomes (150µg/ml) over 6 days. The cells were then fixed-permeabilised and 
stained with monoclonal antibodies against MMP-1, MMP-3, MMP-13 and SerpinA-1 (green) 
and DAPI (blue). Scale, 200μm.   
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6.3 Discussion 
mRNA expression in BM-MSCs 
The tumour microenvironment is known to resemble that of the chronic wound or a 
fibrotic diseased organ (Ueno et al. 2004). Thus, using a fibrosis PCR array, we explored 
the consequence of exosome stimulation on BM-MSCs arising which may resemble 
myofibroblast-like cells found within carcinoma and chronic wound healing sites. For 
analyses of phenotypic differences among the BM-MSCs, an arbitrary threshold of ± 3 
fold change was used. A lower threshold would have given us more candidates, but our 
confidence that these changes can be validated will be reduced. Here the selected 
threshold will help us to find the more extreme changes, which may be easier to validate 
and potentially have a bigger biological effect, with regard to the function of 
differentiated BM-MSCs. 
 
Exosome treated BM-MSCs had some overlapping features to that of sTGFβ-1 treated 
BM-MSCs as they both had elevated INHBE and IL1-A. INHBE is a member of the activin 
beta family, required for the production of activin which was initially described as a 
protein that stimulates the release of follicle stimulating hormone from the pituitary 
(Aroua et al. 2012). In recent years, INHBE has been identified to be overexpressed at 
wound healing sites and skin carcinomas (Antsiferova and Werner 2012). Moreover, 
clinical data showed that circulating levels of INHBE, measured by ELISA, was found to 
correlate with invasive breast cancer and prostate cancer patients with bone metastasis, 
whilst INHBE remained low among normal controls (Incorvaia et al. 2007; Leto et al. 
2006). In addition, the pro-inflammatory cytokine, IL-1A was previously found to be 
highly expressed in prostate cancer tissues, compared to normal prostate or benign 
prostate hyperplasia (BPH), as shown by immunohistochemistry and western blot 
(Ricote et al. 2004). Furthermore, IL-1A knock out mice with melanoma had a much 
lower tumour development in comparison to the wild type mice and in the absence of 
IL-1A, the carcinoma cells were shown to have a low migration rate in matrigel plugs 
(Voronov et al. 2003). Therefore INHBE and IL-1A from sTGF-β1 treated or exosome 
treated BM-MSCs may support tumour progression. Other similarities between sTGF-β1 
treated and exosome treated BM-MSCs is the decreased mRNA levels of integrin beta-8 
(ITGB8). High mRNA of ITGB8 are found in breast cancer patients with lung metastasis, 
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making ITGB8 gene a predictor for lung metastasis in breast cancer patients (Culhane 
and Quackenbush 2009; Hedenfalk et al. 2001). However, ITGB8 expression was not 
observed by sTGF-β1 or exosome treated BM-MSCs. Apart from these similarities, sTGF-
β1 treated and exosome treated BM-MSCs are dissimilar, in which the sTGF-β1 treated 
BM-MSCs have a significant decrease in CCL2, IL5, and HGF. These components are 
required for tumour progression. For example, the monocyte chemoattractant, CCL2 is 
overexpressed in prostate cancer in correlation with the advanced stages (Lu et al. 2006) 
and CCL2 is found to mediate the proliferation and invasion of PCa cells in vitro (Loberg 
et al. 2006) and tumour growth in vivo, as shown using inhibitory experiments (Loberg 
et al. 2007). IL-5 and HGF has also been found to enhance the invasion of bladder cancer 
cells and squamous cell carcinomas, respectively (Lee et al. 2012; Ren et al. 2005). In 
addition, HGF is known to promote tumour angiogenesis (Ren et al. 2005) and the 
decrease in this pro-angiogenic factor, here, by sTGF-β1 treated BM-MSCs agrees with 
the decrease in HGF secreted by the sTGF-β1 treated BM-MSCs, as shown in chapter 5. 
Therefore, unlike exosome treated BM-MSCs, the TGFβ treated BM-MSCs may be 
predicted as being less able to promote disease. 
 
Exosome-treated BM-MSCs have strongly elevated mRNA for MMP-3, MMP-13 and 
SerpinA-1 and to a lesser extent MMP-1, as revealed by the PCR fibrosis array and 
verified by TaqMan qPCR analysis. Furthermore, the protein expression level of MMPs 
and SerpinA-1 in exosome-treated BM-MSCs analysed by immunohistochemistry 
correlated with their mRNA expression. These findings agree with published literature, 
where up-regulation of MMPs such as MMP-3 mRNA expression have been found in 
breast cancer (Witty et al. 1995; Sternlicht et al. 1999; Lochter et al. 1997), and prostate 
cancer (Daja et al. 2003). Most of the MMPs are found to be secreted by the stromal 
cells, rather than the epithelial cells (Witty et al. 1995), thus stromal cells secretion of 
MMPs are of critical importance in tumours. MMPs are well known to break down the 
ECM, by cleaving collagen II, IX, X and XI (Wu et al. 1991; Knäuper et al. 1996). MMP-3, 
in particular, can also disrupt cell-cell junction by cleaving E-cadherin, as shown by a 
marked decrease in E-cadherin by immunohistochemistry (Lochter et al. 1997; Sternlicht 
et al. 1999), allowing the epithelial cells to lose anchorage dependency and invade. 
MMPs are synthesised and secreted as a pro-enzyme and are activated by removal of 
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the N-terminal pro-domain (Becker et al. 1995). Activated MMP-3 are pro-invasive, as 
they have been shown to support migration of the cells through matrigel in a Boyden 
chamber assay and this invasion capacity induced by MMP-3 was abolished when MMP 
inhibitor was added (Lochter et al. 1997). Other than the direct pro-invasive property of 
MMP-3, they can also activate other MMPs, such as pro-MMP-1, pro-MMP-9 and pro-
MMP-13 (Shapiro et al. 1995; Knäuper et al. 1996), by cleaving the N-terminal bond to 
generate fully active MMPs (Suzuki et al. 1990; Knäuper et al. 1993). Therefore MMPs, 
in particular, MMP-3 are important for the invasion of epithelial cells as they can initiate 
an MMP cascade that can further enhance tumour invasion. Additionally, exosome-
treated BM-MSCs also have up-regulated SerpinA-1, which has been found in previous 
studies to be up-regulated by tumour epithelial cells, such as squamous cell carcinoma 
(SCC) (Farshchian et al. 2011) and gastric cancer cells (Shin et al. 2012). SerpinA-1 was 
found to correlate with poor prognosis both at mRNA and protein level. Additionally, 
gastric cancer cells which had been manipulated to overexpress SerpinA-1, enhanced 
the migration and invasion of gastric cancer cells in a transwell system (Kwon et al. 
2014). Therefore SerpinA-1 may also play a role in tumour invasion in prostate cancer.  
 
Exosome treatment also decreased the mRNA of B-cell lymphoma 2 (BCL2) and 
angiotensinogen (AGT) in BM-MSCs. BCL-2 may aid tumour progression via its anti-
apoptotic function (Yip and Reed 2008). Whereas, AGT delays tumour angiogenesis by 
inhibiting the proliferation of endothelial cells. An in vivo experiment demonstrated 
mice of hepatocellular carcinoma overexpressing AGT had a longer survival in 
comparison to hepatocellular carcinoma control cells (Vincent et al. 2009). Thus, even 
though tumour-promoting BCL-2 is decreased in exosome treated BM-MSCs, a greater 
decrease in AGT may aid tumorigenesis. In summary, the fibrosis array revealed 
exosome treated BM-MSCs to impart a phenotype that has some overlap with sTGF-β1 
treated BM-MSCs, but exosome stimulation results in some unique features which 
signify a more tumour-supporting function.
  
158 
 
 
 
 
 
 
Chapter 7: Influence of 
exosome-differentiated BM-
MSCs on endothelial cells 
 
 
 
  
 
Influence of exosome-differentiated BM-MSCs on endothelial cells 
 
159 
 
7.1 Possible influence of differentiated BM-MSCs on endothelial cell 
behaviour 
Access to a disorganised vasculature offers a means of systemic dissemination of the 
tumour cells. Thus the new growth in the vascular network, the process of which is called 
angiogenesis, is important since the proliferation as well as metastatic spread of cancer 
cells depends on adequate supply of O2 and nutrients and the removal of waste 
products. Various studies have shown angiogenesis to directly correlate with the 
incidence of tumour metastasis (Weidner et al. 1991; Macchiarini et al. 1992; Tanigawa 
et al. 1996; Graham et al. 1994). Thus angiogenesis is of critical importance for growth 
of primary neoplasm and provides an avenue for hematogenous metastasis. 
Angiogenesis is a multi-step, multi-cellular process involving the proliferation, migration 
and organisation of endothelial cells into vessel-like structures (Hoeben et al. 2004). 
Various growth factors secreted from cancer epithelial and stroma cells have been 
identified to promote angiogenesis.  For example, the expression of vascular endothelial 
growth factor (VEGF) and its receptor, VEGFR-2 was significantly higher in metastatic 
than non-metastatic neoplasms and was found to directly correlate with vessel count in 
specimens from colon or gastric cancer patients (Takahashi et al. 1995, 1996).  In 
addition, expression of interleukin (IL-8), basic fibroblast growth factor (bFGF) and plate-
derived endothelial cell growth factor (PD-ECGF) were also observed to correlate with 
vessel count in gastric carcinomas (Kitadai et al. 1998; Tanimoto et al. 1991; Takahashi 
et al. 1998). These components may therefore be involved in supporting vessel 
formation but the source of these factors have not been thoroughly investigated. 
Immunohistochemical staining, however, showed that the growth factors are released 
from epithelial cells and stromal cells such as fibroblasts as well as infiltrating stromal 
cells such as macrophages (Kitadai et al. 1998; Tanimoto et al. 1991). 
 
Tumour-associated myofibroblasts are pro-angiogenic as demonstrated in many 
studies. For example, breast cancer cells admixed with tumour myofibroblasts revealed 
extensive vascular formation in a xenograft model (Orimo et al. 2005). In contrast 
capillaries were far less developed when cancer cells were admixed with non-cancerous 
fibroblasts. Likewise, myofibroblasts from gastric cancer enhanced endothelial cell tube 
formation in vitro (Guo et al. 2008). It should be noted, however, that not all 
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myofibroblasts are pro-angiogenic. Recent studies have shown α-SMA positive 
myofibroblasts generated from sTGF-β1 induced fibroblasts did not have elevated 
angiogenic growth factors (Webber et al. 2014). In contrast, prostate cancer (PCa) 
exosome induced fibroblasts differentiated into myofibroblasts which were pro-
angiogenic, as observed by elevated growth factors and their ability to promote 
endothelial vessel-like structure formation in vitro (Webber et al. 2014). Additionally PCa 
myofibroblasts (tumour educated in vivo) were pro-angiogenic unlike the normal non-
myofibroblastic stroma. However the normal non-myofibroblastic stroma became pro-
angiogenic myofibroblasts after PCa exosome stimulation. Therefore, only some forms 
of myofibroblasts exhibit a pro-angiogenic influence, possibly through the production of 
VEGF-A, HGF and other factors. 
 
I have shown PCa exosomes, to be a vital factor for BM-MSC differentiation into 
myofibroblast-like cells. Whether these exosome-differentiated MSCs exert tumour 
promoting functions akin to myofibroblasts at tumour sites has yet to be explored. In 
this chapter, I will explore the effects exosome-differentiated BM-MSCs have on 
endothelial cells. The hypothesis is that exosome-differentiated BM-MSC and their 
secreted factors drive the angiogenesis behaviour of endothelial cells.  
  
Influence of exosome-differentiated BM-MSCs on endothelial cells 
 
161 
 
7.1.1 The effects of exosome-differentiated BM-MSCs on endothelial cell proliferation 
and survival 
Whether or not exosome-differentiated BM-MSCs exhibit a pro-angiogenic function was 
explored in this chapter. To do this several aspects of endothelial cell behaviour, such as 
their proliferation, migration and organisation into vessel-like structures in vitro, in 
response to exosome-differentiated BM-MSCs was investigated. Angiogenesis studies 
requires an appropriate endothelial cell source, such as the human umbilical vein 
endothelial cell line (HUVECs). HUVECs are the most commonly studied endothelial cell 
type in angiogenesis as they are well characterised and conveniently accessible and so 
HUVECs were used for the experiments. 
 
The proliferation and survival properties of HUVECs were examined by equally seeding 
the cells (1x104) in vitro in the presence of BM-MSC conditioned medium (CM) which 
had been normalised for cell number. The CM was collected from BM-MSCs untreated 
or pre-treated for 4 days with sTGF-β1 (1ng/ml) or DU145 exosomes (150μg/ml) and 
added to the HUVECs in the absence of exogenous endothelial-cell growth factors. After 
6 days of culture, cell number and cell viability was determined by flow cytometry using 
the ViaCount reagent. The ViaCount assay distinguishes viable and non-viable cells 
based on differential permeabilities of two DNA-binding dyes within the ViaCount 
reagent; the nuclear dye which stains only nucleated cells and the viability dye, which 
brightly stains dying cells. The data shows the endothelial cell numbers poorly expanded 
with CM from the untreated BM-MSCs, whilst there was a higher proliferative response 
to CM from sTGF-β1 treated BM-MSC (figure 7.1A). This was significantly stronger, 
however following exosome-treated BM-MSC CM which resulted in a > 4-fold elevation 
of endothelial cell numbers at day 6. Exosome-differentiated BM-MSCs must therefore 
produce factors which support endothelial cell expansion. The viability of the 
endothelial cells grown in untreated BM-MSC CM was >75%, but there was a small 
increase using CM from either sTGF-β1 or exosome treated BM-MSCs (Figure 7.1B). 
Therefore survival of endothelial cells is supported by CM from exosome treated BM-
MSCs and to a lesser extent from sTGF-β1 treated BM-MSCs CM. 
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Viability of endothelial cells when cultured in untreated or exosome 
treated BM-MSC conditioned medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 7.1: Exosome-treated BM-MSC CM increase HUVEC cell proliferation 
1x104 primary HUVEC were cultured with conditioned media normalised for cell number from 
BM-MSC pre-treated for 4 days by sTGFβ or DU145 exosomes. Following 6 days in culture, 
HUVECs were harvested and total viable cell number (A) and percentage viability (B) were 
measured using the ViaCount system on a GUAVA flow cytometer. (Bars, mean ± SD, of 
triplicates, One-way ANOVA with Tukey’s multiple comparison post-test, **p<0.01, 
***p<0.001. 
(A) (B) 
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7.1.2 The effect of conditioned medium from exosome-differentiated BM-MSCs on 
endothelial migration 
For angiogenesis to occur, endothelial migration is essential. Hence the influence of 
exosome-differentiated BM-MSCs on endothelial cell migration using an endothelial 
monolayer scratch assay was examined. One of the major advantages of this simple 
scratch assay is that it mimics to some extent the migration of the cells in vivo. For 
example, the removal of part of the endothelium in blood vessels will induce migration 
of endothelial cells into the denuded area close to the wound (Liang et al. 2007). So, by 
creating an empty space in a monolayer of endothelial cells, the cells should be able to 
migrate to cover the scratch created, in response to particular stimulus. 
 
The confluent monolayer of endothelial cells was growth arrested overnight, followed 
by removal of the media and then a scratch was created using a 200µL pipette tip as 
mentioned in materials and methods. The endothelial cells were then cultured in 1:1 
ratio of EBM-2 media to conditioned media from BM-MSCs, which had been untreated 
or pre-treated with TGF-β1 or DU145 exosomes (150μg/ml) over 4 days. Images of 
scratch closure were taken over 24h and the distance between the wound margins was 
measured. Conditioned media, from exosome-treated BM-MSCs accelerated scratch 
closure, with full closure occurring by 24h (figure 7.2A,B). In contrast the scratch 
exposed to sTGF-β1 treated BM-MSC conditioned media was only 50% closed by 24h 
(figure 7.2B). At this time point, the endothelial cells were alive but poorly adherent in 
the presence of CM from untreated BM-MSC, and as such it was not possible to 
determine the position of the scratch margins at 24h. Nevertheless, scratch closure for 
this treatment was clearly less complete at 6, 12 and 18h compared to the other 
treatments and this phenomenon of loss of plastic adherence was apparent in three 
independent experiments. Therefore, exosome-treated BM-MSCs exhibit heightened 
capacity to encourage endothelial cell motility. 
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Motility of endothelial cells in the presence of BM-MSC conditioned medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7.2: Conditioned media from exosome-differentiated MSCs accelerate 
endothelial migration. 
Monolayer of HUVEC was scrapped using a 200l pipette tip to create a single vertical 
scratch. CM normalised for cell number from BM-MSCs pre-treated with sTGFβ (1ng/ml) 
or DU145 exosomes (150µg/ml), were added, and the distance between two sides of the 
scratch, highlighted by vertical white lines and arrows, was monitored at specified time 
points microscopically up to 24 hr. Scale bar 200µM (A). The distance of scratch closure 
was measured using Image J. The symbol † depicts a loss of HUVEC adhesion at 24h, hence 
scratch width could not be measured (B). (Graph shows Mean ± SD, of duplicate wells per 
treatment. Data are representative of three such experiments. One-Way ANOVA with 
Tukey’s multiple comparison test *p<0.05, **p<0.01, ***p<0.001). 
(A) (B) 
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7.1.3 The effect of exosome-differentiated BM-MSCs on the formation of vessel-like 
structures 
The process of angiogenesis, resulting in a highly ordered network of blood vessels, 
requires proliferation and precise control over the migration and branching of 
endothelial cells (Aase et al. 2007). To measure proliferation, migration and cell 
organisation, an in vitro tubule-formation assay was performed, through co-culture of 
pre-treated BM-MSCs monolayers with endothelial cells as described by Sheldon et al 
(2010). BM-MSCs were left untreated or treated with sTGF-β1 or DU145 exosomes with 
or without anti-TGFβ neutralising antibody (10μg/ml) for 4 days prior to the drop-wise 
and scattered addition of endothelial cells to the wells. After a further 6 days of culture, 
cells were fixed and stained for the endothelial marker CD31. In wells containing either 
the untreated or sTGF-β1 treated BM-MSCs, some clusters of CD31-positive cells formed 
on top of the BM-MSC monolayer, but these were relatively rare, forming short 
structures with no evidence of branching (figure 7.3A). In contrast, exosome-treated 
BM-MSCs allowed the support of multiple branched, long and wide structures consistent 
with supporting more elaborate vessel-like structures. Additionally, these CD31 positive 
vessel-like structures occupied a significant area of the well they were cultured in (figure 
7.3B). However, the addition of anti-TGF-β1 neutralising antibody, along with the 
exosomes, generated rare vessel-like structures which were short and thin with very 
little branching and did not occupy a large area of the culture system (figure 7.3A,B). 
Therefore, exosome-differentiated BM-MSCs support the proliferation, motility and 
organisation of endothelial cells and is consistent with a pro-angiogenic function. Even 
though sTGF-β1 had no effect on the formation of multi-branched vessel-like structures, 
blockage of exosomal TGF-β1 attenuated the ability of the BM-MSCs to support 
endothelial vessel-like structure formation.  
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Vessel like structure formation by endothelial cells co-cultured with BM-MSCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Exosome-differentiated MSCs support endothelial cells to form vessel-like structures. 
Monolayers of BM-MSCs were pre-treated with sTGFβ (1ng/ml) or DU145 exosomes (150µg/ml) with or without anti-TGFβ neutralising antibody (10μg/ml) for 
4 days, at which 50% of the culture medium was removed, and replaced by the same volume of EBM-2 endothelial cell culture medium lacking growth factors, 
containing 20,000 HUVEC per well. After 6 day incubation, the co-cultures were fixed and immunofluorescently stained for CD31 (green) and DAPI (blue). Scale 
400µm (A). Quantification of surface area of the CD31-positive structures was performed using Image J (B). (Bars, Mean±SD of triplicate well per condition. One-
way ANOVA with Tukey’s post-test *p≤0.05 and **p≤0.01. Representative of three such experiments). 
 
Untreated BM-MSCs + TGF-β1  
+ Exosome + Exosome 
+ anti-TGFβ 
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7.2 Discussion 
Angiogenesis is a multistep and multi-cellular process that involves proteolytic 
degradation of the extracellular matrix, followed by migration, proliferation and 
organisation of endothelial cells (Hoeben et al. 2004). In this chapter, I have shown that 
conditioned medium (CM) from exosome-differentiated BM-MSCs can strikingly elevate 
endothelial proliferation as well as survival in vitro, in comparison to the untreated BM-
MSC CM. This proliferative effect were also observed by myofibroblasts in various 
cancers (Orimo et al. 2001, 2005; Sobral et al. 2011), suggesting exosome-differentiated 
BM-MSCs have characteristics consistent with tumour-associated myofibroblasts. The 
CM from sTGF-β1 differentiated BM-MSCs, had a much weaker influence on endothelial 
proliferation and survival and so these BM-MSCs were not completely inert. Similar 
observations were reported using sTGF-β1 and exosome-treated fibroblasts, where 
exosome-treated fibroblasts had the greatest proliferative effect upon endothelial cells 
(Webber et al. 2014). Therefore myofibroblasts generated by tumour exosomes have 
characteristics that are consistent with tumour-associated myofibroblasts. 
 
A monolayer scratch assay is a commonly used method by many researchers to examine 
the motility of endothelial cells (Pin et al. 2012; Chim et al. 2011; Chrzanowska-
Wodnicka et al. 2008). The scratch assay, however, does not establish a chemical 
gradient and thus does not replace well-established methods for chemotaxis such as the 
Boyden chamber assays. Nevertheless, the monolayer scratch assay is the simplest and 
an inexpensive method to study cell motility in vitro (Reinhart-King 2008). Using this 
method, my data showed that endothelial cells cultured in CM from untreated BM-MSCs 
were very poorly motile and in fact a good proportion became non-adherent under 
these conditions at 24h, although the cells remained alive. The reason behind this has 
not been investigated thoroughly, but there are however, some studies showing BM-
MSCs to express BMP-9 (Liu et al. 2013) which can inhibit migration of breast cancer 
cells (Ren et al. 2014). Additionally, studies report BM-MSCs to secrete anti-tumorigenic 
factors such as TIMP-1 and TIMP-2, which also inhibit the migration of breast cancer 
cells, in a transwell assay (Clarke et al. 2014). Thus, similar factors may also negatively 
impact endothelial cells motility. In contrast to the untreated BM-MSC CM, my 
experiment showed that the CM from exosome treated BM-MSCs were able to complete 
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endothelial migration by 24h. Similar results was observed using fibroblasts by our 
group, where unlike the untreated or sTGF-β1 treated fibroblasts, the exosome 
differentiated fibroblasts accelerated endothelial cell motility (Webber et al. 2014). Thus 
exosome differentiated BM-MSCs exhibit a clear pro-motility function and may again 
mimic this property of tumour- associated myofibroblasts.  
 
There is currently no gold standard method to study angiogenesis in vitro. Since 
angiogenesis is the formation of blood vessel from pre-existing blood vessels, the use of 
a 3-dimentional ex-vivo mouse aortic ring assay would have been a more physiologically 
relevant assay to use, in comparison to the traditional cell-based assays (Baker et al. 
2011). However, this ex-vivo method has limitations which include the requirement for 
fresh mouse tissue, the lack of non-aortic tissues and the regression of vessels over time, 
giving a limited window for analysis (Baker et al. 2011). In addition, unlike endothelial 
cells from aortic vessels, endothelial cells from veins such as HUVECs are more 
appropriate for studying angiogenesis, as they are prone to generating capillaries, akin 
to ones found at tumour sites. Here, using the co-culturing method, my data revealed 
exosome-differentiated BM-MSCs to be pro-angiogenic as their interaction with the 
endothelial cells were essential for the formation of long and thin multi-branched 
vessels. Furthermore, matrigelTM was not used and so vessel formation was purely due 
to cell-cell interaction between the endothelial cells and the BM-MSCs and not due to 
matrix components. The pro-angiogenic function of exosome-differentiated BM-MSCs 
are similar to tumour-associated myofibroblasts. For example, gastric cancer derived 
myofibroblasts promoted angiogenesis in mice (Guo et al. 2008). Similarly, 
myofibroblasts from prostate cancer or myofibroblasts generated from cancer 
exosome-induced fibroblasts were pro-angiogenic, as observed by endothelial cells 
forming vessel-like structures in vitro. In contrast, myofibroblasts generated using sTGF-
β1- induced fibroblasts failed to support angiogenesis (Webber et al. 2014), indicating 
that not all myofibroblasts are tumour promoting. Here, my experiments demonstrated 
PCa exosomes drive BM-MSCs to differentiate into myofibroblasts which have a pro-
angiogenic phenotype consistent with tumour-associated myofibroblasts. Earlier 
chapters demonstrated the myofibroblastic differentiation of BM-MSCs were 
dependent on exosomes expressing TGF-β1. Likewise, blockage of TGF-β1 here, 
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abrogated the pro-angiogenic function of the differentiated BM-MSCs, suggesting the 
dependence of TGF-β1 bearing exosomes in driving BM-MSCs into pro-angiogenic 
myofibroblast-like cells. 
 
The pro-angiogenic feature of exosome differentiated BM-MSCs may be driven by the 
enhanced secretion of VEGF-A and HGF (shown in previous chapters). Even though the 
role of these growth factors in angiogenesis has not been explored here, various studies 
show that VEGF-A and HGF stimulate angiogenesis (Hoeben et al 2004). The HGF 
receptor, cMET is found on endothelial cells (Takahashi et al. 1995) and activation of the 
receptor induces angiogenesis through the up-regulation of VEGF-A, HGF and down 
regulation of thrombospondin-1 expression, a potent angiogenic inhibitor (Shojaei et al. 
2010; Tomita et al. 2003). Activation of cMET also phosphorylates annexin-1 (ANXA1) 
which induces endothelial cell proliferation and migration (Pin et al. 2012). The 
microRNA, miR-196, represses ANXA1 induced angiogenesis (Luthra et al. 2008), but 
VEGF-A declines the expression of miR-196 (Pin et al. 2012), suggesting that VEGF and 
HGF are both required for angiogenesis. Furthermore, binding of VEGF-A to its receptor 
on endothelial cells, results in activation of various signalling pathways such as the 
extracellular regulated kinase (Erk) pathway which  induces proliferation, migration and 
increases vascular permeability (Murphy et al. 2006). Activation of VEGF receptor also 
leads to the production of nitric oxide by the endothelial cells (Arsham et al. 2002; 
Gerber et al. 1998), resulting in endothelial migration and increased vascular 
permeability (Fulton et al. 1999). Therefore, both VEGF and HGF are pro-angiogenic and 
these factors secreted from differentiated BM-MSCs may stimulate angiogenesis. 
Matrix-metalloproteinase enzymes (MMP-1, MMP-3 and MMP13) are also up-regulated 
by exosome-differentiated BM-MSCs (previous chapter) which may be involved in the 
degradation of the ECM, thus aiding endothelial migration. Additionally, pro-angiogenic 
growth factors can be bound to the ECM matrix via ECM-binding domain (Park et al. 
1993) and studies demonstrate a subset of MMPs (including MMP-1 and MMP-3) to 
cleave the matrix-bound growth factors such as VEGF-A (Lee et al. 2005), thus amplifying 
the pro-angiogenic effect. Taken together, in this chapter, I have shown exosome-
differentiated BM-MSCs to support the proliferation, motility and organisation of 
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endothelial cells into forming vessel-like structures. The data are consistent with a pro-
angiogenic phenotype and function of tumour-associated myofibroblasts.  
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8.1 Influence of exosome-differentiated BM-MSCs on prostate cancer cell 
behaviour 
The progression of tumours requires the cancer cells to be proliferative, motile and 
invasive and myofibroblasts are believed to play an essential role in these properties of 
carcinoma cells. For example, myofibroblasts or fibroblasts isolated from invasive breast 
cancer or non-cancerous stroma from the same patients were administered with the 
breast carcinoma cells in mice. Unlike the fibroblasts, the presence of myofibroblasts 
enhanced tumour growth the most, by promoting tumour cell proliferation (Orimo et al. 
2005). Furthermore, tumour-associated myofibroblasts may direct the invasion of 
cancer cells, as myofibroblasts are found to be concentrated at the invasive front of the 
tumours (Gaggioli et al. 2007; Conti et al. 2011). Additionally, the conditioned media 
(CM) containing HGF from tumour-associated myofibroblasts or sTGF-β1 generated 
myofibroblasts, promoted the invasive capacity of carcinoma cells through a Matrigel (a 
mixture of basement membrane proteins). In contrast, the CM from carcinoma cells 
alone did not provide a pro-invasive effect to such an extent (Lewis et al. 2004; Cat el al. 
2006; Conti and Thomas 2011; Dimanche-Boitrel et al. 1994). Therefore myofibroblasts 
are an important element in tumour progression. 
 
Even though myofibroblasts derived from BM-MSCs are known to recruit to the prostate 
cancer stroma (Luo et al. 2014), the functions of myofibroblasts-derived from BM-MSCs 
has not been widely explored. In earlier chapters, my data revealed that unlike sTGF-β1, 
prostate cancer exosomes differentiate BM-MSCs into α-SMA positive myofibroblasts-
like cells with heightened production of VEGF-A, HGF, MMPs and SerpinA-1. Whether 
myofibroblastic-differentiation of BM-MSCs driven by exosomes possess pro-
tumorigenic function, similar to that of diseased prostate stroma has not been 
investigated. In this chapter, the effects of exosome-differentiated BM-MSCs upon 
prostate cancer cell lines will be investigated. The hypothesis is that exosome-
differentiated BM-MSCs alter the behaviour of tumour cells towards a more aggressive 
phenotype. 
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8.1.1 The effect of conditioned media from exosome-differentiated BM-MSCs on 
prostate cancer cell proliferation and survival 
Cancer-associated myofibroblasts promote tumour growth by up-regulating the 
proliferation of cancer epithelial cells (Orimo et al. 2005). In this chapter, I examined the 
impact of exosome-differentiated BM-MSCs on DU145 prostate cancer cell proliferation 
and survival. To do this, 1 x 104 DU145 epithelial cells were cultured in the presence of 
BM-MSC conditioned medium (CM) which were normalised for cell number. The CM was 
collected from untreated BM-MSCs or BM-MSCs pre-treated for 4 days with sTGF-β1 or 
exosomes. After 3 days of culture, cell number and viability was determined by flow 
cytometry using the ViaCount reagent. In comparison to the untreated CM, a 3.5 fold 
and 7 fold increase (P≤0.001) in the proportion of live cells was observed with sTGF-β1 
or exosome treated BM-MSC CM respectively (figure 8.1). When examining the 
percentage of viable cells, a higher percentage of viable tumour cells was observed with 
CM from sTGF-β1 treated BM-MSCs in comparison to the untreated BM-MSC CM 
(P≤0.05). However, an even greater viability was noted with the exosome BM-MSC CM 
(P≤0.01) where 90% of the cells were viable. Therefore BM-MSCs do produce factors 
which support prostate cancer cell expansion, with exosome-differentiated BM-MSCs 
having the greatest effect. 
 
Proliferation of another PCa cell line, PC3, in response to the same conditions was also 
assessed, with a similar positive effect on proliferation. Whereby, exosome treated BM-
MSC CM resulted in a 5-fold increase in the total PC3 viable cells (P≤0.0001), in 
comparison to the untreated BM-MSC CM (figure 8.2). sTGF-β1 treated BM-MSC CM 
also increased the cell number, but only double the amount to that of the untreated 
BM-MSC CM (P≤0.05). Thus exosome-differentiated BM-MSC CM again resulted in the 
greatest degree of cell expansion. There was no difference in cell survival of the tumour 
cells cultured in the presence of the untreated or sTGF-β1 treated BM-MSC CM. In 
contrast, exosome-treated BM-MSC CM gave a small but significantly increased tumour 
survival (P≤0.01), where the tumour cell viability was more than 80%. Hence, exosome-
differentiated BM-MSCs supported proliferation and survival of both the DU145 and PC3 
cells. 
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Proliferation and survival of DU145 cells when cultured in the different 
BM-MSC CM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1: Exosome-treated MSC CM promote the proliferation of DU145 cells. 
1x104 DU145 tumour cells were cultured in 1:1 ratio of RPMI media and CM from equally seeded 
BM-MSCs (untreated or pre-treated for 4 days with sTGFβ1 at 1ng/ml or DU145 exosomes at 
150μg/ml). Following 3 days in culture, DU145 cells were harvested and viability and cell counts 
performed using the ViaCount system on a Guava flow cytometer (Bars, mean±SD, of triplicates, 
One-way ANOVA with Tukey’s multiple comparison test *p≤0.05, **p≤0.01, ***p≤0.001). 
Representative of three such experiments with the DU145 cell line. 
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Proliferation and survival of PC3 cells when cultured in the different BM-
MSC CM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 8.2: Exosome-treated MSC CM promote the proliferation of PC3 cells. 
1x104 PC3 tumour cells were cultured in 1:1 ratio of RPMI media and CM from equally seeded 
BM-MSCs (untreated or pre-treated for 4 days with sTGFβ1 at 1ng/ml or DU145 exosomes at 
75μg/ml). Following 3 days in culture, PC3 cells were harvested and viability and cell counts 
performed using the ViaCount system on a Guava flow cytometer (Bars, mean±SD, of triplicates, 
One-way ANOVA with Tukey’s multiple comparison test *p≤0.05, **p≤0.01, ***p≤0.001, 
****p≤0.0001). Representative of three such experiments with the PC3 cell line. 
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8.1.2 The effect of conditioned media from exosome-differentiated MSC on prostate 
cancer cell motility 
To investigate if exosome-differentiated BM-MSCs possess tumour-promoting functions 
which can aid metastasis, the effects of CM from exosome-differentiated BM-MSCs on 
the motility of PCa cells were examined using a monolayer scratch assay. To do this, a 
monolayer of DU145 cells was growth arrested overnight, followed by a vertical scratch 
using a pipette tip. The media was replaced with CM normalised for cell number from 
untreated, sTGF-β1 or exosome-treated BM-MSCs and tumour cell motility in response 
to the different BM-MSC CM was then examined by imaging and measuring scratch 
closure over 24h. From an early time point of 6h, the epithelial scratch closure in 
response to the untreated or sTGF-β1 treated BM-MSC CM was less than 50% (figure 
8.3A,B). Whereas, the epithelial response to exosome-differentiated BM-MSC CM was 
much faster, as noted by the scratch closure of more than 60% (P≤0.001) and was  
almost completed after 10h (95%) (P≤0.001). In contrast, untreated or sTGF-β1 treated 
BM-MSC CM were extremely slow (<70%) at this time point. Therefore, soluble factors 
from exosome-differentiated BM-MSCs enhance the motility of tumour cells. 
 
The pro-motility effect was also examined on PC3 cells in the same way. Similar to DU145 
cells, the PC3 cancer cell scratch closure in response to exosome-differentiated BM-MSC 
CM was more than 60% at 6h and closure almost completed at 10h (figure 8.4 A,B). In 
contrast, the motility of PC3 cells was much slower in response to the untreated or sTGF-
β1 treated BM-MSC CM with complete closure observed at 24hr. Therefore, soluble 
factors from exosome-treated BM-MSCs also accelerated the motility of PC3 prostate 
cancer cells. 
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Motility of DU145 epithelial cells in the presence of differented BM-MSC CM 
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Figure 8.3: Exosome-treated MSC CM enhance motility of DU145 epithelial cells.  
Confluent monolayer of DU145 cells were subjected to a single vertical scratch and CM 
normalised for cell number from BM-MSC pre-treated for 4 days with sTGF-β1 (1ng/ml) 
or DU145 exosomes (150μg/ml) were added. Microscopic images of scratch closure were 
taken over 24h. Scale bar 100μm (A). The distance between the two sides of the scratch, 
highlighted by vertical white lines and arrows, was measured (B). Graph shows Mean±SD, 
of duplicate wells per treatment. Two-way ANOVA with Bonferroni post-test ***p≤0.001 
Influence of exosome-differentiated BM-MSCs on tumour cells 
 
178 
 
Motility of PC3 epithelial cells in the presence of differented BM-MSC CM 
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Figure 8.4: Exosome-treated MSC CM enhance motility of PC3 epithelial cells.  
Confluent monolayer of PC3 cells were subjected to a single vertical scratch and CM 
normalised for cell number from BM-MSC pre-treated for 4 days with sTGFβ or 
exosomes were added. Microscopic images of scratch closure were taken over 24h. 
Scale bar 100μm (A). The distance between the two sides of the scratch, highlighted by 
vertical white lines and arrows, was measured (B). Graph shows Mean±SD, of duplicate 
wells per treatment. Two-way ANOVA with Bonferroni post-test ****p≤0.0001. 
 
Influence of exosome-differentiated BM-MSCs on tumour cells 
 
179 
 
8.1.3 The effect of BM-MSCs on tumour growth in a 3D spheroid model 
3D-multicellular tumour spheroids mimic growth characteristics of in vivo tumour more 
closely than in vitro 2-D (monolayer) culture, as spheroids exhibit natural cell-cell 
attachments, elevated cell survival and proliferation in their outer layers, whilst the 
inner hypoxic core have reduced proliferation (due to diffusion gradient) (Pistollato et 
al. 2010). Thus, heterotypic spheroids were used to assess the effects BM-MSCs have on 
tumour growth, under the presence or absence of cancer exosomes. 
 
Exosome-deficient DU145 cells were established by shRNA lentiviral knockdown of 
Rab27a (carried out by Dr Jason Webber). The DU145 non mammalian shRNA control 
(DU145NM Control) or DU145Rab27aKD were used in this experiment as exosome-proficient 
or exosome- deficient cancer cells, respectively. The DU145NM Control or DU145Rab27aKD 
were incubated alone or together with BM-MSC at a ratio of 4 tumour cells: 1 MSC, in 
Poly-hema coated 96-well “u”- bottom plates. The spheroids were cultured in a 1:1 ratio 
of RPMI: DMEM 10% FBS and every other day, 50% of the culture media was replaced 
by fresh media, similar to other protocols used to generate spheroids (Vinci et al. 2012). 
The spheroids were fully established at day 4 (figure 8.5A) with some cellular debris 
around the spheroid. From an early time point of day 4, all the way to day 20, the centre 
of the spheroids containing BM-MSCs was darker in comparison to spheroids with no 
BM-MSCs. This may be because light has to travel through more thickness, indicating 
the presence of a greater number of cells within the inner core of the spheroids. 
 
Spheroid growth was measured over a 20 day period and the free hand tool on image J 
was used to measure the radius of the spheroid which was then used to estimate the 
spheroid volume using the formula; (4/3)r1r2r3 (Wapnir et al. 1996). At an early time 
point of day 4, the spheroid volume in the absence of BM-MSCs was smaller in 
comparison to spheroids containing BM-MSCs. By day 8, the spheroid volume of all 
spheroids declined (figure 8.5B), indicating some contraction of the spheroids, resulting 
in a more compact sphere. In the absence of BM-MSCs however, there was a significant 
decline in tumour size from day 4 to day 20, by 40% and 44% in the DU145NM and 
DU145Rab27aKD spheroids, respectively (P<0.0001). In contrast, spheroids containing BM-
MSCs remained the same size, with only a small decline in volume in spheroids 
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containing exosome-deficient tumour cells with BM-MSCs (P<0.001). Collectively, the 
data shows no spheroid growth over a 20 day period, among the different conditions, 
but the absence of BM-MSCs reduced the spheroid size immensely. However the 
presence of BM-MSCs maintained spheroid size, with the availability of PCa exosomes 
providing the greatest spheroid size stability. This suggests that BM-MSCs promote cell 
proliferation, and under the influence of PCa exosomes, the BM-MSCs have a stronger 
proliferative effect. 
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Tumour growth in a heterotypic spheroid model over a 20 day period 
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Figure 8.5: Spheroids containing BM-MSCs maintain tumour 
growth over 20 days of culture 
Spheroids were established in poly-hema coated plates, composed 
of DU145 cells (non-mammalian control or Rab27KD) alone or with 
BM-MSC (at a ratio of 4:1 respectively), at 104 total cells/spheroid.  
After 4 days when cells had formed firm spheroid structures, 
microscopic images were taken over a period of 20 days. Scale bar 
200μm (A). Over 20 days, the spheroid volume was measured using 
the formula; (4/3)r1r2r3 (B). Graph shows Mean±SD, n=10-15, Two-
Way ANOVA with Bonferroni post-test ****p≤0.0001, ***p≤0.001 
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8.1.4 The effect of BM-MSCs on prostate cancer cell invasion 
Myofibroblasts can remodel the extracellular matrix through enzymes, rendering the 
tumour microenvironment more supportive for tumour cell invasion (Kessenbrock et al. 
2010; Levental et al. 2009). To test if BM-MSCs under the influence of PCa exosomes 
promote the invasion of prostate cancer cells, an invasion assay was carried out using 
heterotypic spheroids. Like before, DU145NM Control or DU145Rab27aKD cells were used in 
this experiment as exosome-proficient or exosome- deficient cancer cells, respectively.  
 
Once the 3D tumour spheroids with or without BM-MSCs were established at day 4, they 
were transferred to fresh wells and MatrigelTM was added burying the spheroids in a 3D 
basement membrane (figure 8.6A). On top of the MatrigelTM was the media which 
consisted of 1:1 (v/v) of RPMI and DMEM in 10% FBS. Each spheroid was microscopically 
examined for 96h, and the area of the outgrowth was measured to ascertain whether 
or not there was any effect on escape of cells out from the spheroid, into the 
surrounding matrix. Both the DU145NM Control and DU145Rab27aKD alone showed a paucity 
of cell outgrowth even at 96 hours (figure 8.6B). In marked contrast, combining BM-
MSCs with the DU145NM cells revealed outgrowth as early as 24hr, and growing beyond 
the field of view at x10 microscope objective at 48 hours. By tiling multiple images, I was 
able to continue to assess invasion for up to 96 hours demonstrating a highly significant 
increase in the matrigel area occupied by extra-spheroidal cells (p≤0.0001) (figure 8.6C). 
Spheroids comprising BM-MSCs and exosome deficient tumour cells resulted in 
outgrowths at a later time point of 48h and outgrowths were drastically less extensive 
by 96 hours, with a clear attenuation of invasion capacity in the absence of an intact 
exosome secretion pathway. In summary, BM-MSCs under the influence of PCa 
exosomes is required to trigger the matrix invasion characteristics of the 3D-spheroid 
model, and attenuating exosome secretion, strongly attenuates tumour invasion. 
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Invasion assay MSC with or without exosome deficient tumour cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Media 
Matrigel
TM 
Tumour  
spheroid 
(A) 
Figure 8.6: Spheroids comprised of BM-MSCs 
and exosome-proficient tumour cells promote 
the invasion capacity of the tumour cells 
Spheroids were established in poly-hema coated 
plates, composed of Du145 cells (non-
mammalian control or Rab27KD) alone or with 
BM-MSC (at a ratio of 4:1 respectively), at 104 
total cells/spheroid.  After 4 days when cells had 
formed firm spheroid structures, they were 
transferred to fresh wells and Matrigel™ was 
added, followed by RPMI:DMEM (1:1) media (A). 
The area occupied by extra-spheroidal cell 
outgrowths was measured daily for up to 96hr. 
For late time-points, multiple images of the 
spheroid-outgrowths were taken and these were 
tiled to form a composite representation of the 
full extent of outgrowth (B). Area of outgrowth 
from the periphery of the spheroid was measured 
using Image J (white line) (C). (Graph shows 
Mean±SD, quadruplicate spheroids per 
treatment, Two-Way ANOVA with Bonferroni 
post-test *p≤0.05, **p≤0.01, ***p≤0.001, 
****p≤0.0001). 
(C) 
(B) 
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8.1.5 RT-qPCR analysis MMP-3 and SerpinA-1 in the spheroids 
The RT-qPCR fibrosis array performed in chapter 6 revealed exosome-treated BM-MSCs 
express high levels of matrix-metalloproteinase (MMP-3) and serpinA-1 in comparison 
to the untreated and sTGFβ-treated BM-MSCs. MMP-3 and serpinA-1 are known to be 
involved in the degradation of the extracellular matrix and thus have the capacity to 
support cellular invasion (Sternlicht et al. 1999; Daja et al. 2003; Tahara et al. 1984). For 
this reason, the level of these transcripts were evaluated in these tumour cell and BM-
MSC heterotypic spheroids used for my experiments. The DU145NM Control and 
DU145Rab27aKD spheroids alone or with MSCs were collected and RNA was isolated using 
Tri Reagent as described in materials and methods. The relative levels of mRNA for 
MMP-3 or SerpinA-1 were compared among the different spheroids using TaqMan PCR 
assay. Relative quantification using the 2-ΔΔCt method was used to observe differences in 
the gene expression of the MMP-3 or SerpinA-1 among the different spheroids relative 
to the DU145NM Control spheroids. The mRNA for MMP-3 and SerpinA-1 was significantly 
up-regulated by 70% and 74% respectively in DU145NM Control with BM-MSCs (figure 8.7). 
In contrast, exosome deficient cells with or without BM-MSCs showed no increase in 
MMP-3 or SerpinA-1. Overall, in agreement with the PCR fibrosis array data in chapter 
6, MMP-3 and SerpinA-1 are confirmed to be highly expressed in tumour spheroids 
containing PCa exosome and BM-MSCs, and the invasive capacity of the tumour cells 
were also elevated in this group the most. Hence MMP-3 and SerpinA-1 may be involved 
in supporting the invasion of the tumour cells. 
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Figure 8.7: Tumour spheroids containing PCa exosomes and BM-MSCs have heightened 
transcripts for MMP-3 and SerpinA-1. 
RNA was isolated from the DU145NM Control and DU145Rab27aKD spheroids with or without BM-MSCs 
at day 23. Quantification of mRNA expression levels for MMP-3 and serpinA-1 in the different 
spheroids were measured relative to the DU145NM Control using qPCR.  (Bars, Mean±SD, technical 
replicates. One-way ANOVA with Tukey’s multiple comparison test, *p≤0.05, **p≤0.01, 
***p≤0.001)  
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8.1.6 The effect of BM-MSCs on tumour growth in a xenograft model 
Tumour growth in the presence of BM-MSCs with exosome proficient (DU145Control Vector) 
or exosome-deficient (DU145Rab27aKD) PCa cells was assessed in mice. Exosome-deficient 
cancer cells were generated using ribozyme targets of Rab27a. This experiment was 
carried out before we had received the more efficient and reliable lentiviral delivery of 
shRNA for Rab27a knock down in DU145 cells. Nevertheless, the ribozyme knockdown 
approach has been used by Dr Jason Webber for many years successfully in xenograft 
model systems in vivo. Our group showed that administration of exosome-proficient 
DU145 (DU145Control vector) cells with fibroblasts accelerated tumour growth in mice, 
whereas exosome-deficient DU145 (DU145Rab27aKD) cells with the fibroblasts failed to do 
this. Therefore cancer exosomes are suggested to be required to educate stromal cells 
to become tumour-promoting. 
 
Since BM-MSCs are also precursors of myofibroblasts, we chose to repeat the above 
mentioned experiment, but substituting fibroblasts for BM-MSCs. In collaboration with 
Prof Wen Jiang and his group, DU145control vector or DU145 Rab27aKD cells alone or with BM-
MSCs were injected into immune-deficient mice, at a 4 tumour: 1 MSC ratio. As a 
negative control BM-MSCs alone were also administered. Tumour growth was assessed 
over a 28 day period by the current standard technique for volume determination by 
using an external caliper to measure the height and width of the tumour. These 
measurements were then used to calculate tumour volume using the formula; 0.523 x 
width2 x length, as described previously (Escudero-Esparza et al. 2012).  
 
Throughout the 28 day period, BM-MSCs administered alone did not cause any tumours, 
as expected. At an early time point of day 8, there was no significant difference in 
tumour volume among the different conditions (figure 8.8). By day 15, however, mice 
containing BM-MSCs with PCa cells resulted in a greater tumour volume, which where 
almost double the size in comparison to the tumours in the absence of BM-MSCs. By day 
28, mice with BM-MSCs and DU145Control vector cells had significantly larger tumours 
(P≤0.001) to that of DU145Control vector cells alone. In contrast, there was no difference 
between BM-MSCs with DU145Rab27aKD cells and DU145Rab27aKD cells alone. Thus, at the 
end point of day 28, it may seem that BM-MSCs with exosome-proficient PCa cells 
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promote tumour growth. However, since there was a very heterogeneous range of 
tumour growth across the different conditions, the effect of BM-MSCs under the 
influence of exosomes on tumour growth is inconclusive. Collectively, the data shows 
that adding BM-MSCs with tumour cells enhances growth in vivo, regardless of the 
exosome-secretion status of the tumour cells. We were disappointed not to have 
revealed a clear cut role of exosomes in this experiment and wanted to explore potential 
reasons why this may have happened. 
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Tumour growth in a xenograft model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.8: BM-MSCs with exosome-proficient PCa cancer cells accelerates tumour growth after 28 days post injection into mice. 
DU145Control Vector or DU145 Rab27aKD cells were administered alone or with BM-MSCs in a 4:1 ratio respectively, into the hindlimbs of immunodeficient mice. BM-MSCs 
alone were also administered into the mice. Tumour height and width was measured using an external caliper and used to calculate tumour volume over 28 days. 
(Graph shows Mean±SD, n=12, except for BM-MSC alone control which has an n=6. Two-Way ANOVA with Bonferroni post-test ***p≤0.001) 
 
Influence of exosome-differentiated BM-MSCs on tumour cells 
 
189 
 
8.1.7 Instability of Rab27a knock down 
Since there was no significant difference between the DU145Control vector with BM-MSCs 
and DU145Rab27aKD with BM-MSCs, this raised the question if the knock down of Rab27a 
using the ribozyme silencing method was stable enough to sustain this exosome-
deficient property of the cancer cells over time. To test this, DU145Control vector and 
DU145Rab27aKD cells were cultured in T75 flasks and RNA was sequentially collected over 
8 weeks of culture. mRNA for Rab27a was assessed using qPCR. After 2 weeks of cell 
culture, there was a decrease in Rab27a gene expression in DU145Rab27aKD cells by 64% 
(P≤0.0001) in comparison to the DU145Control vector cells (figure 8.8). By 4th and the 6th 
week of culture, there was only ~30% loss of Rab27a gene expression in the 
DU145Rab27aKD cells in comparison to the DU145Control vector. The knock down of Rab27a 
was further declined to 7% at 8 weeks of cell culture. Therefore, knock down of Rab27a 
was lost with time, suggesting that exosome secretion is no longer blocked. The 
instability of Rab27a knock down could explain why there was no drastic difference 
amongst the exosome-deficient tumour cells with BM-MSCs to that of exosome-
proficient tumour cells with BM-MSCs. Furthermore, the Rab27a status of DU145 cells 
used for the in vivo work was not confirmed prior to the experiment, thus the cells 
injected into the mice may have already lost the knockdown. This may have allowed BM-
MSCs to differentiate into myofibroblasts under the influence of exosomes and thus 
promote tumour growth in mice containing DU145Rab27aKD with BM-MSCs. 
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Figure 8.9: Stability of Rab27aKD declines over time 
RNA was isolated from DU145 Control Vector and DU145Rab27aKD cells over 8 weeks of cell culture. 
Relative quantification (RQ) of mRNA for Rab27a were evaluated using qPCR, using GAPDH as 
the housekeeping gene. (Bar Mean±SD, n=3, Two-Way ANOVA with Benforri post-test, *p≤0.05, 
****p≤0.0001) 
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8.2 Discussion  
Exosome-differentiated BM-MSCs increase tumour cell proliferation and motility  
Cancer associated myofibroblasts are important determinants of tumour cell behaviour, 
as the stromal cells act to condition the tumour microenvironment, favouring tumour 
growth and metastasis (Orimo et al. 2005; Webber et al. 2014). I have shown that CM 
from exosome-differentiated BM-MSCs strikingly elevates the proliferation of prostate 
cancer cells (DU145 and PC3 cell lines). CM from sTGF-β1 treated BM-MSCs also 
increased the proliferation of PCa cells but to a much lesser extent to that of exosome-
differentiated BM-MSCs. Metastasis is a key consequence of tumour progression, which 
requires carcinoma cells to be motile and invade the ECM, in order to enter the 
circulation and reach a distant organ. In the presence of soluble factors from exosome-
differentiated BM-MSCs there was a heightened motility of PCa cells in a scratch assay, 
almost completing scratch closure by 10 hours. The mechanism behind the pro-
proliferative and pro-motility effect has not been explored here, but published literature 
reports HGF secreted from cancer stroma cells promotes the proliferation and motility 
of carcinoma cells in liver cancer and colon cancer (Jia et al. 2013; Kermorgant et al. 
2001). Moreover, VEGF has been revealed to enhance the proliferation of breast cancer 
cells by inducing the anti-apoptotic protein BCL-2 (Liang et al. 2006). Thus the enhanced 
secretion of VEGF-A and HGF from exosome-differentiated BM-MSCs may also be 
involved and by selectively blocking VEGF-A or HGF, we can determine their relative 
importance in tumour proliferation and motility. 
 
BM-MSCs and tumour growth in vitro 
Spheroids generated with DU145NM Control, DU145Rab27aKD cells alone or with BM-MSCs 
were cultured over 20 days. During growth of the spheroids, a dense core was observed, 
suggestive of a necrotic core from other studies. Such studies have reported cells in the 
inner core to be deprived of oxygen, glucose, ATP and other nutrients, whereas 
metabolic waste accumulates, resulting in a necrotic core (Bertuzzi et al. 2010). Analysis 
of tumour spheroid growth revealed a rapid decline of tumour only spheroids, similar to 
other reports, attaining a limiting size, regardless of how often new media was provided 
or how much open space was made available for growth (Folkman and Holchberg 1973). 
In contrast, the presence of PCa exosomes and BM-MSCs, maintained a consistent 
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tumour size over 20 days. Similar was observed with BM-MSCs with exosome-deficient 
tumour cells but to a lesser extent. The overall shrinkage of the spheroids may have 
been due to the organisation of the cells and cellular contraction (Nyga et al. 2013; 
Sodek et al. 2009), but the presence of BM-MSCs possibly promoted tumour cell 
proliferation and hence the maintenance of tumour cell size. 
 
The presence BM-MSCs with prostate cancer exosomes did not seem to cause an 
immense spheroid growth in comparison to BM-MSCs with exosome-deficient cancer 
cells. However, the measurement of tumour volume may have been a hindrance of 
observing any differences which may have existed. The estimation of tumour volume 
was based on spheroid surface measurement in 2D, which is not a good representative 
of tumour growth, as we are assuming that the spheroids are all perfect spheres but the 
depth of the spheroids may actually be different. Thus, spheroids which look small on 
the surface, may have been greater in depth, but would not be noted based on this 
measurement. 
 
BM-MSCs and tumour invasion in vitro 
Using 3D spheroids in a matrigel invasion assay, the control DU145 cells along with BM-
MSCs drastically supported the invasion of tumour cells through the MatrigelTM. 
Whereas Rab27aKD DU145 cells along with BM-MSCs, did not support tumour invasion 
as well. This suggests that the presence of PCa exosomes, may have generated 
myofibroblasts using the BM-MSCs which are an important element in controlling the 
invasion of cancer cells.  
 
The mechanism behind the pro-invasive property of exosome-differentiated BM-MSCs 
has not been investigated before. Like with proliferation and motility, elevated factors 
from exosome-treated BM-MSCs, such as VEGF-A and HGF (shown in chapter 5) may be 
involved in the invasion of PCa cells. Studies have reported the requirement of VEGF-A 
and HGF secreted by myofibroblasts for supporting the invasion of squamous cell 
carcinoma cells in a transwell matrigel assay (Cat et al. 2006). HGF stimulated 
invasiveness of cancer cells has been associated with the increased secretion of the 
protease, urokinase-plasminogen activator (uPA) and its receptor, uPAR by the cancer 
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cells (Jedeszko et al. 2009). The receptor bound uPA generates a proteolytic cascade 
that contributes to the degradation of the basement membrane and ECM (Kobayashi, 
1996). Similarly, an up-regulation of uPA are also observed by prostate cancer stromal 
cells and exosome-differentiated fibroblasts (Webber et al. 2014), and so high uPA is 
secreted by both cancer epithelial and stromal cells. Therefore HGF secreted from 
exosome-differentiated BM-MSCs may also trigger a proteolytic cascade for ECM 
breakdown. 
 
RT-qPCR analysis revealed mRNA for MMP-3 and SerpinA-1 was highly expressed in 
tumour spheroids containing BM-MSCs with PCa exosome proficient cell. This agreed 
with the high mRNA levels of MMP-3 and SerpinA-1 found in exosome-treated BM-MSCs 
(shown in chapter 6). Therefore, MMP-3 and SerpinA-1 may be involved in promoting 
invasion of tumour cells. By blocking the MMPs and SerpinA-1 selectively, the relative 
importance they have in the spheroid culture for invasion can be determined. MMP-3 
has been shown to promote breast cancer cell invasion in vitro, in a dose-dependent 
manner (Phromnoi et al. 2009), by degrading numerous ECM substrates such as 
collagens, laminins, fibronectin and ECM proteoglycans (Lu et al. 2011; Sternlicht et al. 
1999). Thus inhibiting MMP-3 attenuated the invasion capacity of the tumour cells 
(Phromnoi et al. 2009). Furthermore, SerpinA-1 is up-regulated and correlated with poor 
prognosis in adenocarcinoma (Tahara et al. 1984) and gastric cancer (Shin et al. 2012). 
Immunohistochemical staining of serpinA-1 was shown to increase with increasing 
gastric tumour size and knock down of serpinA-1 decreased invasion and migration of 
the cancer cells (Shin et al. 2012). SerpinA-1 was found to up-regulate mRNA level and 
release of MMP-8 by gastric cancer cells (Kwon et al. 2014).  In addition MMP-3 can 
cleave the precursors of MMP-8 to activate them (Page- McCaw et al. 2007), which can 
further break down the ECM. Therefore spheroids comprising of BM-MSCs with 
exosome-proficient PCa cells can up-regulate matrix remodelling proteins which can 
degrade the ECM and support the invasive nature of the tumour.  
 
The data in this chapter revealed exosome-differentiated BM-MSCs to have a pro-
proliferative and pro-motility effect on prostate cancer cell lines. Furthermore, co-
culture of BM-MSCs and exosome proficient PCa cells, maintain growth and promote 
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the tumour cell invasion in vitro. Therefore BM-MSCs under the influence of PCa 
exosomes are tumour promoting. 
 
BM-MSCs and tumour growth in vivo 
An attempt to examine the dependency of cancer exosomes and BM-MSCs on tumour 
growth in a xenograft model was carried out. DU145 cells, whether exosome-proficient 
(DU145Control Vector) or exosome-deficient (DU145Rab27aKD), had accelerated tumour 
growth over 28 days in the presence of BM-MSCs, but there was no difference in growth 
between the DU145Control Vector cells with BM-MSCs vs the DU145Rab27aKD cells with BM-
MSCs. From the in vitro experiments, we know that exosome-differentiated BM-MSCs 
support tumour progression by substantially increasing tumour cell proliferation. But 
here, it is only at a later stage, of day 28 that tumour volume was the largest in the 
presence of DU145Control Vector with BM-MSCs. After seeing no difference between the 
DU145Control Vector cells with BM-MSCs vs the DU145Rab27aKD cells with BM-MSCs at earlier 
time point, the in vivo experiment was ended at day 28, but that was when the tumour 
promoting effects of exosome-differentiated BM-MSCs started to become noticeable. 
Therefore tumour growth may be dependent on both the cancer exosomes and BM-
MSCs and hence the exosome-generated myofibroblasts from BM-MSCs.  
 
In comparison to previous studies by our group, the DU145Control Vector cells showed 
accelerated growth in the presence of normal fibroblasts over 32 days, whereas 
DU145Rab27aKD cells with fibroblasts showed no growth enhancement and these 
differences were seen from an earlier time point of day 20 (Webber et al. 2014). But it 
is known that myofibroblastic differentiation of fibroblasts only takes 72hr (Webber et 
al. 2010), whereas I have shown α-SMA myofibroblastic differentiation of BM-MSCs to 
take up to 14 days. Therefore a bigger difference in tumour growth between the 
DU145Control Vector with BM-MSCs and DU145RAB27aKD with BM-MSCs may have been 
appeared at a later date. 
 
Furthermore, tumour volume was measured using an external caliper which is the 
current gold standard for volumetric measurements of xenograft tumours, but this 
method is often affected by errors such as variability of tumour shape and subcutaneous 
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fat layer thickness. Other techniques such as the microCT has been found to be more 
accurate (Jensen et al. 2008), as it measures the depth of the tumour more accurately 
than the external caliper which assumes the depth of the tumour is same as the 
outgrowth of tumour measured. This means, that the tumour-promoting effect of 
exosome-differentiated BM-MSCs may be underestimated if the tumour grew inwardly. 
However the most likely reason as to why there was no big difference between the 
DU145Control Vector with BM-MSCs and Du145Rab27aKD with BM-MSCs is due to the instability 
of the Rab27aKD using the ribozyme silencing method, as the mRNA level for Rab27a 
was seen to increase with time of cell culture. Thus, there may have been enough 
exosomes secreted by the cancer cell to generate myofibroblast-like cells from BM-
MSCs which may in turn accelerate tumour growth. A better approach would have been 
to use lentiviral shRNA knock down of Rab27a, which has been used in my spheroid 
model.  However, exosome-deficient DU145 cells using such method was not available 
during the mice studies. 
 
Alternatively, the administration of BM-MSCs that had already been differentiated by 
PCa exosomes in vitro, may have been a better approach to observe a bigger response 
of accelerated tumour growth by the exosome-differentiated BM-MSCs, in comparison 
to the untreated or sTGF-β1 treated BM-MSCs. This would have allowed BM-MSCs to 
have had a head-start on differentiating into myofibroblast-like cells. Nevertheless, the 
in vitro experiments in this thesis revealed exosome-differentiated BM-MSCs to be 
essential for the increase in PCa cell proliferation, motility, invasion and maintenance of 
tumour growth all of which are required for the tumour to progress. 
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9.1 General Discussion  
9.1.1 Summarising Discussion 
Prostate Cancer (PCa) is the most common cancer in men in the UK (NICE 2009) and a 
lot of therapies for PCa are targeted towards the prostatic cancer cells. However, it 
should not be forgotten that the cancer cells exist in close and symbiotic relationship 
with the reactive stromal compartment. Recently there has been a renewed interest in 
the cross-talk between the cancer cells and the stromal cells, with increasing evidence 
for a profound influence of fibroblastic stromal cells in driving disease progression, 
dictating treatment response and ultimately relating to poor clinical outcome 
(Yamashita et al. 2012; Tomas et al. 2010). Several studies have identified common 
characteristics of cancer associated stromal cells across diverse solid cancer types. These 
include the molecular traits of myofibroblasts, which promote tumour cell growth 
directly and stimulate angiogenesis, by providing various growth factors such as PDGF, 
VEGF, FGF and uPA (Webber et al. 2014; Tuxhorn et al. 2002; Orimo et al. 2005; Galie et 
al. 2005; Liang et al. 2005). However, there are some recent reports in pancreatic 
carcinoma where myofibroblasts play a protective role and limits the tumour growth 
(Rhim et al. 2014; Gore et al. 2014). Whilst, such data has not been shown for other 
cancer types, the main paradigm is that cancer associated myofibroblasts promotes 
tumour growth and can be used as an indicator of a poor prognosis. Therefore the 
cancer associated myofibroblasts may represent new potential therapeutic targets. 
However, there remains an incomplete understanding about the stroma, the generation 
of cancer associated myofibroblasts, their cellular and molecular nature and their 
consequence in terms of disease outcome.  
 
There are multiple origins of myofibroblasts and although soluble TGF-β1 secreted by 
cancer cells has remained the principle culprit driving myofibroblastic differentiation, 
studies have shown TGF-β1 expressed on the surface of cancer exosomes to also drive 
this differentiation pathway (Clayton et al. 2007; Webber et al. 2010). Studies by our 
group (Webber et al. 2010) have recently highlighted a role of exosome vesicles in 
delivering TGF-β1 to differentiate fibroblasts into α-SMA positive myofibroblasts, which 
in turn promote cancer growth in vivo (Webber et al. 2014). Additionally, others have 
shown cancer derived exosomes to differentiate MSCs from umbilical cord or adipose 
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tissue into myofibroblasts (Gu et al. 2012; Cho et al. 2011; Cho et al. 2012). However, 
most studies have shown bone marrow-derived MSCs (BM-MSCs) to migrate to the 
tumour sites (Shinagawa et al. 2010; Teo et al. 2012), but the effect that the BM-MSCs 
have in cancer, under the influence of cancer exosomes has not been explored before 
and is the main focus in this thesis. 
 
MSCs exhibit cellular plasticity, capable of differentiating into multi-lineage cell types, 
under appropriate hormonal or growth factor stimulants applied sequentially, often 
over long time periods such as a month. MSCs can differentiate into adipocytes when 
cultured under appropriate adipogenic stimulants (Pittenger et al. 1999). However, the 
addition of sTGF-β1 or the equivalent dose of exosomal TGF-β1 inhibited the adipogenic 
differentiation of BM-MSCs. sTGF-β1 in the presence of adipogenic stimulants, including 
dexamethasone and insulin along with other growth factors may halt MSC 
differentiation towards adipocytes and drive them to differentiate into other cell types. 
For example, sTGF-β1 along with dexamethasone is known to differentiate MSCs into 
osteoblasts (Bruder et al. 1997; Jaiswal et al. 1997). Similarly, MSCs placed in aggregate 
cultured with sTGF-β1, along with dexamethasone, insulin and other factors will 
undergo chondrogenic differentiation (Johnstone et al. 1998; Mackay et al. 1998; Lee et 
al. 2004b). Therefore sTGF-β1 has the capacity to differentiate MSCs into various cell 
types. Interestingly however, exosome associated TGF-β1 and not sTGF-β1 was able to 
skew MSC differentiation away from adipocytes and instead towards α-SMA positive 
myofibroblasts. What is equally remarkable is that a single stimulation with exosomes 
(at 150μg/ml) over 14 days was sufficient to trigger the onset of α-SMA stress fibres, 
suggesting a myofibroblast-like differentiation. My data suggests, cancer exosomes may 
be capable of overriding the natural control of MSC differentiation in vitro, away from 
self-renewal or reparative phenotypes, towards undesirable disease promoting 
myofibroblasts.  
 
Previous studies have shown fibroblasts to exhibit the capacity to differentiate into 
myofibroblasts under the influence of sTGF-β1, and this requires additional factors such 
as endogenous hyaluronic acid production and the interaction between CD44 and the 
EGF receptor (Midgley et al. 2013). However, the detailed myofibroblastic phenotype 
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arising from sTGF-β1 treatement appears to differ from cancer associated stromal cells, 
as it is not pro-angiogenic and fails to enhance PCa growth in xenograft models (Webber 
et al. 2014). In contrast, stimulating the fibroblasts (same stromal cell source) with TGF-
β1 bearing PCa exosomes generated myofibroblasts that mimic those extracted from 
cancerous tissues, such as driving angiogenesis and promoting tumour growth in vivo 
(Webber et al. 2014). In this thesis, the phenotypic differences between sTGF-β1 treated 
and exosomal TGF-β1 treated MSCs have been explored. PCa exosomes differentiated 
BM-MSCs towards a myofibroblastic phenotype exhibiting heightened VEGF and HGF 
secretion. The cell arising, therefore represent those above-mentioned traits of cancer 
associated stroma even though the originating cell source is different. This suggests that 
it is the nature of the trigger (i.e. exosomes), rather than the originating cell type, that 
is the most important for the phenotype and function of the myofibroblast arising. In 
contrast, sTGF-β1 stimulation of BM-MSCs gave a drastically different response that 
lacked the onset of αSMA-stress fibres or elevated VEGF and reduced constitutive HGF 
secretion. Comparing the direct effect of exosomal TGF-β1 and sTGF-β1 highlighted the 
profound difference in the cell response arising, with the exosomal TGF-β1 treated BM-
MSCs being more akin to the stromal cells naturally arising at the site of prostate cancer 
(Webber et al. 2014). A detailed mechanistic explanation for this difference is lacking 
and given the molecular complexity of exosomes secreted by the cancer cell, makes it 
significantly challenging. 
 
It is clear that unlike sTGF-β1, exosome-mediated generation of myofibroblasts from 
BM-MSCs exhibit the characteristic traits of cancer associated stromal cells and these 
myofibroblastic features are dependent on TGF-β1 as shown by blocking TGF-β1 
signalling. This agrees with previous findings using fibroblasts and DU145 exosomes, 
where blocking TGF-β signalling attenuated the differentiation of fibroblasts into α-SMA 
expressing myofibroblasts and the pro-angiogenic function of these differentiated 
stromal cells (Webber et al. 2014). A key difference between sTGF-β and exosomal TGF-
β1 delivery is that exosomes have TGF-β receptor III (a heparan sulphate proteoglycan 
called betaglycan) on their surface which aids the delivery of TGFβ1 to the stromal cells 
for their differentiation into myofibroblasts (Webber et al. 2014). The presence of 
heparan sulphate proteoglycan (HSPG) on exosomes, however only shows the 
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differences between the sTGF-β1 and the exosomal TGF-β1 and not necessarily their 
behavioural differences. Nevertheless, it has been revealed that intact HSPG is required 
for functional delivery of vesicular TGF-β1 (Webber et al. 2014). In the case of 
fibroblasts, cleavage of the heparan sulphate side chains by heparinase III, still 
maintained the tethering of TGF-β1 to the exosome surface (no impact on TGFβ levels), 
however exosome-induced SMAD-3 dependent TGF-β1 signalling was attenuated, 
resulting in the loss of α-SMA expression and the pro-angiogenic function of the 
differentiated fibroblasts. Thus the heparan sulphate side chains appear to have 
functions that control the behaviour of exosomal TGF-β1 and similar interactions may 
apply with BM-MSCs, as precursor cells of myofibroblasts. It should be noted, however 
that cells also express HSPG which can aid the delivery of the TGF-β1 ligand to the TGF-
βR I and TGF-βR II (Lopez-Casillas et al. 1993). Thus this feature alone cannot explain the 
differences in phenotype and function observed between sTGFβ treated and the 
exosomal TGF-β1 treated BM-MSCs. Some studies have shown active sTGF-β1 in culture 
to have a short half-life (Rollins et al. 1989; Coffey et al. 1987) in comparison to the 
latent form of TGF- β1 (Wakefield et al. 1990). The reason behind this is unknown, but 
TGF-β1 expressed on the exosome surface is predominantly in the latent form (Webber 
et al. 2010) therefore exosomal TGF-β1 may exhibit a longer time of bioavailability, a 
facet likely to be very relevant for the slow-differentiation process of MSCs. Still, this 
does not explain the phenotypic and functional differences between the sTGFβ-induced 
and exosome-induced myofibroblasts generated. Exosomes are complex vesicles, 
consisting of various mRNA and miRNA, growth factors, enzymes and molecules 
associated with the biogenesis and secretion of exosomes. The possible co-delivery of 
these contents from exosomes along with TGFβ delivery may influence BM-MSC 
differentiation and is an area of interest for future investigation.  
 
By interfering with the exosome secretion pathway via Rab27a silencing, my data 
clarifies that cancer exosomes are the dominant factor in mediating myofibroblastic 
differentiation. It is acknowledged that the specificity of the Rab27a silencing approach 
for selective inhibition of exosome secretion and not other factors by the cells is 
somewhat controversial (Bobrie et al. 2012) and so reliance on Rab27a knockdown as 
the exclusive approach for evaluating the role of exosomes must be taken with caution. 
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Another approach of reducing the level of exosomes in cancer cell conditioned media, 
is by high speed centrifugation, which generates cell conditioned media that is poor in 
driving myofibroblast differentiation. From this, the differentiation was observed to 
reside in the 120,000 g pelletable fraction, strongly implicating exosomes as 
mechanistically central to cancer mediated control of MSC. It should be noted, however, 
the pellets containing exosomes may also contain other factors. Thus, treating MSCs 
with different density fractions from a continuous sucrose gradient containing 
exosomes, may definitively show that myofibroblastic differentiation of MSCs is 
exclusively focused on exosomal vesicles and not co-pelleted material. But this has yet 
to be tested. Nevertheless, the use of pellets containing exosomes and the Rab27a 
silencing approach collectively provide data supporting these conclusions. 
 
The functional properties of exosome-generated myofibroblasts support the premise 
that cancer exosomes have a disease-promoting influence. Although the direct effect of 
cancer exosomes on angiogenesis has been well documented (Sheldon et al. 2010; Al-
Nedawi et al. 2009), the impact of exosome-differentiated BM-MSCs on this process has 
not to our knowledge been studied. Endothelial cells exhibited enhanced proliferation 
and migration in the presence of soluble factors produced by the exosome-
differentiated BM-MSCs. The endothelial cells have also been documented to form 
complex vessel-like structures in the presence of exosome-differentiated BM-MSCs. 
These structure were akin to those produced using PCa derived stroma cells (Webber et 
al. 2014). Growth factors such as VEGF-A and HGF which are found to be highly secreted 
by exosome differentiation MSCs may be involved in this pro-angiogenic function. To 
investigate this, blocking antibodies against HGF and VEGF can be used to examine if the 
angiogenic influence is abolished. 
 
In a similar fashion, exosome-differentiated MSCs have a direct positive effect on 
tumour cell proliferation and migration, and provide an enhanced tendency for cells to 
invade into the extracellular matrix using a 3D spheroid model. Whether the invading 
cells are principally epithelial or mesenchymal in nature are unknown, but given the 
predominance of tumour cells (4:1) in the spheroids, and the pro-proliferative influence 
of BM-MSC on tumour cells, the invading cells are most likely to be epithelial cells as 
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suggested by their cobblestone appearance. The extensive invasion property was 
abrogated when targeting exosome secretion by Rab27a silencing. Additionally, the 
invasion of the cancer cells were absent when BM-MSCs were left out of the spheroids 
highlighting the role of this stromal cells and exosomes in directing the invasion 
behaviour. This high invasive capacity of the system agrees with additional evidence 
showing exosome-driven elevation of metalloproteinases in BM-MSCs, a feature found 
specifically from exosome treatment and not observed when using sTGF-β1. Such 
factors, which include the collagenases MMP-1 and MMP-13 and the stromelysin MMP-
3, have well documented roles in disease progression and can in particular aid cell 
penetration through the extracellular matrices, supporting invasion and metastasis in 
several types of cancer (Ala-aho et al. 2005). Notably a recent study highlighted BM-
derived myofibroblasts found at the primary tumour site in a skin cancer model as the 
principal source of MMP-13 in situ (Lecomte et al. 2012) and that this MMP was required 
for subsequent invasive behaviour (Lecomte et al. 2012; Zigrino et al. 2009). 
Furthermore, a recent study has demonstrated that down-regulation of MMP-3 in 
cancer associated fibroblasts subsequently attenuated PCa cell invasion (Slavin et al. 
2014). Other transcripts modulated by exosomes were ITGB6 and ITGB8 encoding for 
components of the integrin αvβ6 and αvβ8, respectively, which are implicated in the 
conversion of latent-TGFβ to bioactive TGF-β in several systems (Minagawa et al. 2014; 
Aluwihare et al. 2009). The importance of these exosome mediated changes in BM-MSCs 
for TFG-β1 activation and adhesive functions has not yet been investigated but is an area 
of interest for future investigation. The outcome of my experiments indicates that the 
onset of αSMA stress fibres in stromal cells are not directly coupled to their tumour 
modulating function and therefore a better alternative indicator of stromal functionality 
may be the secretion of certain factors including MMPs, VEGF and HGF. However, we 
don’t know yet if the exosome differentiated BM-MSCs enhanced secretion of MMPs is 
relevant to the heightened invasion that is observed. One way to investigate this would 
be to inhibit specific MMPs such as MMP-1, MMP-3 and MMP-13 using blocking 
antibodies or generating specific MMP deficient cell model using siRNA targets of MMPs 
(Jiang et al. 2005; Gencer et al. 2011; Hayami et al. 2008). This will allow us to examine 
the function of the secreted factors from the stromal cell. One should be aware that 
exosomes themselves may also contain matrix remodelling molecules which may also 
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be responsible for the invasion property of the cancer cells. Exosomes from melanoma 
cells carry the active form of MMP-14 which was able to activate latent MMP-2 and 
degrade collagen type I and gelatin, suggesting exosomal MMP-14 was functionally 
active (Hakulinen et al. 2008). Lastly, exosomes from the differentiated BM-MSCs may 
also contribute the breakdown of the matrix and so the role exosomes play in the 
invasive property of PC is worth investigating in the future. 
 
The spheroid models revealed the tumour size to decline gradually as the inner core 
became necrotic. Other studies have also reported a reduction in tumour growth in 
spheroid models (Folkman et al. 1973) and this was due to the degradation of cells 
within the inner core. However, it was noted that the presence of exosomes and BM-
MSCs maintains the spheroid growth over time, perhaps by enhancing tumour cell 
proliferation. Additionally, exosome-deficient tumours with BM-MSCs also maintains 
tumour growth, but to a much lesser extent. Since the knock down of Rab27a reduces 
exosome secretion and hence an attenuation of exosome generated myofibroblasts 
from BM-MSCs, tumour growth was expected to be attenuated in vivo, similar to 
previous observations using fibroblasts (Webber et al. 2014). However, there was no 
significant difference in tumour size in the presence of BM-MSCs along with exosome 
proficient or exosome-deficient tumour cells after 28 day period. This may have been 
due to the poor stability of the ribozyme method used for silencing Rab27a in DU145 
cells for the in vivo assessment of tumour growth and hence the tumour cells were not 
truly exosome-deficient. Knock down of Rab27a using lentiviral would have been a more 
stable method and thus a better model for evaluation of exosome-dependence on 
tumour growth in vivo. Since BM-MSCs take longer to differentiate into tumour 
promoting myofibroblasts in comparison to fibroblasts, which take only 3 days (Webber 
et al. 2014), the use of pre-differentiated BM-MSCs injected along with tumour cells may 
be a better approach to observe an earlier response and to ensure BM-MSCs had time 
to differentiate. Nevertheless, the collective functional data, such as the pro-invasive 
and pro-angiogenic properties of the differentiated BM-MSCs correlate well with the 
phenotypic alterations induced by exosome stimulation. These changes emphasise the 
profound role of MSCs with tumour cells in driving distinct aspects of disease 
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progression, and that a functional cancer exosome secretion pathway is essential for 
this influence. 
 
In conclusion my study identifies PCa exosomes as potent factors for controlling the 
phenotypic and functional differentiation of BM-MSCs towards pro-angiogenic and pro-
invasive myofibroblasts. The phenotype is similar to that reported for cancer associated 
stromal cells, with exosomes and not other soluble factors required to generate this 
dominant form of differentiation. Therefore molecular targeting of this cancer exosome 
driven process in a clinical setting is likely to attenuate tumour-manipulation of the local 
microenvironment, and slow disease progression. 
 
9.1.2 Future Directions 
Cancer exosomes have been demonstrated to be strong drivers of myofibroblastic 
differentiation and hence aid tumour to progress. Further understanding of the role of 
exosomes may provide avenues for inhibiting exosome secretion by the cell or lowering 
their effect, and thus slowing tumour progression.  
 
Are the responses to cancer exosomes specific to a sub-population of BM-MSCs? 
The nature of the BM-MSCs response to exosome stimulation in terms of the cell 
population has not been addressed, and it is currently unclear as to whether the 
response is homogenous or whether it is a sub-population of MSCs which differentiate 
into myofibroblasts that subsequently proliferate to take over the population. My 
studies have shown around 60-70% of MSCs exhibit αSMA positivity after around 2 
weeks which is quite different from stimulating fibroblasts where almost ~100% of the 
cell population differentiate into αSMA positive myofibroblasts by 3 days (Webber et al. 
2010). Such observations suggest a more heterogeneous response with BM-MSCs as a 
stromal cell source. The question may have in vivo relevance, as the infiltration of the 
cancer microenvironment by a few BM-MSCs may be sufficient to generate a growing 
population of myofibroblastic cells in situ. Addressing such questions will enable us to 
gain a greater insight into such exosome mediated changes in subpopulations of stem 
cells. 
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The in-depth mechanism of exosome induced myofibroblast differentiation  
The full mechanism involved in the generation of myofibroblasts by cancer exosomes is 
still incomplete. Recent studies have demonstrated internalisation of exosomes by 
recipient cells in which the exosomes can incorporate components such as miRNA and 
mRNA into the recipient cells (Valadi et al. 2007; Batagov and Kurochkin 2013). Among 
these molecules found in exosomes, miRNAs have attracted most attention, due to their 
regulatory roles in gene expression. However, there are limitations to the current 
functional studies with exosome associated miRNAs. Firstly, there are numerous 
methods for isolating exosomes, which can result in slight variation in exosomal content, 
including proteins and miRNAs (Rekker et al. 2014; Tauro et al. 2012; Taylor et al. 2011). 
The variability of miRNAs may regulate different signalling pathways, resulting in 
different result outcomes on recipient cells. This makes it challenging to fully understand 
the functions of exosomal miRNAs. Secondly, some studies use RNAse to examine the 
function of miRNA, but one should remember that exosomes can prevent RNAse from 
damaging miRNA held within the vesicle (Koga et al. 2011). Hence in these studies, 
researchers may not be examining exosome-associated miRNA, but instead are 
examining the effects of free miRNAs (extracellular soluble miRNAs). Hence the 
functional results from some studies may not be due to the exosomal associated 
miRNAs.  
 
Identifying miRNAs highly abundant in cancer exosomes and utilising knock down 
experiments of candidate genes may identify those involved in generating tumour-
associated myofibroblastic phenotype. In collaboration with an Australian group, our 
group profiled the miRNAs in DU145 cell derived exosomes, revealing some highly 
abundant miRNA with in silico predicted association with the TGF-β signalling pathways. 
Theoretically, this would implicate miRNA delivery by exosomes as relevant. However, 
following treatment of fibroblasts with exosomes, qPCR primers against miRNAs showed 
no changes in these exosomally carried miRNA species, or indeed any changes in several 
of the top-predicted miRNA targets. Nevertheless differentiation into myofibroblasts 
still occurred (unpublished data, personal communication by Dr Aled Clayton). Thus 
exosomal miRNA are probably not incorporated into the recipient stromal cells 
machinery for controlling mRNA translation or the miRNAs may be degraded rapidly by 
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the cells. Therefore, the exosome-induced myofibroblastic differentiation seems to be 
RNA independent but the data however, requires further investigation. Lastly, a recent 
study obtained exosomes from different sources (including the plasma, seminal fluid, 
dendritic cells, mast cells and ovarian cancer cells) and quantified exosomes using the 
Nanosight Tracking Analysis and the number of miRNA molecules in the exosome 
preparations using qPCR, revealing that on average, exosomes do not contain enough 
miRNAs to have a functional effect (Chevillet et al. 2014). Taken together, this leads us 
to question the emphasis made in the exosome field on miRNA. There is a possibility 
that exosomes do not exert functions via miRNAs and the functional outcomes observed 
in some studies may be due to free miRNAs and not ones associated with exosomes. 
 
Cancer exosome-mediated recruitment of cells  
Several studies have revealed the migration of BM-MSCs into various tumour sites 
(Quante et al. 2011; Shinagawa et al. 2010; Jung et al. 2013). However, the recruitment 
signals involved are poorly understood. In a recent study, mouse-derived bone marrow 
macrophages secreted heightened levels of chemokines following treatment with 
exosomes from M. tuberculosis-infected macrophage, whereas the uninfected 
macrophages secreted low levels of chemokines. The resultant M. tuberculosis-infected 
macrophages possessed the capacity to induce cellular recruitment of immune cells such 
as myeloid cells, neutrophils, macrophages and splenocytes both in vitro and in vivo 
(Singh et al. 2012). Thus exosomes can direct the recruitment of cells. Whether or not 
PCa cells can also generate pro-recruiting exosomes is an open question of considerable 
interest. Additionally, melanoma derived exosomes have been documented to play a 
role in long-distance communication to the bone and mobilise BM-progenitor cells into 
the blood, to influence disease progression. This mobilisation is speculated to be driven 
by the exosomal transfer of MET receptor as noted by elevated levels of MET receptors 
on circulating BM progenitor cells in patients with advanced melanoma. Furthermore, 
in a murine model, the knock down of MET levels in exosomes using shRNA lowered the 
metastasis capacity of the BM progenitor cells. Additionally, the inhibition of exosome 
secretion by knockdown of Rab27a attenuated metastasis (Peinado et al. 2012). 
Therefore mobilisation of BM progenitor cells are exosomal MET-dependent. Whether 
PCa exosomes are capable recruiting BM-MSCs to the prostate in a similar fashion, is in 
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an area of great interest for future investigation, and if so, when along this mobilisation 
route, do BM-MSCs differentiate into myofibroblasts is an open question of considerable 
interest. 
 
Function of exosomes produced by exosome differentiated MSCs 
The function of exosomes released from cancer-associated myofibroblasts have not 
been investigated thoroughly. A recent study demonstrated Wnt11 tethered to CD81 
positive exosomes from myofibroblasts to be internalised by breast cancer cells, which 
in turn promoted breast cancer cell motility and metastasis in vivo (Luga et al. 2012; 
Hoffman et al. 2013). The Wnt 11 ligand was associated with the enhanced motility and 
metastasis of breast cancer cells by signalling through the Frizzled (Fzd) receptors, 
indicating that exosomes from myofibroblasts allow cross-talks between the stromal 
and cancer cells to promote metastasis. Furthermore, a recent study reported exosomes 
from MSCs to increase VEGF expression in tumour cells, resulting in enhanced 
angiogenesis which promoted tumour growth in vivo (Zhu et al. 2012). However, the 
function of exosomes from BM-MSCs differed depending on the phenotype of the BM-
MSCs. For example, exosomes released by BM-MSCs from multiple melanoma patients 
had higher levels of oncogenic proteins, cytokines and adhesion molecules in 
comparison to exosomes from BM-MSCs of healthy individuals (Roccaro et al. 2013). 
Furthermore, in a xenograft model, the exosomes from BM-MSCs of multiple melanoma 
patients promoted disease progression whereas exosomes from BM-MSCs of healthy 
individuals inhibited tumour growth in vivo (Roccaro et al. 2013). This indicates that 
exosomes from stromal cells such as BM-MSCs under disease conditions can be tumour-
promoting. Similar observations were reported by other researchers (Bruno et al. 2013). 
In a similar manner, exosomes released from PCa exosomes-differentiated BM-MSCs 
may also promote tumour growth. Since BM-MSCs in general are immunosuppressive 
(Ringden et al. 2006; Figueroa et al. 2012) their secreted exosome may also exhibit an 
immunosuppressive property which may in turn help cancer cells evade the immune 
surveillance. Investigating the role of exosomes from PCa exosomes-differentiated BM-
MSCs will further our knowledge in the function of exosome generated myofibroblasts 
in tumour progression. 
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Targeting exosomes as a therapeutic approach 
Since my data emphasises the disease promoting nature of cancer exosomes, targeting 
exosomes as a new therapeutic approach may help slow down tumour progression. A 
negative feedback system has been revealed for regulating exosome release by the cells, 
in which the exosomes secreted by normal mammary epithelial cells into the 
extracellular space inhibits any further release of exosomes from the cells (Riches et al. 
2014). The same negative feedback is observed between breast cancer cells and their 
exosomes. Furthermore, when exosomes from normal epithelial cells were added to 
breast cancer cells, there was a marked inhibition in exosome release. The level of 
exosome secretion was actually much lower than that of the untreated normal epithelial 
cells used as a control (Riches et al. 2014).  Fluorescently labelled normal epithelial cell 
derived exosomes were internalised into the tumour cells, suggesting a dynamic 
equilibrium and thus implicating a mechanism for negative feedback control. This 
approach of adding exosomes from healthy cells to cancer cells may be applicable in 
controlling exosome release by prostate cancer cells.  
 
Exosomes have been identified to aid cellular chemoresistance by exporting drugs out 
from the cells, attenuating the beneficial effect of chemotherapy. Instead drugs which 
interfere with the stability of the cytoskeletal components involved in directing the 
exocytosis pathway such as taxanes and vinca alkaloids, may be able to inhibit the 
secretion of exosomal vesicles and hence hindering chemoresistance of the cells (Iero et 
al. 2008). Furthermore, methods involved in altering the exosome composition that are 
tumour promoting may also be a good approach to lower the detrimental effect of 
exosomes. One such example, is the dietary component, curcumin which was found to 
reduce the immunosuppressive activities of breast cancer exosomes against NKs cells. 
Curcumin was speculated to alter the cargo sorting of exosomes during their biogenesis 
into MVBs (Zhang et al. 2007). Thus there are numerous pharmacological approaches 
open for further investigation for blocking the tumour promoting effects of exosomes.  
 
The use of blood filtration is an attractive strategy which could be used to remove 
exosomes from circulation. An adaptive dialysis-like affinity platform technology 
(ADAPTTM) has been developed by Aethlon Medical (Aethlon Medical Inc, San Diego, 
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USA) which can separate particles based on their size and phenotype. This device is 
composed of an outer compartment containing immobilised affinity agents and the 
compartment integrates with a standard renal dialysis machine. As the patient’s blood 
is passed through the dialysis, only particles less than 200nm will pass through the 
porous fibres to the outer compartment and interact with the immobilised affinity 
agents to which exosomes can be selectively attached to. White blood cells and non-
bound serum components, on the other hand, will carry on passing through the dialysis 
and so the blood is free from selected exosomes (reviewed by Marleau et al. 2012). This 
strategy can therefore be used to capture tumour-derived exosomes. For example in 
HER2 positive breast cancer, anti-HER2 antibodies in combination with antibodies 
against exosome associated proteins may enable the entrapment of breast cancer 
exosomes. In a similar manner, this ADAPTTM machine should be able to isolate PCa 
exosomes from the patient’s blood. The safety and efficacy of this ADAPTTM machine for 
exosome removal, however, has yet to be clinically tested. Taken together, recent 
reports highlights some therapeutic approaches which may control the deleterious 
effects of tumour exosomes. 
 
Concluding Remarks 
My studies show for the first time, that prostate cancer exosomes educate BM-MSCs 
into tumour-promoting cells. This emphasises along with literature that cancer 
exosomes are an essential factor for generating a tumour promoting microenvironment 
and thus targeting exosomes is likely to be a valuable therapeutic approach for 
attenuating tumour progression.
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